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Biodegradable Polymeric Biomaterials in Different Forms for Long-acting
Contraception and Drug Delivery to the Eye and Brain
Abstract
Efficacy of many of the new and existing therapeutics is often hampered by the lack of an effective and
compliant method of delivery. Typically, drugs have poor water solubility, short half-lives, and low
permeability across the biological membranes. The result is low bioavailability of the drugs at the target
site and can cause toxicity and side effects at high doses. Often the conventional dosage forms fail to
overcome these limitations. In the recent decades, biodegradable polymeric drug delivery systems have
emerged as promising candidates to solve the challenges of poor solubility, low permeability and
sustained release owing to the advantages of biocompatibility, versatility, and tunable drug release.
Polyesters and polysaccharides are the most common polymers that were explored for drug delivery
applications because of their unique advantages including non-toxic nature, wide availability, relatively low
cost, and flexibility in chemistry. Although a major progress has been in the field of drug delivery, still there
are unmet medical needs which require new materials for delivering drugs such as, injectable systems
that can achieve long-term contraception (five months or longer) at low cost, and drug delivery systems
that can enhance the permeability of drugs across ocular/blood-brain barriers and sustain release as well
for treating chronic diseases such as diabetic retinopathy in the eye and Alzheimer’s disease in the brain.
Therefore, this research has evaluated the potential of different biodegradable polymeric biomaterials
based on polyesters or polysaccharides for long-acting contraception and drug delivery to the eye and
brain to resolve the issues such as poor compliance and adherence to the existing contraceptive dosage
forms or poor solubility and permeability of the drugs across ocular/blood-brain barriers. The first system
includes polyester-based injectable in situ forming depot systems (ISD) for long-acting contraception. The
aim of this project was to develop injectable ISD system containing levonorgestrel (LNG) for
contraceptive effect for five months or longer after single shot that helps to reduce unintended
pregnancies with high patient compliance and low cost. A series of LNG-containing ISD formulations
were designed by employing unique strategies which include the use of poly(lactic acid-co-glycolic acid),
poly(lactic acid) with different biodegradable properties, and blends of these polyesters, use solvent
mixtures of N-methyl-2-pyrrolidone, triethyl citrate, benzyl benzoate, and vary the polymer/solvent ratios,
and various drug loadings. The formulations were evaluated for viscosity, initial burst, in vitro and in vivo
long-term release. In vivo investigation in rats showed the sustained-release pharmacokinetic profile of
LNG from the ISD formulations for at least five months and continued for more than seven months
depending on the composition, and the vaginal cytology studies have demonstrated that formulations
have successfully suppressed the rat estrous cycle. After the end of the treatment, a rapid and predictable
return of fertility was observed in rats. The optimized lead formulation has shown promising injectability
(23 G) and low initial in vivo burst profiles. The results suggested that the developed LNG-ISD
formulations have a great potential for developing into future robust affordable long-acting contraceptive
products for improving patient compliance and adherence. Another type of polymeric biomaterial
systems that were evaluated in this study includes polysaccharide-based biodegradable nanoparticles for
drug delivery across ocular and blood-brain barriers. Depending on the need of the therapeutic
application, two types of polysaccharide-based nanoparticles were investigated for their drug delivery
feasibility which includes: (a) Poly(N-isopropylacrylamide-co-Dextran-lactateHEMA) nanogels for the
potential delivery of hydrophilic peptide (insulin) across ocular barriers for the treatment of diabetic
retinopathy. The in vitro, and ex vivo studies showed that the developed nontoxic nanogels have great
potential to enhance the drug permeability across ocular barriers including the in vitro retinal pigment
epithelium, sclera and cornea barriers for treating diabetic retinopathy; and (b) β-cyclodextrin-poly(βamino ester) nanoparticles as potential drug carriers to enhance the solubility and blood-brain barrier
(BBB) permeability of 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) to treat Alzheimer’s disease.
The nanoparticles sustained the release of 17-AAG for at least one week in vitro and showed increased

permeability (2-fold) of the 17-AAG across BBB in vivo in mice, and resulted in enhanced expression of the
Hsp70 protein in the brain. In conclusion, the developed biodegradable polymeric biomaterials have
shown potential to be used in long-acting contraception and drug delivery to the eye and brain.
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ABSTRACT
Efficacy of many of the new and existing therapeutics is often hampered by the
lack of an effective and compliant method of delivery. Typically, drugs have poor water
solubility, short half-lives, and low permeability across the biological membranes. The
result is low bioavailability of the drugs at the target site and can cause toxicity and side
effects at high doses. Often the conventional dosage forms fail to overcome these
limitations. In the recent decades, biodegradable polymeric drug delivery systems have
emerged as promising candidates to solve the challenges of poor solubility, low
permeability and sustained release owing to the advantages of biocompatibility,
versatility, and tunable drug release. Polyesters and polysaccharides are the most
common polymers that were explored for drug delivery applications because of their
unique advantages including non-toxic nature, wide availability, relatively low cost, and
flexibility in chemistry. Although a major progress has been in the field of drug delivery,
still there are unmet medical needs which require new materials for delivering drugs such
as, injectable systems that can achieve long-term contraception (five months or longer) at
low cost, and drug delivery systems that can enhance the permeability of drugs across
ocular/blood-brain barriers and sustain release as well for treating chronic diseases such
as diabetic retinopathy in the eye and Alzheimer’s disease in the brain. Therefore, this
research has evaluated the potential of different biodegradable polymeric biomaterials
based on polyesters or polysaccharides for long-acting contraception and drug delivery to
the eye and brain to resolve the issues such as poor compliance and adherence to the
existing contraceptive dosage forms or poor solubility and permeability of the drugs
across ocular/blood-brain barriers.
The first system includes polyester-based injectable in situ forming depot systems
(ISD) for long-acting contraception. The aim of this project was to develop injectable
ISD system containing levonorgestrel (LNG) for contraceptive effect for five months or
longer after single shot that helps to reduce unintended pregnancies with high patient
compliance and low cost. A series of LNG-containing ISD formulations were designed
by employing unique strategies which include the use of poly(lactic acid-co-glycolic
acid), poly(lactic acid) with different biodegradable properties, and blends of these
polyesters, use solvent mixtures of N-methyl-2-pyrrolidone, triethyl citrate, benzyl
benzoate, and vary the polymer/solvent ratios, and various drug loadings. The
formulations were evaluated for viscosity, initial burst, in vitro and in vivo long-term
release. In vivo investigation in rats showed the sustained-release pharmacokinetic profile
of LNG from the ISD formulations for at least five months and continued for more than
seven months depending on the composition, and the vaginal cytology studies have
demonstrated that formulations have successfully suppressed the rat estrous cycle. After
the end of the treatment, a rapid and predictable return of fertility was observed in rats.
The optimized lead formulation has shown promising injectability (23 G) and low initial
in vivo burst profiles. The results suggested that the developed LNG-ISD formulations
have a great potential for developing into future robust affordable long-acting
contraceptive products for improving patient compliance and adherence.
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Another type of polymeric biomaterial systems that were evaluated in this study
includes polysaccharide-based biodegradable nanoparticles for drug delivery across
ocular and blood-brain barriers. Depending on the need of the therapeutic application,
two types of polysaccharide-based nanoparticles were investigated for their drug delivery
feasibility which includes: (a) Poly(N-isopropylacrylamide-co-Dextran-lactateHEMA)
nanogels for the potential delivery of hydrophilic peptide (insulin) across ocular barriers
for the treatment of diabetic retinopathy. The in vitro, and ex vivo studies showed that the
developed nontoxic nanogels have great potential to enhance the drug permeability across
ocular barriers including the in vitro retinal pigment epithelium, sclera and cornea
barriers for treating diabetic retinopathy; and (b) β-cyclodextrin-poly(β-amino ester)
nanoparticles as potential drug carriers to enhance the solubility and blood-brain barrier
(BBB) permeability of 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) to treat
Alzheimer’s disease. The nanoparticles sustained the release of 17-AAG for at least one
week in vitro and showed increased permeability (2-fold) of the 17-AAG across BBB in
vivo in mice, and resulted in enhanced expression of the Hsp70 protein in the brain.
In conclusion, the developed biodegradable polymeric biomaterials have shown
potential to be used in long-acting contraception and drug delivery to the eye and brain.
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CHAPTER 1.

BIODEGRADABLE POLYMERIC BIOMATERIALS FOR DRUG
DELIVERY
Introduction

New drug discovery and development is a multi-stage complex and laborintensive process requiring years of time and large amounts of money. According to the
latest report by the Tufts Center for the Study of Drug Development, the average
expenses involved in the new drug development from the discovery stage to market
approval was estimated to be $ 2.558 billion USD [1, 2]. Consequently, enhancing the
safety and efficacy of current therapeutics has been attempted using various strategies
such as novel drug delivery systems, personalized medication, dose alteration, and
therapeutic drug monitoring. Delivering drugs at a sustained and controlled rate, targeted
delivery using drug delivery systems was the most attractive method that has been
pursued extensively [3]. New delivery systems can be developed at relatively low cost
and time than new drug discovery, and this allows to maximize the return on investment,
giving a second life to existing therapeutics, with improved efficacy and patient
compliance [4]. Further, in the recent years, the concept of the drug has changed from the
traditional small molecules to the biologics (such as peptides, proteins, monoclonal
antibodies, RNA, DNA), and this change required the exploration of new delivery
systems because of the failure of the conventional systems. Moreover, with the
progressive shrinkage of the pipelines from pharmaceutical organizations and the release
of many of the drugs from the patent, drug delivery systems are expected to play an
increasingly critical part in the present pharmaceutical landscape [5]. The market related
to drug delivery technology was projected to reach $ 1,504.7 billion USD by 2020 from $
1,048.1 billion in 2015 [6].
“Drug delivery describes the method and approach to delivering drugs or
pharmaceuticals and other xenobiotics to their site of action within an organism, with the
goal of achieving a therapeutic outcome”[1]. Currently, it is widely acknowledged that
the success of a therapeutic molecule depends strongly on the function and efficiency of
the drug delivery system. One of the strategies toward this goal has been the use of
biodegradable polymeric biomaterials for drug delivery [7]. Numerous literature reports
support that polymers have been used as a primary tool to control the drug release rate
from the formulations [7-10]. Biodegradable polymers represent an emerging field, and
significant advances have been made with regard to the development of biodegradable
polymeric materials for formulation and drug delivery applications because of several
advantages such as biodegradability, biocompatibility, versatility, and tunable drug
release [10]. Each drug delivery application is unique and demands materials with
specific physiochemical, biological, mechanical and degradation properties to meet the
requirements to provide effective therapy. As a result, a wide range of natural or synthetic
biodegradable polymers which can undergo hydrolytic or enzymatic degradation are
being investigated. The classification and examples of synthetic and natural
biodegradable polymers that have been widely used as biodegradable polymeric
biomaterials for drug delivery are given in Figure 1-1. These polymers undergo
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Polyesters

Poly(lactic acid), poly(glycolic acid),
Poly(lactic-co-glycolic acid)
poly(hydroxy butyrate), poly(εcaprolactone), poly(β-malic acid),
poly(dioxanones)

Polyanhydrides

Poly(sebacic acid), poly(adipic acid),
poly(terphthalic acid) and various
copolymers

Polyamides

Poly(imino carbonates), polyamino
acids

Phosphorousbased polymers

Polyphosphates, polyphosphonates,
polyphosphazenes

Others

Poly(cyano acrylates), polyurethanes,
polyortho esters, polydihydropyrans,
polyacetals

Polysacharides

dextran, chitosan, cyclodextrins
hyaluronic acid, alginate

Protein-based
polymers

albumin, collagen, gelatin

Synthetic
Polymers

Biodegradable
polymers

Natural
Polymers

Figure 1-1. The classification and examples of biodegradable polymers used in the
fabrication of biomaterials for drug delivery.
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biodegradation through cleavage of hydrolytically or enzymatically sensitive bonds in the
polymer chain leading to polymer erosion [11]. Among the various polymers, polyesters
and polysaccharides are the extensively investigated polymers for drug delivery
applications [12-22].
A significant emphasis was made on innovation for improving the delivery of
therapeutics by designing various drug delivery systems with various objectives which
include: i) treat different conditions located at different physiological locations; ii)
sustained drug release for reduction in dosage frequency and better patient compliance;
iii) minimize the drug concentration fluctuations in vivo and maintain constant drug
levels within therapeutic window; iv) localized drug delivery; v) enhanced delivery of
poorly water-soluble drugs; vi) targeted delivery of therapeutics to a cell- or tissue in a
specific manner; vii) transport of drugs across tight epithelial and endothelial barriers
(transcytosis); viii) delivery of large-molecule therapeutics to intracellular sites of action;
ix) co-delivery of multiple drugs or therapeutic modality for combination therapy; x)
visualization or diagnosis of diseased sites by drug delivery through combining
therapeutic agents with imaging modalities (theranostics) for real-time monitoring on the
in vivo efficacy of a drug; xi) reduced incidence of toxicity and side effects; xii) reducing
drug clearance in the path, and improving drug stability and bioavailability at the targets
[6-10, 23-27]. The other objective or advantage is that manufacturer's development of a
new delivery system of a product helps in extending the patent life [28].
Depending on the drug, application, and therapeutic route, each approach will be
unique and requires polymeric biomaterials with different physical, chemical and
biological properties. As a result, we see drug systems that come in all shapes and sizes:
macro-, micro-, and nano-dimensions. Table 1-1 shows a list of polymeric biomaterials
that have been investigated for drug delivery applications. Some of the inherent
properties or factors of polymeric biomaterials that can have an effect on their
biocompatibility, biodegradability and applicability are: i) physical factors (size and
shape), ii) chemical structure and composition of the material, iii) molecular weight
distribution, iv) morphology (microstructure, amorphous/crystallinity) of the material, v)
physicochemical conditions (ionic strength, pH), vi) hydrophilicity/hydrophobicity, vii)
water absorption, viii) solubility, ix) lubricity, x) surface energy, xi) degradation and
erosion mechanism, and xii) route of administration and site of action [6-10, 23-27, 29].
Although numerous efforts have been made to develop biomaterials for various
drug delivery applications, however, still there are unmet medical conditions which
require novel materials for delivering drugs to enhance the therapeutic efficacy and
patient compliance. The goal of this research was to develop biodegradable polymeric
biomaterials in different forms for loading and release of drugs to meet the unmet
medical needs.
One of such unmet needs is the efficient and affordable sustained release
injectable system for long-acting contraception. Currently, available long-acting
reversible contraceptives (LARCs) include intrauterine system (IUS), intrauterine device
(IUD), preformed implants, and injectable contraceptives. IUS, IUD, and preformed
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Table 1-1.

List of polymeric biomaterials for drug delivery.

Macro-systems
Implants
Oral delivery systems
(tablets/ capsules/ pumps)
In situ depot/implant
Hydrogels
Transdermal systems

Micro-systems
Microspheres
Microcapsules
Micelles
Microgels
Micro-osmotic pump
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Nano-systems
Liposomes
Niosomes
Nanospheres
Solid lipid nanoparticles
Nanostructured lipid carriers
Polymeric nanoparticles
Nanogels
Dendrimers

implants require a trained health care provider for implantation and removal, while the
injectable LARCs are simple to administer and do not need any surgical procedures,
therefore improving patient compliance. Greater than 40 million women worldwide use
injectable contraceptives, and their usage is high in developing nations suggesting their
need[30]. However, in spite of this popularity, rates of discontinuation are also high for
injectable LARCs due to non-adherence. The currently available injectable contraceptives
can provide contraception for 1-3 months, thus requiring women to return to their health
provider four to 12 times a year, which could be challenging in resource-limited settings
of developing nations and may cause discontinuation and prolonged return to fertility due
to users’ difficulty in complying with the multiple-injection schedule. Despite their
effectiveness, presently available LARCs do not address women’s needs or specifications
which may be due to either poor accessibility or high cost [31-34]. Hence there is a
necessity for developing affordable sustained release injectable LARCs that can provide
effective contraception for five months or longer after a single shot. This research was
focused on developing polyester-based injectable in situ forming depot (ISD) system
containing levonorgestrel (LNG) for contraceptive effect for five months or longer after
single shot that helps to reduce unintended pregnancies with high patient compliance and
low cost and thereby expand contraceptive access and options for women around the
globe.
Another unmet drug delivery approach is to enhance the permeability of drugs
across the ocular and blood-brain barriers and sustain the release as well. Although there
are several potent therapeutics for treating diseases related to eye and brain, their efficacy
is still hampered by the lack of an effective method of delivery [35, 36]. Typically, drugs
have short half-lives, do not or hardly cross the ocular or blood-brain barriers, and can
cause toxicity and side effects at high dose. Nanotechnology shows great promise for
transporting therapeutics across biological barriers, reducing drug clearance in the path,
and improving the bioavailability of drugs at the target sites [37-43]. Because of these
advantages, nanoparticles have become increasingly attractive for delivering drugs to the
eye and brain. Most widely investigated nanoparticles for drug delivery across biological
barriers (ocular/BBB) were made of polyesters (poly(D,L-glycolide-co-lactide) [44],
poly(lactic acid) [45-47], poly(ε-caprolactone)[48, 49]); poly(amino ester)[50], lipid
[liposomes [51-54], niosomes [55, 56], solid lipid [57, 58]); polyamines [59-61],
polyethyleneimine; polylysine and dendrimers [62-66]; polysaccharide (chitosan [67-70]
and hyaluronic acid [70]); polyalkylcyanoacrylate [71-74]; albumin [75-77], and
inorganic metals [78]. The polyester nanoparticles have shown to achieve sustained drug
release, but not reported to cross the biological barriers themselves without the need to be
conjugated or coated with some specific functional moieties [44-49]. Liposomes, solid
lipid nanoparticles, dendrimers, surfactant-coated PBCA nanoparticles were reported to
be able to cross the barrier; however, they cannot achieve sustained release and also can
have toxicity issues [57, 73, 79, 80]. The other nanoparticles have not been reported to be
able to either sustain drug release or cross the barrier without the need to be conjugated or
coated with some specific functional moieties. Therefore, to treat chronic eye and brain
diseases such as diabetic retinopathy (DR) and Alzheimer’s disease (AD), respectively,
there is unmet need of nanoparticles that can carry drugs across the ocular/blood-brain
barriers and show sustained release. This work was focused on developing biodegradable

5

polysaccharide-based nanoparticles poly(N-isopropyacrylamide-co-dextran-lactate-2hydroxyethyl methacrylate) (Poly(NIPAAm-co-DEXlactateHEMA) nanogels and β cyclodextrin-poly(β-amino ester) (CD-p-AE) nanoparticles, for sustained release of drugs
across ocular and BB barriers, respectively.
Dissertation Hypothesis and Specific Aims
The central hypothesis of this research was that different biodegradable polymeric
biomaterials based on polyesters or polysaccharides can act as effective delivery systems
for long-acting contraception for five months or longer, and drug delivery across ocular
and blood-brain barriers to treat chronic diseases such as diabetic retinopathy and
Alzheimer's disease in the eye and brain, respectively. The central hypothesis of the
dissertation has been sub-divided into three sub-hypotheses that drive the formulation of
the specific aims of the research:
Sub-hypothesis 1 was that injectable in situ depot system with balanced
biodegradable polymers and solvents can be developed as an effective delivery system
for sustained release of contraceptives such as levonorgestrel for five months or longer
after single SubQ injection through a 23G needle. This hypothesis was tested in Chapter
2. The specific aims were:
1. Design and conduct in vitro optimization and characterization of LNG-containing
ISD formulations.
2. Evaluate in vivo safety, pharmacokinetics and contraceptive effect of LNGcontaining ISD systems in rats.
Sub-hypothesis 2 was that subconjunctivally injectable nanogels composed of
DEXlactateHEMA and NIPAAm can cross the ocular barriers for potential delivery of
drugs such as insulin to treat diabetic retinopathy. This hypothesis was tested in Chapter
3. The specific aims were:
1. Prepare and characterize poly(NIPAAm-co-DEXlactateHEMA) nanogels.
2. Assess in vitro cytotoxicity, in vitro and ex vivo permeability of the
poly(NIPAAm-co-DEXlactateHEMA) nanogels.
Sub-hypothesis 3 was that the nanoparticles composed of β-cyclodextrin and
poly(β-amino ester) can enhance the solubility and BBB permeability of Hsp90 inhibitors
such as 17-AAG to treat Alzheimer's disease. This hypothesis was tested in Chapter 3.
The specific aims were:
1. Prepare and evaluate in vitro drug release of 7-AAG-loaded β-cyclodextrinpoly(β-amino ester) nanoparticles
2. Investigate in vivo efficacy of 17-AAG loaded β-cyclodextrin-poly(β-amino ester)
nanoparticles.
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Innovation
Polyester-based ISD system for long-acting contraception: Although, polyesterbased ISD systems have been one of the successful dosage forms as evidenced by several
market products (Eligard©, Atridox©). However, the major limitations associated with
these long-acting ISD systems are injectability and initial burst. Most of these ISD
systems are high viscous fluids and use thicker-gauge needle (such as 18G/19G) for
injection and this limits the patient compliance. Attempts made to lower the viscosity of
the fluids would usually result in an increase in the initial burst and may also lower the
ability for long term release. In this research, unique strategies were employed to improve
the injectability and initial burst profile, which include the use PLGA, PLA with different
biodegradable properties, and blends of these polyesters; use co-solvents of NMP, TEC,
benzyl benzoate (BB), and vary the polymer/solvent ratios. These strategies helped to
improve the injectability while lowering the initial burst. This resulted in a unique
injectable ISD system containing LNG for long-acting contraception, which can be
injected through a thinner-gauge needle (21-23G) and has an advantage of low cost, the
simplicity of manufacture, ease of application to the body, easy to hide, versatility and
complete biodegradability. The use of approved materials, such as PLA, PLGA, and
solvents used in this study can lessen the product approval time for future clinical trials.
This system stands as an attractive substitute to conventional preformed implants and
microparticles for parenteral sustained release applications.
Polysaccharide-based nanoparticles for drug delivery to the eye and brain
i) Poly(NIPAAm-co-DEXlactateHEMA) nanogels for ocular drug delivery:
Biodegradable and hydrophilic nature of the dextran polysaccharide were slightly
modified by grafting with hydrophobic hydrolytic degradable PLA and then
copolymerized with thermoresponsive poly-NIPAAm and acrylic acid using emulsion
photopolymerization to make nanogels that possess both thermoresponsive,
biodegradable and charge properties. The strategy behind designing poly(NIPAAm-coDEXlactateHEMA) based nanogel delivery system is to combine the merits of
biodegradable nature and nano-sized particulate properties. The degradation property of
the nanogels matrix can be used to modulate the release of encapsulated drugs for an
extended period of time and helps to avoid the removal of the empty device after
treatment. The nanogels will be thermoresponsive and exhibit a phase transition above
lower critical solution temperature (LCST~32°C) and becomes more hydrophobic
because of the strong hydrophobic interactions between the Poly-NIPAAm chains. The
thermoresponsive property of the nanogels makes them more hydrophobic at a
physiological temperature and this slows down the water penetration into the system and
thereby lowers the degradation rate and controls the drug release. Meanwhile, the nanosized dimensions impart the advantages of nanoparticulate systems such as transporting
drugs across biological barriers, improving drug stability and bioavailability at the targets
[18, 37, 81-86]. Additionally, incorporation of carboxylic functional groups through the
addition of acrylic acid imparts charge onto the nanoparticles which can assist in the
internalization of the nanoparticles and can be used for further conjugation with a ligand.
Hence, in an attempt to minimize the constraints and disadvantages of conventional
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ocular drug delivery systems, a contemporary poly(NIPAAm-co-DEXlactateHEMA)
nanogels based sustained drug delivery systems could be very promising.
ii) β -cyclodextrin-poly(β-amino ester) (CD-p-AE) nanoparticles for brain
delivery: This polysaccharide-based biomaterial (β-cyclodextrin (CD)-based
nanoparticles) was formed by combining poly(β-amino ester), which contains ester bond
and amine units with acrylated β-CD. CD-p-AE nanoparticles are cross-linked,
hydrolytically degradable, and catatonically charged, and contains β-CD units.
Incorporation of β-cyclodextrin (β-CD) into the nanoparticle structure facilitates the
loading of hydrophobic drugs and thereby expected to improve the solubility of the
hydrophobic drugs. The biodegradable property of poly(β-amino ester) can be tuned to
control the release rate. Introducing cationic charge onto the nanoparticles was
considered as an effective approach to enhance the permeability across BBB [87, 88].
Dissertation Outline
Different types of biodegradable polymeric biomaterials based on polyesters or
polysaccharides were developed for loading and release of drugs to meet the unmet
medical needs. Basic preliminary preclinical proof of concept studies were also
conducted to investigate the potential applicability of the developed biomaterials in their
designed applications.
Chapter 2 tested the sub-hypothesis 1 that injectable in situ depot system with
balanced biodegradable polymers and solvents can be developed as an effective delivery
system for sustained release of contraceptives such as levonorgestrel for five months or
longer after single SubQ injection through a 23G needle. The background section of this
chapters covers a comprehensive literature review on injectable long-acting
contraceptives. A series of ISD formulations were designed by employing unique
strategies which include the use PLGA, PLA with different biodegradable properties, and
blends of these polyesters, use solvent mixtures of NMP, TEC, BB, and vary the
polymer/solvent ratios, and various drug loadings. The formulations are evaluated for
viscosity, initial burst, in vitro and in vivo long-term release. The effect of different
formulation parameters such as polymer concentration, polymer inherent viscosity, drug
loading and solvent combination on the viscosity, injectability, in vitro release, in vivo
initial burst of drug from ISD systems was evaluated. By tailoring the formulations
parameters, ISD system with suitable injectability and initial burst was obtained. Future
directions evolving from this work were suggested at the end of the section.
Chapter 3 tested the objective that the polysaccharide-based nanoparticles with
the tailored balance of hydrophilicity/hydrophobicity, and charge content can be used to
assist the drugs to cross biological barriers such as ocular and blood-brain barriers and
sustain the release as well. Depending on the need of the therapeutic application, two
types of polysaccharide-based nanoparticles were investigated for their drug delivery
feasibility which includes: (a) poly(NIPAAm-co-DEXlactateHEMA) nanogels for the
potential delivery of hydrophilic peptide (insulin) across ocular barriers for the treatment
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of Diabetic Retinopathy. (b) β -cyclodextrin-poly(β-amino ester) nanoparticles as
potential drug carriers to enhance the solubility and BBB permeability of 17-AAG to
treat Alzheimer’s disease. Future directions pertaining to this work were recommended at
the end of the chapter.
Chapter 4 describes the conclusions of the thesis, identifying the end results of
this work in relation to the overall goal of the thesis.
In the Appendix (Tables A-1 through A-5, and Figures A-1 through A-5),
complete details of the study testing the impact of ionizable modifiers 2(Dimethylamino)ethyl methacrylate (DMAEMA) on mechanical, thermal and hydration
properties of the Poly(HEMA)-based hydrogels was given. The addition of ionic species
such as DMAEMA at low mol% (5 mol%) into poly(HEMA) hydrogels has significantly
altered the mechanical, thermal and hydration properties of the hydrogels. Hydration
properties can be altered by the hydrophobicity/ hydrophilicity & hydrogen bond forming
ability of the added cationic modifiers.
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CHAPTER 2.

INJECTABLE IN SITU FORMING DEPOT SYSTEMS FOR
LONG-ACTING CONTRACEPTION*
Background

Long-acting Reversible Contraceptives
Birth control is still a major concern worldwide. The most common approach to
controlling fertility to prevent unintended pregnancy is oral administration of birth
control pills. However, this method suffers from limitations such as daily ingestion of
pills, needs continuous user attention, and daily variations in blood concentrations of the
drug leading to unwanted side effects [89]. Alternatively, a long-term, systemic,
controlled delivery of contraceptive drugs is beneficial, and is gaining attention in
preventing pregnancy, as well as in postmenopausal therapy because of the advantages
such as: convenient and don't require daily action, provides continuity of drug supply,
avoids the variability in absorption and metabolism associated with oral therapy,
minimize the fluctuations in blood concentration thereby lowering the side effects, and
cost effective on overall usage [90, 91]. Further, there is less chance of over/under-dosing
with the sustained release dosage form regimen, and patient compliance with a multi-day,
-week, or - month sustained release regimen is superior to frequent oral dosing.
Long-acting reversible contraceptives (LARCs) are birth control methods that
provide contraception over a prolonged period (months to years) without the need of user
activity and are proven to be most effective in lowering the rates of unintended
pregnancies [92]. There is a wide gap in terms of therapeutic duration among the
currently available LARCs on the market. LARCs based on preformed implants that are
available on the market such as Implanon®, Nexplanaon®, Norplant®, Implanon® and
Sino-Implant® offer extended and effective contraception for up to 3-7 years. However,
such long duration is undesirable for some women, and these preformed implants are not
-------------------* Parts of this chapter were adapted or reprinted with permission from
(i) “Pharmaceutical research. Long-acting injectable hormonal dosage forms for
contraception. 32(7). 2015. p. 2180-2191. Wu, L., Janagam, D. R., Mandrell, T.D.,
Johnson, J.R., Lowe, T.L. © Springer Science + Business Media New York 2015. With
permission of Springer.” (ii) “Development and validation of sensitive LC/MS/MS
method for quantitative bioanalysis of levonorgestrel in rat plasma and application to
pharmacokinetics study. 1003. Ananthula, S., Janagam, D. R., Jamalapuram, S., Johnson,
J. R., Mandrell, T. D., Lowe, T. L. Journal of Chromatography B. p. 47-53. © 2015
Elsevier B.V., with permission from Elsevier.” (iii) “Janagam, D. R., Wang, L.,
Ananthula, S., Johnson, J. R., Lowe, T. L. (2016). An accelerated release study to
evaluate long-acting contraceptive levonorgestrel-containing in situ forming depot
systems. Pharmaceutics, 8(3), 28. © 2016 by the authors; licensee MDPI.”
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biodegradable, so they need to be removed by an experienced clinician at the end of the
treatment [93]. On the other hand, the injectable LARCs (Cyclofem®, Lunelle® and
Depo-Provera®), which are aqueous suspensions of drug microcrystals, can provide
contraception for 1-3 months and this short term contraception can increase flexibility to
women [94]. Injectable LARCs are increasingly used for preventing unintended
pregnancies as they are reversible, can be used on-demand, easy to use and do not require
surgical implantation and removal. They have shown 96% effectiveness with a typical
use [94]. More than 40 million women worldwide use injectable contraceptives [30].
However, because of the short reinjection intervals, the current choice of injectable
contraceptives require women to return to their health-care provider for at least four to 12
times a year [31]. This frequent clinic visits could result in discontinuation due to users’
difficulty in complying with the multiple injection schedules, especially in resourcelimited areas in developing nations. In spite of their high popularity, typical use brings
about much lower adequacy. In substantial part, this difference reflects challenges in
adherence to the preventive regimen and low rates for long-term continuation.
Additionally, presently available long-acting contraceptives do not address women’s
needs or specifications which may be due to either low compliance, poor accessibility or
high cost [31-34]. Therefore, there is still an unmet need for injectable contraceptives
which can provide contraception for five months and up to one year after a single
injection so that better adherence and continuation rates can be achieved [31, 34].
Including this new alternative into the current contraceptive choices will offer great
flexibility, expand contraceptive prevalence, and decrease the burden of patient load on
small clinical facilities and community-based programs [31].
Injectable Long-acting Reversible Contraceptives
In recognition of the potential advantages, significant efforts have been made in
the past decades to develop injectable LARC dosage forms. Among those, the most
common injectable dosage forms that were explored to achieve control release of
contraceptive steroids are drug microcrystal suspensions, drug-loaded microsphere
suspensions, and in situ forming depot (ISD) systems [95-98]. Each dosage form has its
advantages and limitations which are summarized in Figure 2-1. However, only drug
microcrystal suspension based dosage forms (Depo-Provera® and Depo-subQ Provera
104®) are commercially available on the market for 3-month contraceptive protection. So
far no microsphere or ISD based product has been approved for contraception.
Drug microcrystals have advantages of low cost due to fewer process steps and
materials involved, and using water as an administration vehicle, but needs reconstitution
and are difficult to achieve sustained release of APIs for more than three months.
Microspheres have the advantages of using water as a vehicle, and capability of achieving
more than the three-month release of APIs due to the retarding effect of the polymeric
matrix [99-109]. However, more often the microencapsulation processes involve the use
of high temperature and organic solvents which may affect the stability of the
therapeutics, and some toxic organic solvents might be trapped inside. Manufacturing can
be difficult to produce on a large scale and is generally costly for well-defined
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Steroidal Progestogens

•

I Generation: progesterone, norethisterone,
ethynodiol diacetate, norethynodrel, lynestrenol,
medroxyprogesteroneacetate, and megestrol acetate
II Generation: levonorgestrel and norgestrel
III Generation: desogestrel, gestodene, norgestimate,
and etonorgestrel
IV Generation: drospirenone, and dienogest

Long-acting Injectable Hormonal Contraceptive Dosage Froms

Need
reconstitution

Low cost and
simple to
manufacture

Drug
Microcrystal
Suspensions
Commercially available‘Depo Provera®
Contraceptive Injection’ and
‘depo-subQ provera 104®’ for
3 month contraception

Advantages
Disadvantages
Commercial
availability

Can achieve sustained release
for more than 3 months

Water as
vehicle

Initial
burst

Need
reconstitution
Broad
particle size
distribution

Organic solvents
as vehicles

Can achieve sustained release
for more than 3 months
Initial
burst

No need
reconstitution

Drug-loaded
Microsphere
Suspensions

In situ Forming
Depot Systems

High cost to
manufacture

Not available
commercially

Low cost and
relatively simple to
manufacture

Residues of organic
solvents used in
fabrication could be toxic

Microsphere
migration can
be a concern

Formed depots in vivo can
be irregular in dimensions

Not available
commercially

Subcutaneous (SubQ )

Difficult to achieve sustained
release for more than 3 months

Intramuscular (IM)

Water as
vehicle

Injection

Figure 2-1. Flow chart of the advantages, disadvantages, and commercial
availability of injectable LARCs.
Notes: Drug microcrystal suspensions, drug-loaded microsphere suspensions and in situ
forming depot systems (ISD) are the widely studied injectable hormonal long-acting
reversible contraceptive (LARC) dosage forms.
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microspheres. Their storage often presents problems, and also need to be reconstituted at
the time of injection. Because of the particle nature, microspheres fail to form a preferred
continuous and nearly homogeneous, monolithic drug depot matrix. The possibility of
microsphere migration from the site of injection might also be a concern [96]. In situ
forming depots have advantages of simplicity of manufacture, no need for reconstitution,
and versatility. However, they have disadvantages of using organic solvents as vehicles,
forming depots in vivo with non-precise shapes and sizes, and requiring drugs with broad
therapeutic windows [97, 110].
Drug Microcrystal Suspension
The components in a drug microcrystal suspension dosage form are only API
microcrystals and vehicle for injection (water). Thus, this dosage form is simple, easy and
low cost to be manufactured. The microcrystal suspension dosage form can achieve
longer therapeutic effects than the API alone (non-crystal form) due to the slow
dissolution of the API from the drug crystals into the body fluid. When prodrugs are used
to form the drug microcrystals, the combination of dissolution of the prodrugs from the
crystals and subsequent hydrolysis/cleavage of the prodrugs into active entities controls
the release of the API into the body fluid. Considerable efforts have been made to
develop injectable suspensions of contraceptive steroidal progestogen microcrystals
containing either the active drug or prodrug obtained via esterification of the hydroxyl
groups of the active drug. Depending on the contraceptive API types and microcrystal
sizes, up to three-month contraception can be achieved [111, 112]. For examples,
medroxyprogesterone acetate, the most well-known steroid drug, has been formulated
into injectable microcrystals for three-month contraceptive protection. It has been
marketed as Depo-Provera® and Depo-subQ Provera 104® administrated by
intramuscular and subcutaneous injections, respectively. Norethisterone enanthate, an
ester of norethisterone (NET), has been developed as injectable microcrystals for twomonth contraception [112, 113]. Levonorgestrel has been formulated into prodrugs
levonorgestrel cyclobutylcarboxylate and levonorgestrel butanoate (LNG-B) which have
lower water solubility than LNG and have been studied in rats, rhesus and cynomolgus
monkeys, and women [98]. Both the prodrugs could suppress ovulation for 5-6 months in
women at a single dose of 50 mg in the form of microcrystal suspensions. LNG-B
demonstrated better performance in terms of overall toxicity, pharmacokinetic profiles
and pharmacodynamics effects in phase I clinical trials [98, 114]. Currently, several
companies are developing LNG-B crystal suspensions for long-acting contraceptives
[115, 116]. For example, CONRAD is trying to formulate LNG-B for preclinical and
clinical studies aiming at contraception for 4 months after a single injection [116].
Polymer-based Drug Delivery Systems
As discussed in the introduction (chapter 1), a significant emphasis was made in
the recent years on innovation for improving the delivery of a drug by designing various
polymer-based drug delivery systems. Polyester-based drug delivery systems have been
extensively investigated for the long-term controlled delivery of contraceptive steroids
[31]. Polyesters are the earliest and most widely investigated class of synthetic
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biodegradable polymers for drug delivery applications and comprehensively reviewed
[12-17, 117]. These are thermoplastic polymers with hydrolytically sensitive aliphatic
ester linkages in the backbone. Poly(ε-caprolactone)(PCL) , poly(lactic acid)(PLA),
poly(glycolic acid)(PGA) and their copolymers poly(lactic acid-co-glycolic acid)(PLGA)
are some of the well-defined biomaterials with regards to design and performance [7].
Because of their adjustable physicochemical properties such as swelling and
biodegradation kinetics, molecular interaction potential with embedded therapeutics, they
offered several possibilities in the design of new drug delivery systems [118-121]. The
common synthetic scheme to make poly(esters) is by ring-opening polymerization from
the corresponding cyclic lactone monomers (shown in Figure 2-2). Polyesters
predominantly undergo bulk erosion where the polymeric matrices degrade over the
entire cross-section and show non-linear erosion kinetics [122]. Several reviews have
been published on their degradation mechanisms [10, 122-127]. The major advantage of
biodegradable polyester based drug delivery systems is that they provide a continuous
delivery of the drug via diffusion or by polymer erosion to surrounding tissues,
minimizing the variations in blood concentrations of the drug and offers maximum
therapeutic efficiency at a minimum drug dose [128]. Most extensively studied injectable
polymeric systems for long-term release of contraceptive include i) Polymer-based drug
microspheres and ii) Injectable in situ forming depot (ISD) systems.
Drug microsphere suspensions
Microspheres made of polymers have the advantage of using water as a vehicle to
form suspensions for long term (over months) sustained release of different drugs [129134]. Although no microsphere-based product was approved for contraception, longacting leuprolide injections are currently sold in the forms of both microspheres
(LUPRON DEPOT®). Starting in the late 70s, injectable microsphere contraceptive
systems have been developed for long-term contraception, pioneered by Beck and coworkers using PLA (MW 90,000 Da), and/or PLGA (96:4, 92:8, 87:13 and 74:26; MW
about 40,000 Da) to encapsulate NET via oil-in-water (o/w) emulsion/solvent
evaporation process [135]. NET microcrystals were successfully encapsulated into PLA
and PLGA microspheres by o/w emulsion and solvent evaporation technique. Afterwards,
PLGA became the most popular polymer for fabricating microspheres to encapsulate
contraceptive APIs including LNG, gestodene and ethinyl estradiol using o/w or w/o/w
emulsion/solvent evaporation technique [99-102, 104, 106, 136, 137]. PCL is a second
popular polymer for fabricating microspheres to encapsulate contraceptive APIs
including LNG, ethinylestradiol, norgestrel, progesterone and β-estradiol using o/w or
w/o/w emulsion/solvent evaporation technique [138-143]. The quality of microspheres
depended on emulsion types, solvents, temperature, and surfactants/stabilizers. Through
extensive investigation over past several decades, it has been acknowledged that many
factors of microspheres such as their chemical and physical structure (composition,
chirality and crosslinking density), drug loading and distribution, physical property (size,
shape, size distribution, and molecular weight), and fabrication and sterilization processes
significantly affects drug release profiles including release rate, duration of action and
initial burst, and microsphere overall performance in vitro, in animals, and in humans
[99, 102, 106, 135, 136, 141, 144-146].
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Figure 2-2. Ring opening polymerization of selected cyclic lactones to give the
corresponding polyester polymers.
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The composition of the microspheres controls the biodegradation rate of the
microspheres, and in turn, affects the contraceptive API release profiles from the
microspheres. For example, as the hydrolytic degradation rate of the polymers PGA, PLA
and PCL increased in the order of PGA > PLA > > PCL, the microspheres made of the
triblock polymers consisting these three polymer blocks released LNG at a rate increasing
with increasing the amount of the three polymer blocks in the order of PGA > PLA > >
PCL [147]. PCL possessed a good permeability for steroidal drugs but undergoes slow
biodegradation, resulting in the release of LNG from the PCL matrix to be controlled by
diffusion [147-149]. On the other hand, PLA and PGA had a lower permeability to
steroidal drugs but undergo homogeneous erosion, resulting in the release of LNG from
the PCL matrix to be controlled mainly by erosion [147, 150]. The chirality of polymers,
crosslinking density and drug loading of microspheres also play important roles in
controlling contraceptive API release profiles. It was reported that microspheres
composed of D, L-lactide caused more uniform release rate and less initial burst for
progesterone and β-estradiol than those composed of L-lactide [141]. Microspheres with
a higher amount of unencapsulated drug present on the surface would show higher initial
burst [99, 136, 138]. When fabricated microspheres were not uniform, initial burst release
was observed in the in vitro, in vivo and clinical evaluations of the microspheres for
contraception [100, 101, 106, 140, 143, 151, 152]. Even though this initial burst release
might be not very harmful to the users, it might cause API concentration beyond the
therapeutic window and reduce the amount of API available for contraception and the
duration of release [153-155]. Among the methods studied for minimizing the initial
burst release, coating or core/shell structure is one of the most straightforward strategies
[156, 157]. This additional layer of the shell could be created by a dipping, mixing or
emulsion process [132]. It was reported that simply modifying the prototype NET-loaded
PLGA microspheres by adding a polymer/chloroform solution into the suspension of the
prototype microspheres in alcohol aqueous solution significantly reduced the initial burst
and extended the release duration of NET for 40-50 days longer than the prototype
microspheres with a similar size range and NET loading [158]. The reduced initial burst
and extended release duration of NET from the modified microspheres was because the
polymer coating layer added an additional barrier for the drug to diffuse/penetrate
through.
Microsphere size is effective means for modulating contraceptive API release
kinetics [99, 135, 146] and as well as microsphere injectability [99]. Primarily, the size of
microspheres determines the surface area to volume ratio, and thus directs the extent of
surface available for releasing the contraceptive APIs through diffusion. Smaller
microspheres have higher surface area to volume ratio and less diffusion path length for
the APIs, and subsequently, result in quicker API release rate and shorter release
duration. This effect was demonstrated in a study where the release rate of NET and
progesterone increased with decreased size of PLGA [106] and chitosan [159]
microspheres, respectively. The size of microspheres inversely affects the efficiency of
the injectability: the bigger the size is, the more difficult the microspheres can be injected
through clinically used needles. The optimal size range for yield and efficiency of
injection is between 20 and 90 μm [99]. The mean size of microspheres can be controlled
by the concentration of polymers used for fabricating the microspheres. The higher the
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polymer concentration is, the higher the viscosity of the organic phase in emulsion
droplets is, and thus the bigger the mean size is and the more contraceptive APIs are
encapsulated into the microspheres [138, 142]. The molecular weight (MW) of the
polymers used for fabricating microspheres is another important factor affecting
contraceptive API release. The higher is the MW, the slower the polymers degrade and
the longer the APIs are released [147]. For example, microspheres composed of PLGA
with lower MW (12,000 Da) led to 35 day release of ethinyl estradiol, while PLGA with
higher MW (70,000 Da) resulted in 105 day release of ethinyl estradiol [101, 102].
Female baboons, rats, rabbits and mice have been used as animal models to
evaluate serum API levels and contraceptive effect of microspheres after single
intramuscular injection. Beck and co-workers evaluated their NET-loaded microspheres
on female baboons. Their PLA microspheres (10 – 240 μm) could sustain the release of
NET in female baboons for about 180 days, and the ovulation was inhibited through the
6-month treatment period for all three dose levels tested: 75, 50, 25 mg of NET
equivalent [135]. In vivo evaluation of their NET-loaded PLGA microspheres on baboons
showed that the NET release duration was dependent on the particle size and the LA to
GA ratios of PLGA polymers, and the release of NET presented a two-phase pattern
[106]. Beck and co-workers also designed LNG–loaded PLGA(87:13) microspheres and
found that the microspheres released LNG in baboons for up to 6 months with 3-6 month
ovarian function suppression, depending on the dose level [99]. A biphasic release pattern
was seen in LNG release from the microspheres in a similar way as the NET-loaded
microsphere systems. In rat studies, LNG- or LNG and ethinylestradiol-loaded PLGA
and PCL microspheres were found to maintain constant LNG blood level at 0.2-2 ng/mL
for 15 weeks to 5 months [100, 101, 143]. In rabbit studies, it was found that
progesterone was maintained a blood level of 1-2 ng/mL for about 5 months [159], 5
months [160] and 20 days [161] by microspheres made of chitosan, casein and serum
albumin, respectively [159, 160]; and LNG was maintained a blood level of 0.1-0.5
ng/mL for 28 days by microspheres made of casein [104]. In mouse study, LNG- or LNG
and estradiol-loaded poly(ethylene glycol-b-poly(D,L-lactide)) [162], gelatin [163] or
poly(3-hydroxy butyrate) [164] microspheres showed 6 month, 50 day, and 1-3 month
contraceptive effect, respectively. Phases I, II and II clinical trials have been conducted
for the NET-loaded PLA and PLGA microspheres [107-109, 152, 165]. The phase I
clinical trials [165] of these NET-loaded PLA microspheres (size range: 60-240 μm, or
90-212 μm) in 63 women at three centers showed that the release of NET lasted for 6
months after one intramuscular injection, while the serum levels of NET varied in
proportion to the dose injected and the suppression of ovarian function was also highly
dose dependent. Suppression of ovulation for 6 months could be achieved for doses
ranging from 1.33 to 3.45 mg of NET/kg for NET-loaded PLA microspheres with size
60-240 μm [106]. In order to avoid the build-up of PLA at the injection sites due to its
slow degradation, Beck and coworkers designed the second generation NET
microspheres using PLGA [152]. NET-loaded PLGA microspheres (63-90 μm or 90-106
μm) fabricated from PLGA with 86%-88% LA and 14%-12% GA were clinically tested
in women. Microspheres with sizes of 63-90 μm could suppress ovarian function for 3-4
months at dose of 75 mg or 100 mg of NET, while the 90-106 μm microspheres
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suppressed ovarian cyclicity for an average of 22 weeks with the shortest one of 14
weeks and longest one of 26 weeks at similar dose levels [166, 167].
It would be reasonable to assume that well-defined polyester microspheres with
core/shell structures and narrow particle size distribution could be fabricated to
encapsulate the contraceptive APIs for reduced initial burst release and extended
contraception period, although no attempts have been made in this direction.
Injectable in situ forming depot systems
The ability to inject a combination of drug and a biodegradable polymer in liquid
form to a localized site and have the biodegradable polymer form a depot matrix
entrapping the drug has a number of advantages. Some of these advantages include 100%
loading efficiency, easy administration, few processing steps and relatively simple
manufacturing process, potential for low cost, no need for reconstitution, prolonged
delivery, completely biodegradable, and no need for surgical removal at the end of the
treatment [168-172]. Because of these advantages, ISD systems have emerged as an
attractive alternative to the preformed implants and microparticles in the field of
parenteral sustained release formulations [170]. Other common terms that are used in
literature for defining these systems include in situ forming implants or in situ gelling
systems.
ISD formulations are liquids before injection and transform in the body to a gel or
solid depot at the site of injection. Various mechanisms can be used to trigger this
solidification process which includes phase separation induced by pH [173-175], solvent
exchange [176, 177] or temperature [178], and physical or chemical crosslinking [179],
in situ solidifying organogels [180]. However, the phase separation based ISD systems
involving solvent exchange have attracted considerable attention from the pharmaceutical
industry because of its advantages compared to its counterparts, as they do not depend on
critical temperature (for temperature-sensitive ISD systems), change in pH (for pHsensitive ISD systems), presence of ions (for charge-sensitive ISD systems) for the phase
separation to form a depot [181]. Moreover, commercially available raw materials can be
used for the development of these formulations (30, 99,100).
Solvent exchange based ISD formulation is a solution or suspension containing
drug and biodegradable polymers dissolved or dispersed in pharmaceutically acceptable
water-miscible organic solvents, respectively [31, 170, 171, 182-184]. Upon injection
into the tissue, this ISD system forms a solid depot of polymeric matrix at the injection
site because of the phase separation (in situ polymer precipitation) by solvent exchange,
as the water-miscible organic solvent diffuses into the surrounding aqueous medium
while the aqueous body fluid penetrates into the organic phase [170, 181, 184, 185]. The
drug entrapped in the depot is then slowly released out into the surrounding body fluid
due to the degradation of the polymers and diffusion of the drug, goes into the systemic
circulation and then reaches target sites. The biodegradable polymers will eventually
completely degrade at the injection site over a period, and be cleared out from the body.
Because of the complete biodegradation, the ISD system does not need any surgical
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removal at the end of the treatment. This phenomenon of phase transition is explained by
several other terms in the literature which include: “solvent induced phase inversion
[181], in situ polymer precipitation [186, 187], solvent exchange [188], solvent/nonsolvent exchange [189], solvent removal [190], solvent-removal precipitation [186], nonsolvent induced phase separation [191], and liquid–liquid phase separation [192]”.
Table 2-1 lists out the common solvents/plasticizers used in ISD formulations. The ISD
technology has been developed for safe and efficient delivery of drugs in vivo for a
various period of weeks to months [31, 170, 183, 193], to treat cancer, infections,
hormonal disorders, pain, immunomodulation, neurological disorders and metabolic
disorders [170, 194]. Several ISD systems are currently available as marketed products
such as Eligard® and Atridox® [170]. However, as mentioned earlier no ISD product is
available for contraception.
Dunn et al. pioneered this concept in 1990 by employing biodegradable polyesters
such as PLGA and PLA in water-miscible organic solvents such as NMP and DMSO
(95,99,101). The concept of in situ depot formation was soon adopted to develop longacting injectable contraceptives (102,103). Dr. Shukla’s and Dr. Johnson’s group from
the University of Tennessee Health Science Center (UTHSC) has been actively involved
in the development of ISD formulations for sustained release of contraceptive APIs such
as LNG and ethinylestradiol for long–acting contraception [195-197].
The studies were started with Precirol ATO 5 as a depot matrix, Labrafil 1944 CS
as a solvent/plasticizer and LNG as an API for contraceptive [198]. The injectability of
such systems was strongly dependent on the Precirol concentration and the size of the
needle used. Lower maximum force for injection was observed for lower Precirol
concentrations and larger gauge needles. The same trend was observed for the ISD
systems developed from PLGA/PLA [199]. In vitro release kinetics demonstrated that the
release rate of LNG from the resulting depots was affected by the Precirol concentrations
used in the formulation and the LNG crystal sizes [198]. Moreover, zero order release of
LNG was achieved up to 30 days in vitro for formulations containing 10 wt% Precirol,
and 2 wt% LNG with drug crystal size of 6 μm [198]. In vivo investigation demonstrated
that the durations of suppression on rat estrous cycles after single subcutaneous (SubQ)
injection were significantly influenced by the LNG loading in the 10 wt% Precirol
formulation with 20, 27 and 41 consecutive days for rats receiving 1 mL of the
formulations containing 0.25, 0.50 and 2.00 wt% LNG loading, respectively [198]. These
short contraception durations might be attributed to the fast degradation of the formed
depots which disappeared in the injection sites around 35 to 45 days post-injection [198].
In order to achieve longer contraception protection after a single injection,
polyesters such as PLGA (various ratios of LA to GA) and PLA with a different intrinsic
viscosity (molecular weight) were evaluated as the depot matrix [199, 200]. The effects
of varying drug loading, polymer concentration, polymer inherent viscosity and
copolymer composition on in vitro release of LNG were studied. Increasing the LNG
loading from 1 to 8% w/w increased the cumulative amount of LNG released in vitro on
day 30 from 1.195 to 3.4045 mg per gram of formulation made from PLGA50:50. The
cumulative amount of LNG released on day 30 decreased from 2.06 to 0.628 mg per
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Table 2-1.

Common solvents (plasticizers) and their key features.

Solvent

Structure

Viscosity (cP @
25°C)
1.65 [157]

Water miscibility
(mg/mL)
1000 [201]

1.99 [155]

miscible [202]

Benzyl benzoate
(BB)

8.292 [203]

practically
insoluble [201]

Triethylcitrate
(TEC)

35.2 [156]

57 [175]

5.05 [204]

35 [163]

8–18 [160]

miscible [202]

17 [164]

64 [201]

0.45 [169]

82.3 [205]

CH3

N- methyl-2pyrrolidone (NMP)

N

O

O

Demthyl sulfoxide
(DMSO)

S
H3C

CH3

OH

Benzyl alcohol
(BA)

Glycofurol

Triacetin

O

Ethyl Acetate (EA)
H3C

CH3
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gram of formulation when PLGA50:50 concentration increased from 20 to 80% w/w.
Increasing the PLGA50:50 inherent viscosity from 0.15 to 1.07 dL·g-1 decreased the
cumulative amount of drug released on day 30 from 14.17 to 0.935 mg per gram of
formulation. In vitro drug release rate was found to decrease with increasing proportion
of lactide in lactide-glycolide copolymers. Drug release from the system was due to a
combination of diffusion and polymer degradation. ISD systems prepared from
PLGA50:50/NMP (33:67 w/w) with different LNG contents were further investigated in
vivo on Sprague-Dawley albino female rats for contraceptive effect after SubQ injection.
The duration of in vivo activity of the LNG released from the in situ formed depots was
evaluated by monitoring the estrous cycles of the female rats. The sizes of the in situ
formed depots decreased with time, and the depots disappeared completely from the
injection site between day 45 and 70 after injection. Formulations containing 2 and 4%
w/w LNG suppressed the rat normal estrous cycles for 65.5 and 103.5± 8.5 days at a dose
level of 1 ml·kg-1, respectively [199, 200]. The formulation containing 2 wt% of LNG in
32.67 wt% PLGA (inherent viscosity of 0.59) and 65.34 w% NMP was further evaluated
on Japanese quails with Depo-Provera® as a control [206]. The dose level was 40 mg API
equivalent per kg and the injection site was the left pectoral musculature. Quails treated
with the LNG-containing ISD system stopped laying eggs for 67 ± 4.1 days, while
resume ovarian recrudescence (evidenced by egg laying) on day 59 after treatment (one
bird; range, 59-70 days). For the birds treated with Depo-Provera®, two of seven birds
stopped egg-laying for 19 and 49 days, respectively, while for the other five birds, the
average duration of not egg-laying was 5.8 ± 2.3 days (range, 2- 8 days). The
contraceptive duration observed on these quail was consistent with that observed in rats
for the same formulation [199, 206]. The formulation containing 4 wt% LNG was further
evaluated at the dose level of 40 mg/kg body weight (equivalent to 1 mL·kg-1 body
weight) on Feline Queens via subcutaneous injection [207]. Blood and fecal samples
were collected weekly for the first 5 weeks to build the baselines. Initial treatment
injections were given at the beginning of week 6, and all queens received a second
injection with the same dosage at the beginning of week 16 (68 days after initial
treatment). The results demonstrated that the follicular activity and estrogen secretion in
the domestic cats could be suppressed for at least 36 weeks after the two injections of the
formulation [207].
Based on the above in vivo evaluations, cottontop tamarins, a small new world
nonhuman primate, were used to further evaluate the contraceptive effect of the PLGAbased formulations [208]. The formulation was slightly modified to contain 24 wt%
PLGA50:50 as the depot matrix and 72 wt% NMP/triethyl citrate (TEC) (90:10, v:v) as
the solvent, and denoted as F1. The F1 formulation was subcutaneously injected into
cottontop tamarins at an LNG dose level of 45.53 ± 2.52 mg/kg. The normal ovarian
cycle of the cottontop tamarin was suppressed for 102.0±20.9 days indicated by the fecal
PdG and E1C concentrations. In order to extend the suppression duration, the type and
intrinsic viscosity of the polyester used in the formulation were adjusted to increase the
viscosity of the formulation and slow the degradation of the in situ formed depots.
Another two formulations were obtained: formulation F2 containing 4 wt% LNG, 8 wt%
PLGA50:50, 8wt% PLGA85:15, 8wt% PLA and 72wt% NMP/TEC(90:10); and
formulation F3 contained 4 wt% LNG, 4.8 wt% PLGA50:50, 19.2 wt% PLA and 72wt%
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NMP/TEC (9:1). After subcutaneously injected at LNG dose levels of 46.60 ± 3.30 (for
F2) and 48.08 ±3.39 (for F3) mg/kg, the F2 and F3 formulations suppressed the normal
ovarian cycles of cottontop tamarins for 120.4 ±46.0 days and 134.8 ±32.8 days,
respectively. With the further modification of the formulation F3 including increasing
LNG content from 4 wt% to 6 wt%, reducing the weight percentage of the mixture
solvent NMP/TEC (9:1) from 72 wt% to 70 wt%, a formulation F4 was obtained. After
subcutaneously injected at the LNG dose levels of 71.89 ±8.90 mg/kg, the F4 formulation
extended the suppression of the normal ovarian cycles of cottontop tamarins to 198.8
±70.3 days. However, both the F3 and F4 formulations did show some initial burst. The
initial burst release could reduce the API available for the contraceptive, in other words,
the release duration could be longer if the initial burst release could be eliminated.
Additionally, the polymeric solution formulations had problems with relatively broad
duration of the contraception. It has been documented that the initial burst release and/or
duration of the API release could be adjusted by varying the polymer/solvent ratio, using
a blend of polymers with different end groups, molecular weight, and degradation
properties, and adjusting the hydrophobicity/hydrophilicity of the solvents [194, 209]. It
has been reported that zero-order release of LNG was achieved in vitro from ISD systems
containing PLA (MW 11,000) and a mixture of benzyl benzoate and benzyl alcohol for 3
months with almost no initial burst and less than 40% of loaded LNG released out after 3
months [210]. Moreover, in order to minimize the initial burst release, the API could also
be encapsulated into microparticles and then dispersed/suspended in the ISD systems
[209, 211]. It has been demonstrated that by encapsulating naltrexone base in PLA
microparticles prepared via melting/fusion/grounding process, the in situ forming
PLGA/NMP depot systems dispersed with these naltrexone/PLA microparticles showed
significantly reduced initial burst compared with the PLGA/NMP systems loaded with
naltrexone base [209].
Summary
Overall, the previous efforts to develop polymer-based injectable LARCs have
generated a lot of positive data supporting the feasibility of long-acting injectable
contraceptives for more than 3 months’ contraceptive protection after one intramuscular
or subcutaneous injection. However, not many reached the market, and there are not
many efforts to continue such investigations with a targeting goal of commercializing the
products for contraception. Therefore, there is still an unmet need for affordable
injectable LARCs which can provide contraception for more than three months to one
year after a single shot so that better adherence and continuation rates can be achieved.
Hypothesis and Specific Aims
The long-term goal of the project in chapter 2 was to develop injectable dosage
forms for sustained release of contraceptives for prevention of unintended pregnancies
for six months or longer after a single injection. The immediate objective was to design
and develop LNG containing injectable ISD system for contraceptive effect for five
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months after a single injection. The ISD formulation contains the drug LNG,
biodegradable polyesters, and a vehicle for injection. LNG is a synthetic levorotatory
hormone that is widely used as a contraceptive to prevent unwanted pregnancy in females
[212-216], also used as an API for the development of long-acting contraceptives Sinoimplant® and Jadelle [34, 217]. It has very limited solubility in water (2.05 mg·L-1) which
offers to ensure prolonged release. It is superior to medroxyprogesterone regarding bone
loss [1, 2]. The design and development plan for ISD systems is given in Figure 2-3.
The hypothesis of the project in chapter 1, which was the sub-hypothesis 1 of the
overall hypothesis of the dissertation, was that injectable in situ depot system with
balanced biodegradable polymers and solvents can be developed as an effective delivery
system for sustained release of contraceptives such as levonorgestrel for five months or
longer after single SubQ injection through a 23G needle. The specific aims of the project
include:
Specific Aim 1: Design and conduct in vitro optimization and characterization of
LNG-containing ISD formulations. The ISD formulations containing PLGA, PLA as a
polymer matrix, LNG as an API, and NMP and its mixture with TEC, acetyl triethyl
citrate (ATEC), benzyl benzoate (BB), benzyl alcohol (BA), ethyl acetate (EA) were
prepared. The optimization parameters included polymer type/molecular
weight/viscosity/degradation, polymer/solvent ratio, LNG content, injectability, and in
vitro acyline release kinetics in PBS (pH 7.4) and accelerated conditions.
Specific Aim 2: Evaluate in vivo safety, pharmacokinetics and contraceptive effect
of LNG-containing ISD systems in rats. ISD formulations that were injectable through the
23G needle and shown stable in vitro depot integrity, and long-term in vitro LNG release
(≥ 3 months) were injected SubQ into female Sprague-Dawley (SD) rats. Their safety,
one day short-term and 6-month long-term pharmacokinetics and contraceptive effects
including suppression of estrous cycle were evaluated.
Materials and Methods
Chemicals and Reagents
Levonorgestrel (>99.99%) was provided by Family Heath International (FHI360).
Levonorgestrel-D6 (LNG-D6) was purchased from Hexonsynth (Middle Sex, UK). Esterterminated poly(D, L-lactic-co-glycolic acid) (50:50) with an inherent viscosity (iv) of
0.55-0.75 dL/g was purchased from Lactel Absorbable Polymers (Birmingham, AL).
Ester-terminated poly(D, L-lactide) with iv 0.40-0.50 and 0.60-0.80 dL/g were purchased
from Lakeshore Biomaterials (Birmingham, AL) and Evonik (Birmingham, AL),
respectively. Blank rat plasma was ordered from Bioreclamation IVT, USA. The
following chemicals and solvents were obtained from Fisher Scientific (Pittsburgh, PA):
TEC, NMP, BB, BA, ATEC, EA, sodium chloride (crystalline/certified ACS), sodium
hydrogen phosphate (98+%), potassium phosphate monobasic (extra pure 99+%),
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ISD Formulation
In situ solid
depot formation

Pharmaceutically
acceptable Solvents

• Polylactic acid (PLA)
• Poly(lactic-glycolic acid)
acid (PLGA)
PLGA)
Biodegradable
Polymers

• N-methylpyrrodine (NMP)
• Benzyl benzoate (BB)
• Triethyl citrate (TEC)
• Acetyl triethyl citraye (ATEC)
• Benzyl Alcohol (BA)
• Ethyl Acetate (EA)

Advantages
• Easy administration
• FDA approved materials
• Easy to manufacture, fewer
processing steps than
microspheres
• Potential for low cost

Figure 2-3.

•
•
•
•
•

• Levonorgestrel
(LNG)

23G needle

Drug
Drug-Polymer solution/ suspension injected
through 21-23 gauge needles into the body
where it forms a biodegradable depot/implant

No reconstitution necessary
Long-acting contraception
Completely degradable
No surgical removal needed
100% loading efficiency

Achieve robust near constant LNG plasma
concentration and contraceptive effect
with no or minimal initial burst for 6-12
months

Design and developmental plan of injectable ISD dosage forms.

Notes: ISD formulation is a solution or suspension containing LNG and biodegradable
polymers (PLA or PLGA) dissolved or dispersed in pharmaceutically acceptable watermiscible organic solvents (NMP, BB, TEC, ATEC, BA, EA), respectively. Upon
injection into the tissue, this ISD system forms a solid depot of polymeric matrix at the
injection site because of the phase separation (in situ polymer precipitation) by solvent
exchange. The LNG entrapped in the depot is then slowly released out into the
surrounding body fluid due to the degradation of the polymers and diffusion of the drug,
goes into the systemic circulation and then reaches target sites
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potassium chloride, water (HPLC grade), acetonitrile (HPLC grade), methanol (HPLC
grade), ethanol (HPLC grade), hexane, formic acid, and Tween 20.
Preparation of Formulations
The formulations with composition listed in Table 2-2 and Table 2-3 were
prepared as follows: LNG was weighed and added to the mixture solvent of NMP/TEC or
NMP/BB (9:1 v/v) in a 20 mL vial. The vial was vortexed at 500 rpm until LNG was
dissolved. Weighed PLGA-50:50 and PLA polymers were then added and vortexed at
500 rpm until a uniform solution was obtained.
In Vitro Evaluation
Viscosity Measurements
Shear viscosity of the formulations was measured by using the cone and plate
geometry technique by flow procedure on an AR-G2 rheometer, TA Instruments, Waters
Corporation, (New Castle, USA), and the results analyzed by TA universal analysis 2000
software. All measurements were performed at 25 °C with a 20 mm stainless steel cone
with 1° Cone angle, TA Instruments, Waters Corporation, (New Castle, USA) at a gap
of26 μm. The sample was allowed to equilibrate for 5 min at 25 °C before measurements
were conducted. Shear viscosities were measured in the range of shear rate from 0.001 –
1000 s-1 and then in descending order. The slope of the curve shear stress vs. shear rate
was calculated to get the average shear viscosity of the solutions that exhibited plastic
flow. The experiments were repeated thrice, and the results were shown as mean ± SD.
In Vitro Release Study
Real-time (long-term) in vitro release study
The formulations were injected (400 μL) through a syringe into a PTFE mold
having a cylindrical cavity of 12.5 mm in diameter and 5 mm in depth. The mold was
then transferred into a 500 mL jar, and 400 mL PBS (pH 7.4) release medium was
carefully added to the jar. The jar was then placed into a 37 qC shaking incubator
(MaxQ800, Thermo Scientific, Waltham, MA) and constantly shaken at 50 rpm. At
selected time points over a 6-month period, 1 mL of the release medium was collected for
drug analysis using HPLC (see Section 2.3.4 for details), and then the entire medium was
replaced with fresh PBS (pH 7.4) to maintain the sink condition. Each formulation was
run in triplicates for the studies.
Accelerated release study
The 64 and 96 formulations were selected for conducting a short-term in vitro
release study the same way as for the long-term in vitro release study as described
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Table 2-2.

The composition of set-1 ISD formulations.
Formulation
#
64-Tamrin
55
56
57
61
62
67
68
96
97
98
99
100

PLGA 50:50
wt %
iv-0.63
4.7

PLG 85:15
wt %
iv-0.63

12.2
12.2

PLA
wt %
iv-0.25

PLA
wt %
iv-0.47

12
12
12
12
12
12.2
12.2

4.1
4.1
4.1
4.1
4.1

20.3
20.3
20.3
20.3
20.3

PLA
wt %
iv-0.63
18.8
12
12
12
12
12

LNG
wt %

Solvent (9:1)
wt %

6
4
4
4
4
4
2.5
2.5
2.5

70.5 NMP/TEC
72 NMP/BB
72 NMP/BA
72 NMP/ATEC
72 NMP/EA
72 NMP/TEC
73.1 NMP/TEC
73.1 NMP/BB
73.1 NMP/BB
73.1 NMP/BB (8:2)
73.1 NMP/BB (7:3)
73.1 NMP/TEC (7:3)
73.1 NMP/ATEC (7:3)

Notes: Units of inherent viscosity (iv): dL·g-1; molecular weights (based on GPC) of polymers according to the certificate of analysis
are PLA (iv-0.25): 27 kDa; PLA (iv-0.47): 67 kDa; PLA (iv-0.63): 102 kDa.
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Table 2-3.

The composition of set-2 ISD formulations.

Formulation PLGA 50:50
#
64-Tamrin
96
96j
96k
96l
96m
96n
96o
96p
96q
96r
96zz

iv-0.63
wt%
4.7
4.1
4
4
4
4
4
4
4
4
4
4

PLA

PLA

LNG

Solvent (9:1)

iv-0.47
wt%

iv-0.63
wt%
18.8

wt%

wt%

6
2.5
2.5
2.5
2.5
4
4
4
4
4
4
4

70.5 NMP/TEC
73.1 NMP/BB
73.5 NMP/TEC
77.5 NMP/TEC
81.5 NMP/TEC
72 NMP/TEC
76 NMP/TEC
80 NMP/TEC
72 NMP/TEC
72 NMP/TEC
72 NMP/TEC
72 NMP/EA

20.3
20
16
12
20
16
12
16
12
4
4

4
8
16
16

Notes: Units of inherent viscosity (iv): dL·g-1; molecular weights (based on GPC) of
polymers according to the certificate of analysis are PLA (iv-0.25): 27 kDa; PLA (iv0.47): 67 kDa; PLA (iv-0.63): 102 kDa.
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previously in Section 2.3, except for that the release conditions were the four conditions
listed in Table 2-4 instead of PBS (pH 7.4) at 37 qC and the study was over a two week
period instead of long-time period (conditions designed by Dr. Wang). The correlations
between the release kinetics and mechanisms of LNG from ISD systems (64 and 96)
under real-time and accelerated conditions were established. The best-correlated
condition was used to conduct the short-term (24 h) accelerated release study during the
screening of the set-2 formulations.
HPLC Measurements
The collected release medium samples were analyzed for LNG content using
HPLC (Shimadzu Scientific Instruments, Inc. Columbia, MD) installed with a reverse
phase column BDS Hypersil C-18, 3 μm, 100x4.6 mm. Acetonitrile (ACN)/0.01% formic
acid in water (65:35 v/v) was used as a mobile phase. The flow rate was set at 0.8
mL·min-1, and the detection wavelength was 245 nm. The injection volume was 50 μL.
The column temperature was kept at 25°C. The standards for calibration were 0.070,
0.100, 0.250, 0.500, 0.750, 1.00, 2.50 μg·mL-1 of LNG dissolved in PBS (pH 7.4
correlation coefficient was R2>0.99). The cumulative release amount of LNG was
calculated from the LNG concentrations determined in the samples.
In Vivo Evaluation
LC-MS/MS Method Development and Validation for Analysis of LNG in Rat
Plasma
Liquid chromatography (LC) was performed on a UPLC system (Shimadzu
Corporation) consisting of a binary pump, column oven, and degasser units. 10 μL of
sample extracts were injected into the reversed-phase Luna C18 (2) column (50 x 2.0 mm
i.d., 3 μM; Phenomenex, Torrance, CA, USA) by using an autosampler (Eksigent, part of
AB SCIEX). Acetonitrile/water mixture (70/30, v/v) containing 0.01% formic acid was
used as a mobile phase and was pumped at a flow rate of 0.3 mL·min-1. Total run time
was 3 min for each sample injection. The column temperature was kept at 25 °C. The LC
elute was introduced into the Applied Biosystems Triple Quad™ 4500, a triplequadrupole tandem mass spectrometer equipped with turbo spray ionization source, for
quantification of the analytes in positive ion mode (ESI+). Detection of the analyte ions
was performed in a multiple reaction monitoring mode and transitions of m/z
313.10→245.10, and 319.10→251.10 were used for LNG and LNG-D6, respectively.
Analyst®1.6.2 software was used for processing the data. The detailed experimental
conditions are: ion spray voltage 4500 v, collision gas 8 psi, temperature 500 °C,
collision energy 23v, entrance potential 10v, collision exit potential 12v, declustering
potential 81v, curtain gas 40 psi, ion spray gas I 60 psi and ion spray gas II 60 psi

28

Table 2-4.
Release testing conditions used for accelerated in vitro release method
development.
Condition
A
B
C
D

PBS
(% v/v)
100%
Adjusted to 100%
Adjusted to 100%
Adjusted to 100%

Ethanol
(% v/v)
0
25%
25%
25%
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Tween 20
(% w/v)
0
0
0.5%
0.5%

pH
7.4
7.4
7.4
9.0

Temperature
(°C)
50
50
50
50

Preparation of standard and quality control samples
For the LNG calibration standard solution preparation, LNG was accurately
weighed and dissolved in the mixture of methanol and water (50/50, v/v) to obtain a stock
solution with a concentration of 1 mg·mL-1. This stock solution was then diluted with
methanol/water (50:50, v/v) mixture to obtain working stock solutions at concentrations
5, 10, 25, 50, 100, 250 and 500 ng·mL-1. Furthermore, these working stock solutions
were diluted 10 times with blank rat plasma to obtain working standard solutions at
concentrations 0.5, 1, 2.5, 5, 10, 25 and 50 ng·mL-1.Quality control samples for LNG
were also prepared from a separate set of working stock solutions as mentioned above at
three concentrations 0.5 (low; LLOQ), 5 (medium; MLOQ) and 50 (high; HLOQ) ng·mL1
. Being the structural analog of LNG, LNG-D6 was used as an internal standard (IS). A
stock solution of LNG-D6 was prepared in a mixture of methanol and water (50:50, v/v)
to obtain the final concentration of 250 μg·mL-1. All the stock solutions were stored at 20 °C and were brought to room temperature before use.
Extraction procedure
100 μL of rat plasma containing LNG and LNG-D6 was taken in a
microcentrifuge tube, and 500 μL of hexane/ethyl acetate (80/20, v/v) mixture was added
followed by vortexing for 3 min. The tubes were centrifuged at 10,000 x g at 4 °C for 10
min. Supernatant organic phase containing the LNG and LNG-D6 was collected into
another microcentrifuge tube and subjected to vacuum vaporization. The resultant residue
was dissolved in 50 μL of reconstitution solvent methanol/water (50/50, v/v) mixture and
vortexed for 2 min for proper mixing. In this process, 100 μL of rat plasma was
concentrated to 50 μL resulting in increased sensitivity. From the extracted sample, 10
μL was injected into the LC/MS/MS system for analysis.
Matrix effect
Matrix effect is the effect of rat plasma constituents on the ionization of LNG and
LNG-D6. Due to the endogenous compounds from rat plasma, the ionization of an analyte
can be suppressed or increased. It is determined by comparing the analyte peaks obtained
from samples spiked in the solution of the rat plasma extracted by hexane/ethyl acetate
(80/20, v/v) mixture(post-extracted spiked samples) with those spiked in mobile phase
acetonitrile/water mixture (70/30, v/v) containing 0.01% formic acid (neat standard
samples). Matrix effect was calculated at LLOQ (0.5 ng·mL-1), MLOQ (5 ng·mL-1) and
HLOQ (50 ng·mL-1) concentrations (n=6) for LNG and at 25 ng·mL-1 (working
concentration) for LNG-D6, using the Equation 2-1 listed below.
Ψ ൌ

ୣୟ୩୰ୣୟ୭୭ୱ୲ିୣ୶୲୰ୟୡ୲ୣୢୗ୲ୟ୬ୢୟ୰ୢୗୟ୫୮୪ୣ
ୣୟ୩୰ୣୟ୭ୣୟ୲ୗ୲ୟ୬ୢୟ୰ୢୗୟ୫୮୪ୣ

ͲͲͳ כ

(Eq. 2-1)

Specificity and sensitivity
Blank plasma, and analyte LNG (LLOQ) and internal standard LNG- D6 spiked
plasma samples were treated according to the extraction procedure mentioned above prior
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to analysis by the LC/MS/MS. The chromatograms for the blank plasma and spiked
plasma samples were compared to identify any peaks during the analysis. Specificity was
evaluated by checking any significant interference in the chromatograms at the peak
regions of LNG and LNG- D6. The LLOQ and Limit of detection (LOD) were defined at
the lowest concentrations that resulted in a signal to noise(S/N) ratio of 10 and 3,
respectively.
Recovery efficiency
The recovery efficiency(%RE) for the analyte LNG and internal standard LNGD6 was calculated by comparing the peak areas of the LNG/LNG- D6 added into blank
plasma and extracted using the extraction mixture solvent hexane/ethyl acetate (80/20,
v/v) with those of LNG spiked directly into the extraction mixture solvent (post-extracted
standard samples) at the three LNG QC (0.5, 5and 50 ng·mL-1) and one LNG- D6
working (25 ng·mL-1) concentrations, using Equation 2-2 listed below:
ୣୟ୩୰ୣୟ୭୶୲୰ୟୡ୲ୣୢୗୟ୫୮୪ୣ

Ψ ൌ ୣୟ୩୰ୣୟ୭୭ୱ୲ିୣ୶୲୰ୟୡ୲ୣୢୗ୲ୟ୬ୢୟ୰ୢୗୟ୫୮୪ୣ ͲͲͳ כ

(Eq. 2-2)

Linearity
Seven calibration standard concentrations in the range of 0.5 – 50 ng·mL-1 (0.5, 1,
2.5, 5, 10, 25 and 50 ng·mL-1) were extracted and analyzed for drawing the calibration
curve. The peak areas were calculated, and peak area ratios (Analyte/IS) were fitted to
linear regression analysis using 1/x2 as a weighing factor. The concentrations of the
samples were back calculated from the standard curve and were compared to deviation
from the theoretical concentrations. The deviations should be within ±20% and ±15% for
the LLOQ and other concentrations, respectively. The correlation coefficient (r2) for the
calibration curve should be 0.99 or higher.
Accuracy and precision
Accuracy was determined as the percentage of the difference between the mean
calculated concentration and the theoretical value, as shown in Equation 2-3 below:
Ψ   ൌ ቂͳ െ

ሺୡ୲୳ୟ୪ିୣୟୱ୳୰ୣୢሻେ୭୬ୡୣ୬୲୰ୟ୲୧୭୬
ୡ୲୳ୟ୪େ୭୬ୡୣ୬୲୰ୟ୲୧୭୬

ቃ ͲͲͳ כ

(Eq. 2-3)

Precision indicates the reproducibility and measures the closeness among the replicates.
It was determined as the percentage of the standard deviation from the arithmetic mean of
the calculated sample concentrations and expressed as the percent of the coefficient of
variation (%CV), as shown in Equation 2-4 below:
ୗ୲ୟ୬ୢୟ୰ୢୈୣ୴୧ୟ୲୧୭୬

Ψ ൌ ቀୣୟ୬େ୭୬ୡୣ୬୲୰ୟ୲୧୭୬ቁ ͲͲͳ כ
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(Eq. 2-4)

Intra-day assay accuracy and precision
Seven calibration standard samples with concentrations in the range of 0.5-50
ng·mL (0.5, 1, 2.5, 5, 10, 25 and 50 ng·mL-1) and three QC samples, LLOQ (0.5 ng·mL1
), MLQC (5 ng·mL-1) and ULOQ (50 ng·mL-1) were prepared separately in 6 replicates,
and analyzed for accuracy and precision measurements using chromatography for 3
consecutive days. The accuracy should be within ±20% and ±15%forthe LLOQ and all
the other concentrations, respectively. The %CV should not exceed 20% and 15% for the
LLOQ and all the other concentrations, respectively.
-1

Inter-day assay accuracy and precision
The data obtained above for the intra-day assay accuracy and precision were reanalyzed for inter-day assay accuracy and precision using all three days’ data for each
concentration (18 samples in total), and the results were reported. Both the accuracy and
%CV should be within ±20% and ±15%forthe LLOQ and all the other concentrations,
respectively.
Stability
Stability of the LNG in the rat plasma and final reconstitution solvent under
specific experimental conditions was evaluated. Three QC samples with concentrations in
the rat plasma, 0.5 (low), 5 (medium) and 50 ng·mL-1 (high) were prepared in 6 replicates
for these studies. Long-term stability of LNG was investigated by measuring the accuracy
after the QC samples were stored at -80 °C (storage condition) for 15 days and under 5
cycles of the freeze-thaw process from -80 °C to room temperature. In process stability
was tested after the QC samples were kept in the rat plasma at room temperature for 4 h.
Post-operative stability was studied after the final processed samples were kept in the
reconstitution solvent methanol/water (50/50, v/v) mixture at room temperature for 8 h at
10 °C (autosampler injector temperature) for 24 h. LNG was considered to be stable if the
percent change in concentration was within ±15%.
LNG pharmacokinetics in rat
To evaluate the applicability of the developed method, the SubQ pharmacokinetic
profile of LNG in rats was determined. 2.5 month old female Sprague Dawley rats (n=6)
were ordered and housed in plastic cages at controlled temperature (24±0.5 °C) and light
controlled environment (12h light/12h dark). Rats were provided with normal rat chow
and water ad libitum. All the experiments were approved by the University of Tennessee
Institutional Animal Care and Use Committee (IACUC). Before the study was conducted,
rats were anesthetized by isoflurane inhalation and 4mg of LNG in 400 μLNMP solution
was injected subcutaneously into each rat. 200-250 μL of blood samples were collected
from the experimental rats and put into Li-heparin coated blood collection tubes at 0.25,
0.5, 1, 4, 8, 24, and 48 h time points post the injection. The tubes were centrifuged at a
speed of 12,000 g for 10 min, and the obtained plasma samples were stored at -80 °C for
further analysis. LNG was extracted from the plasma samples using hexane and ethyl
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acetate solvent mixture as described in the above sections. The resulting solutions were
diluted to the concentrations that fell in the standard curve concentration range. The
pharmacokinetic parameters were calculated by non-compartmental analysis using
Phoenix WinNonlin 6.3 (Certara, NJ).
In Vivo Pharmacokinetic Study of Formulations
All the rats were ordered from Harlan Laboratories (Indianapolis, IN, USA), and
housed in metabolic cages under controlled temperature (24 ± 0.5 °C) and light
environment (12 h light/12 h dark). They were permitted to move freely and provided
with normal rat chow and water ad libitum. All the experiments were approved by the
University of Tennessee Institutional Animal Care and Use Committee (IACUC).
Female SD rats (~2.5 month old) with a heparin-coated polyethylene catheter inserted
into each rat’s right jugular vein were used to determine the initial burst concentrations of
LNG in the plasma (24 h study). Formulations were prepared and exposed to UV light in
cell culture hood for 1 hour, and the desired amount of formulation was transferred into
sterilized syringe with a 21G/23G needle. Before the study was conducted the rats were
anesthetized by isoflurane inhalation and the selected formulations were injected
subcutaneously into each rat. About 0.05–0.1 mL of blood was withdrawn through the
indwelling catheter to clear the heparin in the line. Afterwards, another 0.20-0.25 mL of
blood sample was collected through the catheter and put into Li-heparin coated microcentrifuge tubes at 0.25, 0.5, 1, 4, 8, and 24 h time points post the injection. After each
blood sampling, the catheter was flushed with 0.25-0.5 mL of heparinized saline solution
to prevent blood coagulation inside the catheter. Periodically the rats were supplemented
saline to replace the fluid volume.
Long-term studies were carried out on normal female SD rats. The rats were
measured for body weight and anesthetized by isoflurane inhalation, and the formulation
was then subcutaneously injected into rats at the flank place at a dose of 10 mg LNG. At
pre-set time points, body weights of the rats were measured and about 0.2-0.3 ml blood
was withdrawn from the tail vein of the rats under anesthesia. All blood samples were
placed in Li-heparin coated micro-centrifuge tubes. The plasma samples were obtained
by centrifuging the blood-containing micro-centrifuge tubes at a speed of 12,000 × g for
10 min and then stored at −80 °C until analysis. All plasma LNG levels were analyzed
according to the LC-MS/MS method described earlier.
Vaginal Cytology
Periodically the rats were examined for estrous cycle progression by vaginal
cytology. At intermittent pre-set weeks, vaginal smears were taken from each rat in the
groups in the morning at approximately the same time of the day to minimize the
incidence of transitional and missed stages. Cells from the vaginal cell lining were
collected by flushing the vagina by introducing 0.3-0.4 mL of normal saline into the
opening of the rat vagina using eye droppers and gently aspirating the content for four
times with the same drop of saline to collect more cells. The resulting cell suspension is
placed on a clean slide fixed and stained with a Diff-Quick solution and observed
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microscopically. The reproductive cycle (estrous cycle) of female rats is characterized as
proestrus, estrus, metestrus and diestrus. Three types of cells could be recognized: round
and nucleated ones are epithelial cells; irregular ones without nucleus are the cornified
cells, and the little round ones are the leukocytes. The proportion of them was used for
the determination of the estrous cycle phases [218].
Fertility Study
Female rat fertility study was conducted after the end of the treatment (when the
drug levels were stopped detecting in vivo). The rats were housed in standard cages
grouped as two female rats and one male rat in each cage. Vaginal smears were collected
and evaluated for the stage of estrous. At the time of insemination, females were
separated from the male rats, and body weights were measured every alternative day
(This study was conducted by our lab member Dr. Ananthula).
Results and Discussion
Screening of Set-1 ISD Formulations
Although long-acting ISD systems have proven to be effective, the major
limitations associated with these systems are injectability and high initial burst
[194]. Most of these ISD systems are high viscous fluids and need a lower (thicker)
gauge needle (such as 18G/19G) for injection, which will be painful and limits the patient
compliance [194]. Attempts made to lower the viscosity of the fluids would usually result
in an increase in the initial burst and may also compromise the long-term drug release. A
high initial burst would lead to a loss of a major percentage of the drug during initial few
hours’ post injection and result in a smaller proportion of the total drug load left in the
system/depot for long-term release. This high initial release may also lead to toxic levels
of the drug in the plasma.
Therefore, the three key attributes that were considered during the formulation
optimization are:
•
•
•

Low viscosity so that it can be injected through 23 G needle
Low initial burst
Long-term release profile for at least 5 months

Previously an ISD formulation (# 64) was used to evaluate the feasibility of using
LNG as an effective contraception option for cottontop tamarins, and the results
demonstrated that subcutaneous LNG depot injection (64 formulation) was an effective,
reversible contraceptive option for the management of cotton-top tamarins [197]. 64
formulation has shown promising potential by demonstrating long-term in vivo
suppression of ovarian cycle in cottontop tamarins for 6 months. However, the limitation
associated with this formulation is its high viscosity which makes it difficult to inject
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through 23 G needle. Therefore, formulation 64 was chosen as the base ISD formulation
on which further design and optimization were carried out to achieve an ideal and robust
lead formulation that would satisfy the requirements of injectability, initial burst, and
long-term release profile. In the earlier study, LNG was loaded into 64 formulation and
directly injected in vivo in cottontop tamarins, and the drug levels were detected only in
the feces [197]. Thus, no in vitro characterization data was available for 64 formulation in
terms of viscosity, injectability, in vitro release, and in vivo initial burst, and long-term
profiles of the drug levels in the plasma. Therefore, 64 formulation was selected to
characterize further in this study along with other formulations for the viscosity,
injectability and in vivo profile in rats to get a better understanding of the formulation and
guide the optimization and development process.
In this project, to addresses some of the limitations of the ISD systems such as
injectability, and initial burst in a unique and promising way, an initial set of formulations
(set-1) were designed using a rationale approach of incorporating PLA alone or
combining a blend of PLGA/PLA with different inherent viscosities, using solvent
combination NMP and other hydrophobic co-solvents, and varying the ratios of polymer,
as well as the solvent for dissolving the LNG, and varying drug ratios (Table 2-2). The
PLGA polymer concentration used in Atrigel® based marketed ISD formulations
(Eligard®) is in the range of 33-44 wt% (in NMP), based on therapeutic duration (1-6
months), but such a high polymer percentage makes them difficult to be injected through
a thinner needle (21-23 G). To maintain the viscosity low, the polymer concentration
during the study was adjusted around 24 wt%. However, lowering the polymer
percentage in ISD formulations would usually result in high burst and reduced
therapeutic duration. Therefore, to compensate this and achieve low initial burst and
extended release profile, a hydrophobic polymer PLA with a high inherent viscosity (or
MW) is incorporated in the preparations either alone or in combination with PLGA 50:50
or 85:15. Because of its hydrophobic nature, PLA degrades at a slower rate and absorbs
less water than PLGA [15]. Among set-1 formulations (Table 2-2) that were designed:
one subset of formulations (55, 56, 57, 61 and 62) exclusively contained PLA as the
polymer, while the polymer composition in another subset (96, 97, 98, 99, 100) contained
a blend of PLA and PLGA. Mixing two polymers of different MWs permits the control of
the timing associated with degradation release [219]. NMP is used as the primary solvent
(at least 70% of the solvent) in the formulations because of its low viscosity, established
safety profile, and use in commercial products for human use [181, 190]. Hydrophobic
solvents such as TEC, BB, BA, ATEC are used as co-solvent in the formulations, as it
was reported in the literature that the low affinity (hydrophobic) solvents in the polymer
solutions would slow down the solidification rate and increase the chance for a more
uniform release over an extended time period, lower initial burst, and uniformly dense
depot morphology with a smaller pore size [181, 194]. However, the hydrophobic
solvents such as TEC (35.2 cP) and BB (8.3 cP) are viscous solvents than NMP (1.65 cP)
and increasing the percentage of co-solvent (e.g., TEC, BB) would increase the viscosity
of the formulations, therefore the levels were adjusted to 10-30 wt% of the solvent. The
drug loading was lowered from 6% to 2.5-4% to avoid any potential drug solubility
issues with long-term storage. The initial screening of the set-1 formulations for the
manual injectability has shown that all formulations can be injected through 23 G needle,
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while 64 formulation can only be injected through 21 G needle. The formulations that
contained higher proportions of co-solvent (20 and 30%) showed slight difficulty
compared to the formulations that contained 10% of the co-solvent.
In Vitro Release of ISD Formulations Set-1
The majority of in vitro drug release studies for the ISD systems have been
conducted using variants of the sample-and-separate methodology. The studies were
conducted by either injecting the formulation directly into a release medium or dialysis
membrane which is then placed in a release medium, or holding the pre-formed gel or
depot in a retainer including dialysis membrane [12]. However, the method of injecting
the ISD formulation directly into the release medium usually generate depots of irregular
shapes, which in turn results in unpredictable in vitro drug release. The dialysis method is
dependent on the permeation of a drug across the dialysis membrane [32] and sometimes
does not work for the release of certain drugs. Therefore, to avoid the potential issues
mentioned above, in this study a simple and inexpensive in vitro release technique was
developed for the screening of the formulations using a cylindrical mold made of
polytetrafluoroethylene (PTFE) with defined geometry (2.5 mm in diameter and 5 mm in
depth) to study in vitro drug release kinetics from injectable ISD systems. The
formulations were injected into the mold and then immersed in the release medium in a
glass jar (Figure 2-4), and the drug would diffuse out from the top surface into the
release medium in a controlled manner. Though this method might not mimic well the in
vivo drug release profile, it was sufficient and effective for achieving the objective of this
study which is to screen formulations at early development stage.
The cumulative percentage release of LNG from the set-1 ISD formulations for
two months is given in Figure 2-5. Apart from 64 formulation, two formulations (55, 96)
were selected (one from each subset) to continue the long-term release study. The
rationale for choosing these two formulations was that they had shown slowest LNG
release profile in vitro, and favorable injectability compared to the other formulations. As
55 formulation contained only PLA while 96 formulation has contained a blend of PLA
and PLGA, selection of these formulations also help to investigate the effect of the
polymer composition (i.e. using either PLA alone or a blend of PLA/PLGA) on long term
release. The composition of the three formulations (55, 64 and 96) along with their
viscosity and injectability values is given in Table 2-5. Viscosity data has demonstrated
that 55 and 96 formulations have shear viscosities 0.64±0.04 Pa.s and 0.67±0.05 Pa.s,
respectively, and can be injected through 23 G needle, while the 64 formulation has a
higher shear viscosity of 1.71±0.01 Pa.s and shown injectability through 21 G needle.
Even though the overall polymer percentage is similar in all three formulations, the
higher viscosity of 64 could be attributed to the differences in terms of drug concentration
or loading (6% vs 4%/2,5%), PLA polymer inherent viscosity (0.63 vs 0.47), and cosolvent (TEC vs BB). However, the primary factor that resulted in an increased viscosity
of the 64 formulation could be the higher inherent viscosity (high MW) of the polymer
(PLA – 0.63 i.v.) used in the formulation. Figure 2-6 shows the long-term percent
cumulative in vitro LNG release and release rate from the ISD formulations 55, 64, and
96 at 37 °C in PBS (pH 7.4).
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Depot
Release Medium

Figure 2-4.

Teflon mold holding the depot for in vitro LNG release studies.

Notes: The ISD formulations were injected into the Teflon mold (2.5 mm in diameter and
5 mm in depth) and then immersed in the jar containing release medium for in vitro
release studies. At selected time points the release medium was sampled, and complete
medium was replaced with fresh medium to maintain sink conditions

37

14

64
61
98

% Cumulative Release

12

55
62
99

56
96
100

57
97

10
8
6
4
2
0
0

15

30

45

60

Days
Figure 2-5. In vitro cumulative LNG release percentage from set-1 ISD
formulations.
Notes: The set-1 formulations (Table 2-2) were tested for in vitro release for a period of
about 2-months. 55 (open diamond), 64 (open circle), and 96 (open triangle) formulations
showed slowest in vitro profile and were selected for long-term evaluation.
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Table 2-5.

The composition and viscosity of the 55, 64 and 96 formulations.
F#
55
64
96

PLGA50:50
(iv-0.63)
wt%
4.7
4.1

PLA
(iv-0.25)
wt%
12

PLA
(iv-0.47)
wt%
12

PLA
(iv-0.63)
wt%
18.8

20.3

LNG
wt%

Solvent (9:1)
wt%

4
6
2.5

73.1 NMP/BB
70.5 NMP/TEC
73.1 NMP/BB

Shear
viscosity
Pa.s
0.64±0.04
1.71±0.01
0.67±0.05

Injectability
gauge
23
21
23

Notes: Units of inherent viscosity (iv): dL·g-1; molecular weights (based on GPC) of polymers according to the certificate of analysis
are PLA (iv-0.25): 27 kDa; PLA (iv-0.47): 67 kDa; PLA (iv-0.63): 102 kDa.
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Figure 2-6. In vitro cumulative LNG release (A), and in vitro LNG release amount
per day (B) from the ISD formulations.
Notes: The release of LNG from 55 (diamond), 64 (circle) and 96 (triangle) ISD
formulations in PBS medium (pH 7.4) at 37 °C. The complete composition of the
formulations listed in Table 2-2. Each point represents the mean±SE, n=3.
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The in vitro release of LNG from ISD formulations showed a slight initial burst
phase followed by near zero order release. The burst effect in the initial phase of the
release is commonly observed with ISD formulations and is dependent on the phase
inversion dynamics during the solidification of the matrix, as well as the drug-polymer
interaction [184, 220]. Following this initial phase, the release of LNG was slow, and less
than 10% of LNG release from the depot formulations was observed over a 6-month time
period. The observed initial burst and the overall percent cumulative LNG release at the
end of five months in vitro release were low, and this can be attributed to the release
model used in this study where the drug release from the Teflon mold is only limited to
the single surface. When the formulations are in the near zero order release stage, 55, 64
and 96 released about 4-18 μg, 2-9 μg, and 3-18 μg LNG per day, respectively, after dose
normalization. The differences in the release profile could be attributed to the differences
in the composition of the formulations regarding the polymer type, inherent viscosity of
the PLA polymer, drug loading, and co-solvent. 55 and 96 formulations, which have a
greater percentage of smaller inherent viscosity PLA polymers, showed faster release
profile compared to the 64 formulation which has higher inherent viscosity PLA. In the
literature, it was explained that a polymer with lower inherent viscosity could get
hydrated and swell better, and thus could release drug faster [221]. The in vitro depots of
formulations 55 and 96 were significantly porous compared to the depot of 64
formulations. Figure 2-7 shows the pictures of in vitro depots of the formulations at two
months. The order of porosity was 55 > 96 >> 64. The in vitro depots of 55 and 96
formulations have shown signs of disintegration starting at 3 and 4 months, respectively.
The depot of 55 showed quick disintegration and resulted in complete loss at about 4
months, while the depot of 96 was disintegrated by 5 months. Even through the depot of
55 constitute 100% PLA (more hydrophobic than PLGA), but the higher porosity and
faster disintegration of the depot of 55 over 96 could be attributed to the presence of
lower inherent viscosity PLA polymer. 50% of the polymer concentration used in 55
formulation was of lower inherent viscosity PLA (0.25 iv), while the polymers used in 96
formulation were of higher inherent viscosity (PLGA-0.63/PLA-0.47 iv). On the other
hand, the depot of the 64 formulation remained intact until the end of the study (~6.5
months). The high amount of PLA with a higher inherent viscosity (0.63) used in 64
formulation might have shown slow degradation and extended the release for a longer
time.
To understand the release mechanisms of LNG from the depots made of 55, 64
and 96 formulations, all the release data in Figure 2-6 were fitted using empirical power
law (Korsmeyer–Peppas Model, Equation 2-5) [40] as shown below:
ெ

ெ  ൌ ݇ ݐ
ಮ

(Eq. 2-5)

Where Mt and M∞ are the amounts of drug released at time t and infinite (in this
study the initial drug amount was used as M∞), respectively, Mt/M∞ is the fraction of drug
released at time t, k is the rate constant related to diffusion coefficient, and n is the release
exponent related to release mechanism. The correlations between n value and release
mechanisms are: n < 0.5, non-Fickian diffusion due to increasing hydrophobicity with
time; n = 0.5, Fickian diffusion; 0.5 < n < 0.1, anomalous (combination of Fickian and
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55

64

96

Figure 2-7. In vitro depot pictures of ISD formulations 55, 64 and 96 in Teflon
molds after two months release study.
Notes: The porosity of the in vitro depots formed by the 55, 64, and 96 formulations was
in the order of 55 > 96 > >64, and this order was correlated to the molecular weights of
the polymers used in the formulations.
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Case II diffusion) diffusion; n = 1, Case II diffusion due to polymer chain relaxation; and
n > 1, Super Case II diffusion due to polymer chain relaxation [40,41]. The Equation 2-5
has frequently been used to analyze the drug release from several modified polymeric
drug delivery systems including both swellable and non-swellable systems [41,42]. The
fitting parameters determined by the linear regression of log (percent cumulative release)
against logt in for the LNG release from the depots made of 55, 64 and 96 formulations
are given in Table 2-6. The release exponent n values ranged from 0.46 to 0.69
suggesting different release mechanisms for the formulations 55, 64 and 96. The
evaluation of these three formulations was further continued to preclinical studies in rats
to study the long-term in vivo LNG release.
LC-MS/MS Method Development and Validation for Analysis of LNG in Rat
Plasma
To conduct the preclinical pharmacokinetic studies of the LNG-loaded ISD
formulations in rats, a sensitive and reliable bioanalytical method is needed to detect the
in vivo drug concentrations. LC/MS/MS technique is a rapid, selective and sensitive
analysis method that has been widely used for quantifying the concentration of a broad
range of drugs in the plasma. There are several reports in the literature about using
LC/MS/MS for detecting LNG from human plasma [222-225], environmental water, and
sewage effluent [226-229]. However, there is no report about using LC/MS/MS for
detecting LNG from small animal plasma. The method for detecting LNG from human
plasma used the relatively large amount of plasma about 0.5-1 mL. This volume of
plasma is difficult to be obtained from small animals such as mice and rats. Hence, a
highly sensitive LC/MS/MS analytical method with a lower limit of quantification
(LLOQ) in the nanomolar or ng/mL range needs to be developed. Therefore, a sensitive
LC/MS/MS method was developed for bioanalysis of LNG over a concentration range of
0.5-50 ng·mL-1 using limited volume (100 μL) of rat plasma. The liquid-liquid extraction
method was employed to extract LNG from rat plasma as it is a fast and convenient way
for the extraction especially when a large number of samples are needed to be analyzed in
short period of time. The liquid-liquid used in this study was the mixture of hexane and
ethyl acetate which is relatively inexpensive and can be easily applied in both academic
and industry settings. For reasonable accuracy and precision, the deuterated analog of
LNG (LNG-D6) was used as an internal standard (IS) for quantification of the samples as
it has similar functional groups and the boiling point as LNG and is not a natural
component of rat plasma. LNG was rapidly eluted and detected in the chromatogram in
less than one minute. The developed method was validated for matrix effect, specificity,
recovery efficiency, accuracy, precision, linearity and stability of the analyte LNG and
published [230]. The validated method was further used to study the pharmacokinetics of
LNG after SubQ injection in rats.
LC/MS/MS method development
Various sample pre-treatment or extraction methods were investigated to remove
interfering compounds from rat plasma. Organic solvents such as methanol, hexane, ethyl
acetate, chloroform, ether with different hydrophobicity and ratios were used to develop
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Table 2-6.
Fitting parameters determined by the linear regression of log(Mt/M∞)
against logt in Power law for the LNG release from the depots made of 55, 64 and 96
formulations.
Formulation
#
55
64
96

Korsmeyer-Peppas (Mt/M∞= k.tn )
R2
n
0.99
0.69
0.97
0.63
0.99
0.46
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the liquid-liquid extraction procedure along with the evaluations for matrix effect,
recovery efficiency, and reproducibility. Hexane/ethyl acetate (80/20, v/v) mixture was
found to be efficient in terms of low matrix effect, high recovery percentile, and good
peak reproducibility. Hexane/ether (70/30, v/v) mixture was also found to have good
peak resolution and extraction efficiency. However, it had an issue with peak
reproducibility due to the volatile nature of ether under the experimental conditions.
For better peak resolution and shorter run time, solvents such as methanol,
acetonitrile and water were tested as mobile solvents in different combinations and
concentrations. Better resolution of peaks was achieved with acetonitrile/water (70/30,
v/v) mixture at a flow rate of 0.3 mL·min-1. Moreover, the addition of 0.01% formic acid
in the mobile phase helped to obtain the smallest peak width and better peak asymmetry.
To optimize ESI conditions for LNG and LNG- D6, scans were conducted in positive ion
detection mode. The full scan mass spectrum of LNG was shown in Figure 2-8, revealing
a peak at m/z 313.10 correlated to protonated LNG ion [M+H]+, and other peaks
correlated to fragmented ions which were obtained after the collision of the protonated
ion. The fragmented ions 109.10 and 245.10 were used for specificity and sensitivity
testing. The fragmentation m/z 313.10 → 245.10 was used for identification of LNG and
further quantification.
Specificity
The specificity was fully evaluated by screening the chromatograms of the blank
plasma samples collected, plasma samples spiked with LNG and IS LNG- D6, and plasma
samples collected from rats subcutaneously injected with LNG. Figure 2-9 illustrated
representative LC/MS/MS chromatograms and demonstrated the absence of any
chromatographic or mass spectrometric interference in the collected blank rat plasma
samples. The retention time for the analyte LNG and IS LNG- D6 were between 1.9 to
2.0 min. No interference peaks were observed in any of the samples at the LNG and
LNG- D6 retention times due to endogenous matrix components, indicating the efficient
specificity of the conditions.
Limits of detection and quantification and linearity
In this work, the LOD and LLOQ for LNG extracted from 100 μL of rat plasma
were quantified to be ~0.2 and 0.5 ng·mL-1 respectively. In the literature, there is no
LC/MS/MS method reported for detecting LNG from small animal plasma although there
are some papers on LC/MS/MS methods for detecting LNG from human plasma. Among
the papers for detecting LNG from human plasma, LLOQ values of 0.265 [224], 0.25
[225], 0.1[222] and 0.05 ng·mL-1[223] were reported. Even though these LLOQ values
for human plasma were lower than the LLOQ obtained in this work for rat plasma, they
required five to ten times amount of plasma (500-1000 μL vs. 100 μL) which would be
difficult to be obtained from small animals. Furthermore, the lowest LLOQ value 0.05
ng·mL-1 for human plasma was obtained by using solid phase extraction procedure [223]
which was much more labor intensive than the simple liquid-liquid extraction procedure
used in this work. Therefore, the existing LC/MS/MS methods for detecting LNG from
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Figure 2-8.

The product ion mass spectrum of the LNG at m/z 313.10.
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320

Figure 2-9.
D6).

Representative chromatograms of LNG and internal standard (LNG-

Notes: (a) Blank plasma sample collected from a rat, (b) purchased plasma sample spiked
with LNG and IS- LNG-D6, and (c) plasma sample collected from a rat after
subcutaneously injected with LNG (spiked with IS).
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human plasma were not suitable for detecting LNG from small animal plasma. The
LC/MS/MS method developed in this work is a new and highly sensitive method for
detecting LNG from small animal plasma. The calibration lines showed good linearity
(with r2 =0.9996 ±0.003) over the concentration range 0.5-50 ng·mL-1 within six
regression curves with high reliability and reproducibility. A typical regression equation
(n=6) was y= (0.0515±0.0025) x + (0.0807±0.0079) and a characteristic calibration curve
for LNG was shown in Figure 2-10. From the graph, the concentrations of the standard
plasma samples were back-calculated for estimating the level of accuracy. Based on the
calculations, it was found that the accuracy percentage for the back-calculated
concertation of each calibration standard was within the acceptable ±20% and ±15%
limits for the LLOQ and all the other plasma standard samples, respectively. Table 2-7
lists the characteristic calibration data for LNG.
Accuracy and precision
Seven standard samples 0.5, 1, 2.5, 5, 10, 25 and 50 ng·mL-1 (Table 2-8 and
Table 2-9) along with three QC samples LQC (0.5 ng·mL-1), MQC (5 ng·mL-1) and HQC
(50 ng·mL-1) (Table 2-9) were tested for intra-day and inter-day accuracy and precision.
All the standard samples showed 90.88-110.33%, 88.67-107.09% and 86.09-104.16%
intra-day accuracy and 0.38-5.59%, 0.66-3.09% and 0.36-3.62% intra-day CV on Day 1,
2 and 3, respectively (Table 2-8). They also showed 92.97-107.03% inter-day accuracy
and 0.91-8.82% inter-day CV for 3 consecutive days (Table 2-8). The QC samples LQC,
MQC and HQC had 112.60%, 96.31% and 107.00% intra-day accuracy and 2.52%,
0.96% and 0.71% intra-day precision, respectively; and 105.27%, 86.75% and 100.32%
inter-day accuracy and 2.20%, 1.64% and 0.67% inter-day precision, respectively (Table
2-10). The QC sample intra-day and inter-day accuracy and precision (CV) were within
±20% for LLOQ and ±15% for all the other concentrations, indicating satisfactory quality
assurance for the accuracy and precision.
Matrix effect
The matrix effect was calculated for the three LNG QC samples LQC (0.5 ng·mL), MQC (5 ng·mL-1) and HQC (50 ng·mL-1) and internal standard LNG- D6 (25 ng·mL-1,
given in Table 2-11). The matrix factors were 0.95, 0.96, and 0.96 for the LQC, MQC,
and HQC samples, respectively, indicating that there was 4~5% chance of ion
suppression due to the matrix. At the same time, matrix factor for the internal standard
was 0.97, indicating a 3% ion suppression effect.

1

Recovery efficiency
Based on the pre-extracted and post-extracted plasma standards, the recovery
efficiency was found to be 90.80-92.65% for the three LNG QC samples LQC (0.5
ng·mL-1), MQC (5 ng·mL-1) and HQC (50 ng·mL-1) and 96.76 % for the internal standard
LNG- D6 (Table 2-11). Being non-polar in nature, hexane/ethyl acetate mixture (80/20,
v/v) was efficient to extract the hydrophobic LNG and LNG- D6 with little interference of
the matrix components.
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Figure 2-10. Representative calibration curve for LNG in rat plasma.
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Table 2-7.
Linearity and summary of calibration curves for LNG in rat plasma
(n=6) with back-calculated concentrations.
Concentration
ng·mL-1
0.5
1
2.5
5
10
25
50

Mean calculated
concentration
ng·mL-1
0.466
1.02
2.46
5.20
10.3
24.9
49.5

SD
0.022
0.049
0.093
0.250
0.358
0.613
0.952

50

Mean
accuracy
%
93.2
102.2
98.2
104.0
103.4
99.6
99.0

SD

CV
%

4.43
4.91
3.71
5.01
3.58
2.45
1.90

4.75
4.80
3.78
4.81
3.47
2.46
1.92

Table 2-8.
Intra-day assay accuracy and precision determination of LNG
standards in rat plasma for 3 consecutive days (n=6).
Day

Concentration
ng·mL-1
0.5

Mean calculated
concentration
ng·mL-1
0.465

1
1

1

1

0.026

Mean
accuracy
%
93.00

5.59

1.103

0.011

110.33

1.02

2.5

2.272

0.036

90.88

1.60

1

5

4.865

0.067

97.31

1.39

1

10

10.983

0.078

109.83

0.71

1

25

25.033

0.379

100.13

1.51

1

50

50.648

0.191

101.30

0.38

2

0.5

0.472

0.015

94.47

3.09

2

1

0.968

0.020

96.80

2.09

2

2.5

2.217

0.015

88.67

0.66

2

5

4.776

0.058

95.51

1.22

2

10

10.709

0.076

107.09

0.71

2

25

24.679

0.213

98.72

0.86

2

50

49.782

0.441

99.56

0.89

3

0.5

0.499

0.018

99.80

3.62

3

1

0.937

0.025

93.70

2.67

3

2.5

2.495

0.047

99.79

1.89

3

5

4.304

0.016

86.09

0.36

3

10

10.416

0.103

104.16

0.99

3

25

24.517

0.259

98.07

1.06

3

50

49.974

0.232

99.95

0.46

51

SD

CV
%

Table 2-9.
Inter-day assay accuracy and precision determination of LNG
standards in rat plasma (n=18).
Concentration
ng·mL-1
0.5

Mean calculated
concentration
ng·mL-1
0.479

1

0.018

Mean
accuracy
%
95.76

3.74

1.003

0.088

100.28

8.82

2.5

2.328

0.147

93.11

6.32

5

4.648

0.301

92.97

6.48

10

10.703

0.284

107.03

2.65

25

24.743

0.264

98.97

1.07

50

50.135

0.455

100.27

0.91

52

SD

CV
%

Table 2-10.

Accuracy and precision for LNG QC samples in rat plasma.

Day

Concentration
ng·mL-1

Intra-day (n=6)

0.5

Mean calculated
concentration
ng·mL-1
0.563

Intra-day (n=6)

5

4.816

0.046

96.31

0.96

Intra-day (n=6)

50

53.498

0.382

107.00

0.71

Inter-day (n=18)

0.5

0.526

0.012

105.27

2.20

Inter-day (n=18)

5

4.338

0.071

86.75

1.64

Inter-day (n=18)

50

50.160

0.338

100.32

0.67
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SD
0.014

Mean
accuracy
%
112.60

CV
%
2.52

Table 2-11.
LNG-D6.

Matrix effect and recovery efficiency results of LNG QC samples and

LNG

0.5 (LQC)

Peak area
Spiked
Spiked
before
after
extraction extraction
1.47E+04 1.27E+04 1.40E+04

LNG

5 (MQC)

8.91E+04 7.98E+04

LNG

50 (HQC)
25

Analyte Concentration Spiked in
ng·mL-1
methanol

LNG-D6

0.95

Recovery
efficiency
%
90.80

8.62E+04

0.96

92.65

6.13E+05 5.50E+05

5.94E+05

0.96

92.64

6.42E+04 6.05E+04

6.26E+04

0.97

96.76

54

Matrix
factor

Stability
Lack of stability results in non-reproducible outputs during the analysis. Hence,
the stability of the analyte during the experimental conditions, from the stage of storage
to chromatography analysis is necessary. In this stability study, five experimental
conditions were used for three LNG QC samples LQC (0.5 ng·mL-1), MQC (5 ng·mL-1)
and HQC (50 ng·mL-1) and the results were shown in Table 2-12. Long term stability
mean accuracy of LNG stored at -80 °C (storage condition) for 15 days and under 12
cycles of freeze-thaw process from -80 °C to room temperature was 111.07%, 95.65%,
and 98.60%; and 108.53%, 97.45% and 100.17% for LQC, MQC, and HQC samples,
respectively. In-process stability mean accuracy of LNG stored in the reconstitution
solvent methanol/water (50/50, v/v) mixture at room temperature for 4 h was 113%,
96.72% and 104.25% for LQC, MQC, and HQC samples, respectively. Postoperative
stability mean accuracy of LNG after keeping the final processed samples at room
temperature for 8 h at 10 °C (autosampler injector temperature) for 24 h was 102.93%,
91.57%, and 98.15%; and 114.4%, 102.72% and 105.76% for LQC, MQC, and HQC
samples, respectively. All the QC samples showed 91.57-114.4% stability mean accuracy
values in the acceptable quality limit under the five experimental conditions.
Application to pharmacokinetic study in rats
The developed LC/MS/MS method was successfully applied to quantify LNG
concentration in the rat plasma after LNG in 400 μL NMP solution (4 mg/rat) was
subcutaneously injected into female SD rats (n=6). The calculated LNG concentrations in
rat plasma were graphed as a function of time for two days of pharmacokinetics study, as
shown in Figure 2-11. The pharmacokinetic parameters of LNG were calculated by noncompartmental analysis and listed in Table 2-13, which showed that Cmax, AUC(0-48hrs),
t1/2, Vd/F and CL/F were 229.17±49.23 ng·mL-1, 888.85±229.17 ng·h·mL-1, 22.07 ±
4.97 h, 424.94 ± 130.29 L·kg-1, and 16.36 ± 3.12 L·h-1·kg-1, respectively. The t1/2
obtained here was well in agreement with the literature reported t1/2 (23 h-1) obtained by
radioimmunoassay [231].
In Vivo Evaluation of the Selected ISD Formulations (55, 64 and 96)
Following the in vitro assessment of the ISD formulations, the 55, 64 and 96
formulations have been chosen for SubQ administration into the right flank of rats at 10
mg per rat (roughly 40 mg/kg) for in vivo evaluation. Figure 2-12 illustrates the longterm plasma LNG profiles of the formulations 55, 64 and 96 starting from day 1 to day
210. 55 and 96 formulations released LNG constantly resulting in rat plasma
concentration of 1-3 ng·mL-1 (n=8) up to 3 and 5 months, respectively and even extended
to 7 months in two rats. On the other hand, 64 formulation released LNG continuously
resulting in rat plasma concentration 0.5-3 ng·mL-1 (n=8) for 7 months or longer. Similar
to the in vitro release results, 64 formulation showed sustained release in vivo, which
could be due to the denser depot and slower degradation of the higher molecular weight
(103 kDa) PLA polymer in 64 formulation. The in vivo study showed that the
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Table 2-12.

Stability of LNG QC samples at the various experimental condition.

Freezer (-80 °C)

LQC
Calculated
Mean
concentration accuracy
mean ± SD
%
-1
ng·mL
0.555 ± 0.032
111.07

MQC
Calculated
Mean
concentration accuracy
mean ± SD
%
-1
ng·mL
4.783 ± 0.139
95.65

HQC
Calculated
Mean
concentration accuracy
mean ± SD
%
-1
ng·mL
49.300 ± 0.110
98.60

Freeze & Thaw (5 cycles)

0.543 ± 0.021

108.53

4.873 ± 0.136

97.45

50.087 ± 1.280

100.17

In the rat plasma at room
temperature for 4 h
In the reconstitution solvent
stored at room temperature for 8 h

0.565 ± 0.026

113

4.836 ± 0.074

96.72

52.127 ± 1.300

104.25

0.515 ± 0.024

102.93

4.578 ± 0.235

91.57

49.077 ± 1.612

98.15

In the reconstitution solvent
stored in injector at 10 °C for 24 h

0.572 ± 0.031

114.4

5.136 ± 0.100

102.72

52.879 ± 0.578

105.76

Condition
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Figure 2-11. LNG concentration in rat plasma (n = 6) as a function of time after
SubQ injection of LNG solution in NMP (16 mg·kg-1).
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Table 2-13. Pharmacokinetic parameters of LNG in rat plasma (n=6) after SubQ
injection of LNG in NMP solution (16 mg·kg-1).
Parameters AUC(0-48hrs)
ng∙h·mL-1
Average
888.85
SD

200.54

Cmax
ng·mL-1
229.17
49.23
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Tmax
h
0.25

t1/2
CL/F
h
L·h-1·kg-1
22.07
16.36

Vd/F
L·kg-1
424.94

4.97

130.29

3.12

LNG Plasma Concentration/ ng/mL

8
Formulation Injection Dose
mg/kg
55
40

6

Injection Volume
μL
250

64

40

160

96

40

400

4

2

0
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Days

Figure 2-12. Plasma concentration of LNG (long-term levels) as a function of time
after SubQ injections of ISD formulations.
Notes: The LNG containing ISD formulations 55 (open diamond), 64 (open circle), and
96 (open triangle) were injected subcutaneously into female SD rats at dose of 10 mg per
rat (~40 mg.kg), and the plasma samples were analyzed for LNG levels over a period of
~7 months. Each point represents the mean±SE (n=8). 55 and 96 formulations showed
the robust release of LNG for 3 and 5 months, respectively while 64 formulation released
LNG continuously for 7 months or longer.
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formulations maintained drug levels above the threshold (~0.2 ng·mL-1) to maintain the
contraception in rats for prolonged time [232]. No significant swelling or abscessation
was observed at the injection site; further, histology study of the injection site at the end
of the study did not reveal any significant interactions. Monitoring the rat weights during
the treatment period showed that the rats injected with LNG gained more weight than the
control rats (Figure 2-13), and this behavior was consistent with the LNG-induced
weight gain data in humans [233]. Both 96 (5 months) and 64 (> 7 months) formulations
have successfully outperformed the current existing injectable contraceptives (3 months)
in terms of therapeutic duration. Further, LNG is superior to medroxyprogesterone (API
in Depo-Provera) regarding the bone loss [1, 2]. Therefore, injectable contraceptives of
LNG stands as a promising alternative to the existing injectable LARCs.
Apart from the pharmacokinetic evaluation, the efficacy of the formulations was
also examined by studying the vaginal secretions of the rats injected with LNG. Unmated
lab female rats show cyclic changes in the vaginal cytology through the span of the
estrous cycle, and these progressions are biological markers of variances in the release of
the ovarian hormones. In most non-pregnant lab rats, a complete cycle of such changes
happens each 4 or 5 days [234]. Figure 2-14 shows the cyclic changes in the estrous
cycle represented by the vaginal cytology images. Normal estrous cycle progression in
rats is 4 day (M D P E M) or 5 day (D D P E D or M D D E M). Periodical examination
of the vaginal secretions of the rats after injecting with the formulations revealed that the
rats were acyclic indicating that formulations successfully suppressed the normal estrous
cycles in the rats. Figure 2-15 shows representative images of vaginal cytology after
injecting the formulation (96) for consecutive days showing acyclic progression. The
group of rats injected with 96 formulation was selected, and the vaginal examination was
continued after five months to demonstrate if the LNG-loaded ISD formulation effects
are reversible in the rats after the end of the treatment. The results revealed that the rats
resumed estrous cycles after clearance of the LNG indicating that the effects of the
formulations are reversible. Further, when these female rats were co-caged with male rats
for fertility study, the results demonstrated that 6 out of 8 rats become pregnant (#96)
after clearance of the LNG at about 8 months after initial injection suggesting the return
of fertility after the treatment.
Initial In Vivo Burst Study of 64 and 96 Formulations
One of the primary limitations of ISD formulations is the initial burst, so it is
essential to analyze the initial burst drug levels in plasma for ISD formulations. As 55
formulation showed poor long-term in vivo performance, only 64 and 96 formulations
were selected to conduct the in vivo initial burst study. A short-term pharmacokinetic
study was conducted where the drug levels were detected immediately during the early
time intervals within 24 h after injecting the formulations (64 and 96). The initial burst
levels of the formulations were detected and compared to the data obtained by injecting
LNG solution alone (in NMP), (Figure 2-16). The Cmax, Tmax and AUC(0-24h) of the drug
solution and formulations is given in Table 2-14. LNG solution in NMP without the
polymers has resulted in a Cmax of 231.7±17.8 ng·mL-1 and AUC(0-24h) of 725.4 ± 45.5
ng·hr·mL-1 (n=6) at a dose of 4 mg per rat (roughly 16 mg/kg), while the presence of
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Figure 2-13. Changes in body weights of rats subcutaneously injected with ISD
formulations.
Notes: The LNG containing ISD formulations (n=8) 55 (open diamond), 64 (open circle),
and 96 (open triangle) were injected subcutaneously into female SD rats at a dose of 10
mg per rat (~40 mg.kg) and the body weights monitored over a period ~7 months. The
control rat weights are represented by cross mark (n=2). Each point represents the
mean±SE. The rats injected with LNG showed increased weight gain compared to the
control.
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Proestrus

Estrus

Metestrus

Diestrus

Figure 2-14. Four stages of rat estrous cycle and characteristic features.
Notes: Proestrus (P) - nucleated epithelial cells; Estrus (E) - anucleated cornified cells;
Metestrus (M) -leukocytes, cornified, and nucleated epithelial cells; Diestrus (D) leukocytes
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Figure 2-15. Representative image of the cycle progression in rats injected with
formulation (F-96).
Notes: Cycle Progression: DDDDDDPEMDDDDDD, representing acyclic.
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Figure 2-16. Plasma concentration of LNG (initial burst levels) in female SD rats
as a function of time over 24 h after SubQ injection of ISD formulations and control
LNG.
Notes: LNG solution: 4 mg LNG in 400 μL NMP (square, n=6); 64 formulation (circle,
n=5), and 96 (triangle, n=3) formulations containing 10 mg LNG. Each point represents
the mean±SE. Formulations showed a significant suppression of Cmax and AUC(0-24h)
compared to the control LNG solution.
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Table 2-14. Pharmacokinetic parameters of LNG solution in NMP, 64 and 96
formulations in rat plasma after SubQ injection.
Formulation
#
LNG in NMP (n=6)
64 (n=5)
96 (n=3)

Injection dose
mg·Kg-1
16
40
40

Cmax
ng·mL-1
231.7±17.8
20.8±7.88
103.6±2.88
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Tmax
h
0.29±0.04
0.35±0.06
0.33±0.08

AUC(0-24 h)
ng·hr·mL-1
725.4±45.5
35.6±9.13
319.0±20.2

polymers in the formulation has significantly suppressed the amount of LNG release into
the systemic circulation even though the dose (10 mg/rat) was 1.5 times higher compared
to the LNG solution. 64 and 96 formulations resulted in a Cmax of 20.8±7.9 ng/mL (n=5),
and 103.6± 2.9 ng·mL-1 (n=3), respectively, meanwhile the AUC(0-24h) were found to be
35.6±9.13 and 319.0±20.2, respectively. 64 formulation has shown significant lower
burst (5 times lower Cmax) compared to the 96 formulation, and the reduced initial burst
might be due to the altered phase inversion dynamics [184, 220] as a result of increased
polymer molecular weight (102 kDa vs 63 kDa), drug loading (6% vs 2.5%), injection
volume (160 μL vs 400 μL), and change in solvent (NMP/TEC vs NMP/BB), but the
primary factor is assumed to be the polymer MW. Polymer MW is a critical parameter
that can affect the drug release and it is reported in the literature that increased polymer
molecular weight has shown a significant lower burst because of the formation of the
denser structure of the depot [184, 235, 236]. On the other hand, the lower molecular
weight PLA used in 96 formulation resulted in reduced viscosity (0.67±0.05 Pa.s vs.
1.71±0.01 Pa.s for 64) causing more faster release of organic solvent and LNG, which
might lead to a fast phase inversion type depot formation having greater porosity and fast
release [237]. Other factors that may have involved for the initial burst in vivo for the
formulations is the interstitial pressure/compressive forces exerted on the depot by the
surrounding tissue environment which forces the solvent and drug to efflux out fast
increasing the rate of depot formation in vivo [185, 238]. Although the polymer
percentage (~24%) used in the prototype formulations is lesser than that employed in
Eligard® (33-44%), still the formulations showed promising in vivo burst profile,
suggesting that the use of polymer blend has a favorable effect. Additionally, the use of
polymer blend and low polymer concentration (24%) has enabled to incorporate high
molecular weight polymer into the formulations to achieve low burst while maintaining
the favorable injectability (21/23G).
Summary of the observations based on the in vitro and in vivo evaluation of the
formulations 55, 64, and 96 from set-1 formulations is given in Figure 2-17. Formulation
64 showed at least 7 months’ in vitro and in vivo LNG release with its in vitro depots
maintaining integrity until the end of the study, and has shown low in vivo burst. The 55
formulation could last only for 3 months in vitro and in vivo. 96 formulation showed 5Ǧ 7
month LNG in vitro and in vivo release profile, with detectable LNG concentration in 3
rats at 7 months post injection, but has shown 5.5 times higher in vivo burst LNG levels
than 64 formulation. This promising data indicated that a formulation in between 64 and
96 would probably achieve robust 6-7 month LNG release, with better injectability and
low initial burst.
Design of Formulation Set - 2
The major difference in composition between the 64 and 96 formulations is PLA
intrinsic viscosity (0.63 vs. 0.47) or MW and amount (18.8% vs. 12%), solvent type
(NMP/TEC vs. NMP/BB) and LNG amount (6% vs. 2.5%). In order to improve the
formulation release duration, injectability, and lower the burst following optimization
strategies have been adopted:
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Figure 2-17. Key results summary of 55, 64 and 96 ISD formulations.
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Started with the 96 formulation and replaced the PLA (iv 0.47) in the 96
formulation with PLA (iv 0.63, higher viscosity/MW, the polymer used in the 64
formulation) at 3 different weight amounts: 20%, 16%, and 12%.
Replaced BB solvent in the 96 formulation with TEC (solvent used in the 64
formulation) or ethyl acetate (EA, studies showed that EA maintained good in
vitro gel integrity and drug release profile [239])
Increased the drug loading to 4% (but maintained below 6% to avoid any
solubility issues).
Kept the PLA polymer amount (~20%) as 64, but used a blend of PLA (iv 0.47)
and PLA (iv 0.63).
In Vitro Accelerated Release Study

Conducting the real-time release under physiological conditions (PBS, pH 7.4)
can take months to years depending on the required drug release duration (Figure 2-6),
which is laborious and expensive. Therefore, a fast and reliable accelerated in vitro
release method that can predict the real-time release in a short time is needed to save time
and money [11,12]. Unfortunately, although several accelerated in vitro release methods
have been developed for PLGA or PLA-based microspheres and preformed implants
[12], but there is no accelerated in vitro release method for injectable ISD systems
reported in the literature yet. Studies were conducted to develop an accelerated in vitro
drug release method for LNG-loaded ISD systems for rapid screening/ differentiation/
optimization of long-acting contraceptives, and also provide some guidance that can be
useful for the development of accelerated release methods for ISD systems in general.
The selection of appropriate stress conditions for accelerating the drug release is
dependent on the nature and composition of the formulation, stability of the drug and
release medium, release mechanisms, and requirements related to the sampling interval
and duration of the study [14]. In this work, different combinations of four conditions of
release media including: (a) temperature [11,14–27]; (b) presence of organic solvents
such as alcohol, acetone, acetonitrile as co-solvents [12,15,28]; (c) presence of
surfactants [18,28–31], and (d) pH [12,15,16] were used to develop an accelerated in
vitro drug release method for screening ISD systems for long-term release of LNG for
contraception. The correlations between the release kinetics and mechanisms of LNG
from ISD systems under real-time and accelerated conditions were established [240].
Accelerated (short-term) in vitro release
96 and 64 formulations were used as control formulations for developing the
accelerated release condition. As the real-time in vitro LNG release took months (Figure
2-6) to be conducted, four different release conditions were explored as listed in Table
2-4 to develop an accelerated short-term (2 weeks) release method that would correlate
well with the real time long term release so that it can be used for screening ISD systems
for sustained release of LNG. The accelerated release profiles of the formulations 96 and
64 at four different conditions tested are shown in Figure 2-18I, II, respectively.
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Figure 2-18. Short-term (accelerated) in vitro LNG release from formulations 96
(I) and 64 (II) at four accelerated conditions.
Notes: (A) PBS, pH 7.4, 50 °C (filled diamond); (B) 25% ethanol in PBS, pH 7.4, 50 °C
(filled square); (C) 25% ethanol in PBS, 2% Tween 20, pH 7.4, 50 °C (cross mark); (D)
25% ethanol in PBS, 2% Tween 20, pH 9, 50 °C (filled triangle). Each point represents
mean±SD, n = 3).
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Under elevated temperature alone (condition A: PBS, pH 7.4, 50 °C), Figure
2-18I, II show that only 3.2% and 0.97% of LNG was released from the formulations 96
and 64, respectively, during 14 days. These amounts were slightly higher than those
corresponding amounts, ~2.97% (96) and ~0.47% (64), at 37 °C (Figure 2-6). When the
release was conducted at elevated temperature, the drug release rate would increase as the
drug diffusion and polymer degradation rate increased with temperature [11,15–22,34].
However, at elevated temperature, the polymer’s mobility also increased, which could
cause a decrease in the drug release rate as the polymer movement could change the
depot surface morphology and cause surface pore closure [11]. Possibly due to the
competing effects mentioned above, the overall drug release rates from the two
formulations did not increase too much when the temperature was increased from 37 to
50 °C. Further investigation is needed to test this hypothesis.
To achieve a higher LNG release rate, the temperature could be further increased.
However, to avoid any potential high temperature related stability concern of the drug,
we set the release temperature at 50 °C and explored the effects of additional parameters
such as addition of organic solvent ethanol (condition B), and addition of ethanol and
surfactant Tween 20 (condition C) in the release media on the drug release rate. Organic
solvents such as alcohol, acetone, and acetonitrile added to the release medium as cosolvents were reported to accelerate drug release due to the swelling property of the
hydro-alcoholic solvent which could cause the morphological changes such as surface
pitting and pore formation of depots with time (hydro-alcoholic effect) [12,15,28]. As
ethanol is more environmentally friendly than acetone and acetonitrile, we chose ethanol
as a co-solvent for the accelerated release study. Surfactants such as Tween 20, Brij 35P,
Triton X-100 could form micelles in the release medium to extract out the hydrophobic
drug loaded in the depot so that the drug would be released faster from the depot
[28,35,36]. In this accelerated release study, we chose ethanol as a co-solvent and Tween
20 as a surfactant. Figure 2-18I (96B),II (64B) showed that replacement of 25% of the
release medium with ethanol did not cause much change in the LNG release rates from
the two formulations 96 and 64 during the initial three days; the LNG release slowly
increased during days 3 to 7, and the LNG release increased significantly during days 7 to
14 and about 9-fold on day 14. These results suggested that the hydro-alcoholic effect did
not work so well to accelerate LNG release during the first 3 days. To study if the further
addition of surfactant would accelerate more LNG release, we added Tween 20 at 2 wt%
in the release media and found that the addition of Tween 20 did not have much effect on
the LNG release from formulations 96 and 64 during the first 7 and 5 days, respectively;
decreased the LNG release from formulation 96 during 7–14 days, however, it increased
the LNG release from formulation 64 dramatically after day 5 (Figure 2-18I(96C),
II(64C)). The different effects of Tween 20 on LNG release from 96 and 64 formulations
could be due to the differences in the porosities of the depots at condition C, which led to
variation in the amount of Tween 20 micelles formed in the polymer matrix. The depot
formed from 96 formulation probably generated more and faster pores than that from 64
formulation (similar to the real-time conditions, Figure 2-7) as the corresponding
inherent viscosities of the PLA used for the 96 and 64 depot preparation were 0.47 and
0.63 dL/g, respectively. The more porous 96 depot may have allowed more surfactant to
come inside the depot to form more micelles to hold more drug inside the depot. As a

70

result, the addition of surfactant Tween 20 would have caused a significant amount of
micelles formed inside the depot formed from 96 formulation so that LNG was released
less from the depot under condition C than condition B after 7 days. The above
interpretations of the results need further investigation.
As the three accelerated conditions A, B and C were unable to cause fast release
during the first three days, then the pH of the release medium was increased from 7 to 9
(condition D). Figure 2-18I, II show that the release of LNG from both the 96 and 64
formulations was significantly increased during the first three days under condition D in
comparison to the other three conditions A, B, and C. The reason was probably due to the
faster degradation of PLGA/PLA in the depot caused by alkaline pH 9, which was
already well documented in the literature [37,38]. After 3 days, LNG was continuously
released under condition D with amount about 8–10 times on day 14 than under condition
A (pH 7.4); and higher and lower under condition D than condition C (pH 7.4, 25%
ethanol, 2% Tween 20) after three days for formulations 96 and 64, respectively. These
results were probably due to the balance of the polymer degradation and micelle
formation inside and outside the depots.
The long-term goal of this study was to develop injectable formulations for
sustained release of contraceptives for five months to years. Due to the intended long
term release, the real-time 4–6 months in vitro release in Figure 2-6 and the accelerated
2-week release in Figure 2-18 did not reach 80% LNG release, but instead reached <10%
and <35%, respectively. According to FDA recommendation, an in vitro release should
be conducted until the time point when 80% or higher or a plateau of drug release is
attained [39]. However, the objective of the study was to identify an accelerated release
condition that could be used to differentiate formulations during early formulation
screening stage quickly rather than to develop a standard in vitro release protocol. The
identified accelerated release condition D for a period of 2-week release study was
sufficient and effective to achieve this objective.
Release kinetics and correlation between accelerated and real-time releases
To understand the release mechanisms of LNG from formulations 96 and 64 in
real-time and accelerated conditions, all the release data in Figure 2-18 were fitted using
empirical power law (Korsmeyer–Peppas Model, Equation 2-5) [40]. Table 2-15 lists
the parameters k, n and coefficient of determination (r2) after fitting the release curves of
96 and 64 formulations in Figures 2-6 and 2-18 using Equation 2-5.
The release curves in Figures 2-6 and 2-18 could be fitted well by Equation 2-5
with r ≥ 0.94 except for 64B and 64C which had slightly lower r2 values of 0.86 and
0.88, respectively. The n values ranged from 0.22 to 1.59 suggesting different release
mechanisms under the four accelerated conditions for the formulations 96 and 64. The
conditions A, B, and C either slightly increased (96A, 64A, 64B, and 64C) or decreased
(96B and 96C) the release rate constant k. The condition D significantly increased the k
values by about ~10.2 and ~5.8 times for formulations 96 and 64, respectively, but well
mimicked the release kinetics under real time condition for the two formulations with the
2
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Table 2-15. Fitting parameters determined by the linear regression of log (Mt/M∞) against logt in Equation 2-5 for the LNG
release from the depots made of formulations 96 and 64 under real time and four accelerated release conditions.
Formulation
(Release
condition)
96(A)
96(B)
96(C)
96(D)
96 (long-term)
64(A)
64(B)
64(C)
64(D)
64 (long-term)

Power law (Korsmeyer–Peppas model)
(Coefficient of
n (Release
k (Rate constant)
determination)
exponent)
0.96
1.62
0.22
0.94
0.50
1.59
0.97
0.57
1.15
0.99
9.23
0.41
0.99
0.90
0.46
0.99
0.26
0.52
0.86
0.41
0.97
0.88
0.49
1.24
0.97
1.28
0.64
0.97
0.22
0.65

r2
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similar fitting linearity (r2 = 0.99 for both 96D and 96; r2 = 0.97 for both 64D and 64) and
release mechanisms (n = 0.41 and 0.46 for 96D and 96, respectively; n = 0.64 and 0.65
for 64D and 64, respectively). These results are visually illustrated in Figure 2-19 (I, II).
To further correlate the short- and long-term LNG releases, the times required to
achieve the same amounts of LNG to be released from the formulations 96 and 64 under
condition D (days) and real-time (months) are shown in Figure 2-20 [26,34]. Excellent
correlations between the release times under condition D and real-time were obtained
with r2 = 0.98 and 0.99 for formulation 96 and 64, respectively. These results suggested
that the condition D was able to reduce the release time significantly compared to the
real-time, and allows for the prediction of LNG long-term release from ISD systems in a
short period. Therefore, condition D was used to screen the set-2 formulations for initial
in vitro release screening.
Screening of Set-2 ISD Formulations
Various formulation variables were investigated to reduce the undesired burst. In
each experiment, the standard formulations 96 and 64 were repeated as a reference for
comparing viscosity (injectability) and initial drug release, respectively. Initially the
formulations (96j- 96o) were screened for shear viscosity and the initial release in 24
hours at accelerated condition D. The results showed that lowering the polymer
concentration from 24% (96j, 96m) to 20% (96k, 96n) to 16% (96l, 96o) has resulted in a
significant decrease (at least 2 fold) in the viscosity (Figure 2-21A) of the formulations.
However, lowering the polymer percentage has led to significant increase in the initial
release compared to the 64 formulation (Figure 2-21B). Thus, the polymer concentration
played a significant role in the ISD formulations. A higher polymer concentration led to a
more viscous solution, which might have delayed the polymer precipitation and resulted
in a less porous polymer matrix with a slower drug release [241]. On the other hand,
increasing the drug loading from 2.5% (96j/96k/96l) to 4% (96m/96n/96o) lead to
increase in the viscosity(~1.2 to 2 fold) and a decline of the injectability of the
formulations, and the extent of increase is more prominent in case of the formulations
that had high polymer percentage (96j vs. 96m). At low polymer percentages, the drug
release rate was increased with increased drug loading which was consistent with the
literature [194]. However, in the case of formulations with high polymer percentage
(24%), increased loading has resulted in decreased initial release rate. This opposite
pattern could be attributed to significantly increased viscosity (~ 2 fold) of the 96m (4%
LNG) formulation compared to the 96j (2.4% LNG), which might have decreased the rate
of phase inversion dynamics and slowed the initial release [241].
It was observed that the formulations that showed promising release profile as 64
are 96j and 96m. This suggested that 24% of the polymer may be needed to get the
desired slow release profile as 64 formulation in vivo. However, injectability at such high
polymer percentage is a drawback. Therefore, keeping the polymer percentage (24%) and
PLA amount (20%) constant, the higher inherent viscosity PLA (0.63 iv; 103 kDa MW)
was substituted with a lower inherent viscosity PLA (0.47 iv; 67 kDa MW) at various
proportions to design 96p, 96q, and 96r formulations. Higher drug loading is favored in
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Figure 2-19. Power law kinetics (plot of log percent release vs. log of time in days)
of formulations.
Notes: 96 (I; triangle) and 64 (II; circle) in real-time (open symbols) and accelerated
(filled symbols) release condition D. Each point represents mean±SD, n=3
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75

2.5

A

64

96

96 j

96 k

97 l

96 m

96 n

96 o

10

% Cumulative LNG Release

2.0

Shear Viscosity [Pa. s]

B

12

1.5

1.0

8

6

4

0.5
2
0.0
64

96

0

96j 96k 96l 96m 96n 96o

0

Formulations

4

8

12
16
Hours

20

24

Figure 2-21. Shear viscosity (A) and LNG in vitro release in accelerated condition
D (B) of different ISD formulations.
Notes: Polymer percentage: 24% in (96j, 96m); 20% in (96k, 96n), 16% in (96l, 96o).
Complete composition listed in Table 2-3. Each point represents the mean±SD, n=3.
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terms of injection volume, as it would result in a smaller injection volume at the same
dose. Therefore, 4% LNG was loaded into the formulations instead of 2.5% and tested for
the shear viscosity. Figure 2-22 shows the shear viscosities of the 96p, 96q, and 96r
formulations. The 96r formulation has a viscosity of (0.75±0.02 Pa.s), similar to that of
96 formulation (0.65±0.05 Pa.s) and can be easily injected through 23 gauge needle.
Another formulation 96zz was prepared by replacing the TEC in 96r formulation
with ethyl acetate. The rationale for designing 96zz is that EA could increase not only the
hydrophobicity of the preparation but also decrease the viscosity. Further, earlier studies
from our group showed that EA maintained good in vitro gel integrity and drug release
profile [239]. Replacement of TEC with EA has resulted in a decrease in the mean
viscosity of the formulation from 0.75 to 0.66 Pa.s. Apart from the low viscosity, another
desirable attribute of these 96r and 96zz formulations is that both formulations showed
slower release rate of LNG than 64 formulation during the initial accelerated in vitro
release study (Figure 2-23). The order of in vitro LNG release rate during the initial 4
hours was 96zz < 96r < 64.
Both 96r and 96zz formulations which have shown injectability through the 23G
needle and promising in vitro release profile were selected for in vivo burst study and
injected SubQ into the rats at a dose of 10 mg LNG. Figure 2-24 shows the comparison
of plasma LNG concentration as a function of time in first 24 h after injecting the
formulation 96r, 96zz, and 64. The Cmax, tmax, and AUC(0-24h) of 96r and 96zz were
estimated and given in Table 2-16. The Cmax and AUC(0-24h) of LNG for the formulations
were in the order of 64 < 96r < 96zz. The initial release of LNG from 96r, 96zz and 64 in
vivo was opposite to that observed in vitro. This difference could be attributed to the
differences in the in vitro and in vivo conditions and the physiochemical characteristics of
the formulations. During in vitro studies, as the formulation was injected into the mold
and placed in the jar containing release medium, no external forces were acting on the
depot. On the other hand, when the ISD formulation was injected in vivo, a high amount
of shearing forces from the surround tissue environment will be acting on the depot.
These surround forces could exert a squeezing on the depot expelling the solvent quickly
in comparison to the in vitro depots which experience no external forces. Another factor
could be related to the viscosity of the formulations. The Cmax of the formulations was
increased with a decrease in the viscosity of the formulation, which could be due to
higher rate of phase inversion dynamics with decreased viscosity leading to faster initial
release [241]. Although 96r and 96zz formulations have similar composition except for
co-solvent (TEC vs EA), a significant difference (2.7 fold) in the Cmax was observed
between 96r and 96zz. EA has more 1.44 times higher water miscibility and 77.9 fold
lower viscosity than TEC. Because of the high water miscibility (1.4 fold) and significant
low viscosity (77.9 fold) of the co-solvent EA compared to TEC, the solvent mixture
NMP:EA (96zz) might have left the system rapidly compared to the NMP:TEC (96r)
mixture during in vivo conditions because of tissue compressive forces. This fast
diffusion of the solvent along with dissolved drug might have resulted in the higher initial
release of LNG in vivo for 96zz formulation compared to 96r. The 96r formulation has
shown promising in vivo profile close to 64 formulation. To this end, the optimized
formulation 96r has favorable attributes which include injectability through a 23G needle
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Figure 2-22. Shear viscosities of 64, 96, 96p, 96q, and 96r formulations.
Notes: LNG Loading and polymer percentage in formulations (96p, 96q, and 96r) is 4%
and 24%, respectively. However, the formulations varied in the polymer composition.
Complete composition listed in Table 2-3. Each point represents the mean±SD, n=3.
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Figure 2-24. LNG Plasma concentration measured in rats as a function of
time after SubQ injection of 64, 96r, 96zz formulations.
Notes: Dose: 40 mg∙kg-1. The difference between 96r and 96zz is the co-solvent (TEC vs
EA). Each point represents the mean±SE, n=3-5.
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Table 2-16. Pharmacokinetic parameters of 96r and 96zz formulations in rat
plasma after 24 hours post SubQ injection.
Formulation
#
96r (n=3)
96zz (n=5)

Injection dose
mg·Kg-1
40
40

Cmax
ng·mL-1
29.0 ± 6.39
79.0 ± 11.1
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Tmax
h
0.20± 0.02
0.25± 0.08

AUC(0-24 h)
ng·hr·mL-1
149.14 ± 12.19
231.22 ± 33.07

(close to 96 formulation), and slow in vitro release, and low initial in vivo burst (close to
64 formulations). The lead formulation 96r has great potential to show a long-term in
vivo LNG release.
Conclusions
A series of LNG-containing ISD formulations were designed by employing
unique strategies which include the use PLGA, PLA with different biodegradable
properties, and blends of these polyesters, use solvent mixtures of NMP, TEC, BB, EA
and with varying polymer/solvent ratios, and drug loadings. This study has investigated
and effect of formulation variables on injectability, in vitro release and in vivo initial
burst of LNG-containing ISD systems.
In the process, new methods have been developed and reported for detecting LNG
in rat plasma, and for accelerated in vitro release of LNG from ISD formulations for rapid
screening. The details and the finding from these two new methods are:
•

•

A simple and sensitive LC/MS/MS method for quantitative bioanalysis of
levonorgestrel in rat plasma was developed and validated and applied to
pharmacokinetics study of LNG in rats. LNG was successfully extracted and
quantified in rat plasma using the presently developed LC/MS/MS method, and
the resultant mass spectra was satisfactory in terms of identification, least
interference from matrix components and better quantification. The developed
liquid–liquid extraction method using hexane/ethyl acetate (80/20, v/v) mixture
was fast and efficient in terms of matrix effect and recovery efficiency. Moreover,
this technique required a small amount of rat plasma (100 μL) unlike any
previously reported methods which used 0.5–1 mL of human plasma. Calibration
curve was successfully constructed within a concentration range of 0.5–50 ng·mL1
. The developed method was successfully validated for specificity, accuracy,
precision and stability. Furthermore, this validated method was successfully
applied to study LNG pharmacokinetics after single SubQ injection of LNG alone
and LNG-containing ISD formulations in rats.
An accelerated release study to evaluate long-acting contraceptive LNGcontaining ISD systems was developed. In summary, elevated temperature,
addition of alcohol and surfactant, and change of the pH of the releasing medium
to basic could result in an increase in the drug release rate of ISD systems, due to
higher degradation of the depot polymers, increase of the porosity of the depot
matrices, and thus fast diffusion of the drug out of the depots. The developed
accelerated release condition D (25% ethanol in PBS, 2% Tween 20, pH 9, 50 °C)
shortened the 4-5 month real-term LNG release from formulations 96 and 64 in
PBS (pH 7.4) at 37 °C to days without changing the drug release mechanisms.
The developed accelerated release method has significance not only in helping
rapid screening of formulations for the development of ISD-based contraceptives
containing LNG, but also for providing guidance for the development of
accelerated in vitro release testing methods for ISD systems in general.

82

The summary of the key findings during the screening and optimization of ISD
formulations for contraception that were outlined in this chapter:
•

•

•
•
•

During the initial screening, the formulations 64 and 96 suppressed the rat normal
estrous cycles for 5 and ≥7 months, respectively after one SubQ injection. No
significant swelling or inflammation was observed at the site of injection. After
the end of the treatment, a rapid return of fertility was observed in rats. The
prototype injectable ISD formulations (64 and 96) studied for long-acting
contraception exceeded the current commercial products Depo-Provera®/DeposubQ Provera 104® in terms of duration (≥ 5 vs. 3 months), and Eligard® in terms
of needle size (21-23 vs. 18-20 G). However, 96 formulation with promising
injectability showed significantly higher burst compared to 64 formulation.
Therefore, the optimization process was further continued to get a balance
between injectability and initial burst.
The shear viscosity and injectability of the formulations was found to be
proportional the polymer concentration, polymer inherent viscosity (or MW), and
drug loading. In vitro LNG release studies demonstrated that polymer
concentration and polymer inherent viscosity were the critical variables
controlling the in vitro release. Decrease in polymer concentration (from 24% to
14%), or polymer inherent viscosity (from 0.63 to 0.47) in formulations with
similar composition has resulted in a decrease in shear viscosity (~ 3 to 7 fold),
increased injectability (23 G needle), but showed faster in vitro LNG release.
Formulations with TEC as secondary solvent showed a low initial burst in vivo
compared to the similar formulations EA as co-solvent.
The initial in vivo burst of LNG release was found to vary as a function of
polymer concentration, polymer inherent viscosity, and co-solvent used in the ISD
formulation.
The formulations with the optimum balance between the injectability (23 G
needle) and the LNG release was obtained with a total polymer concentration of
24%, a solvent combination of NMP/TEC and a shear viscosity between 0.7-1
Pa.s. The optimized lead formulation 96r designed by a unique blend of PLGA
and PLA polymers with different molecular weights has shown favorable
injectability (23G) and in vivo initial burst, and has a high chance that it can show
a promising long-term in vivo LNG release. The optimized formulation will serve
as better candidates in terms of injectability and burst release and can be further
investigated for long-term release and stability studies.

In conclusion, the results have demonstrated that the injectable ISD formulations
can serve as an effective means of administering LNG with minimal tissue toxicity for
long-term contraception suggesting that the designed ISD formulations have great
potential for developing future robust and affordable injectable LARC products that
could improve access to family planning around the globe.

83

Future Work
There is a high possibility that the optimized formulation (96r) could show a
promising long-term in vivo LNG release. Therefore, the future work of this project
include: i) conducting long-term in vivo PK studies with the 96 r formulation in rats to
evaluate the extended release profiles of the LNG for five months, vaginal cytology,
fertility study and in vivo safety, ii) continuation of the formulation optimization iii)
developing a protocol for the terminal sterilization of the formulations, iv) evaluation of
the stability of lead formulations upon storage, v) scale-up of lead formulations
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CHAPTER 3. POLYSACCHARIDE-BASED NANOPARTICLES FOR DRUG
DELIVERY ACROSS OCULAR/BLOOD-BRAIN BARRIERS
Background
Since past few decades, several new chemical entities have been discovered as
potent therapeutics for treating various diseases. In spite of the potency, more often their
efficacy is still hampered by the inability to reach the target site of action [35, 36]. These
hurdles for the effective therapy of drug molecules (small or biologicals) could be
attributed to the physicochemical properties of the drug molecules and the various
barriers imposed by the body [242]. The human body possess various external (e.g. skin,
intestine) and internal (bloodstream, the cytoplasm of tissue) physiological barriers which
constitute the interface between different physiological environments so that a selective
compartmentation is made for the effective regulation of distinct physiological functions
in the body [242]. These act as a boundary between inside and outside of units such as a
cell (e.g. cell membrane) or organ (e.g., cornea of the eye, BBB of brain) and usually
permit the entry of oxygen and some key solutes, maintain water homeostasis and restrict
the entry of other components and foreign materials [243]. They control the impact of
external environment on the human body [35, 242]
Although these barriers are body’s natural defense mechanism against foreign
invaders, unfortunately, they pose significant hurdles to the drug therapy. Drugs need to
traverse several physiological barriers to reach the target site to achieve effective drug
concentration levels [36]. For instance, skin is the biggest obstruction to the topical drug
delivery, while an epithelial layer of the GIT blocks the entry of drugs given orally. Even
when administered via the parenteral route, drugs still need to overcome many barriers,
either in blood or at the site of action. For example, the BBB and blood-retinal barrier
(BRB) are the tightest barriers which prevent the entry of drugs from the bloodstream
into the central nervous system and internal ocular tissues, respectively [243, 244]. In
addition to the physiological (physical) barriers, another category of biological barriers
that impede the drug activity are the biochemical and chemical barriers such as enzymatic
degradation and elimination, the presence of efflux transporters [245-247].
For a drug to show its therapeutic activity, it is essential to overcome the
physiological barriers and achieve desired concentrations at the target site [36]. These
barriers may comprise of a single (e.g., intestinal epithelium) or multiple (e.g., skin,
cornea) layers of cells that regulate the nutrients, electrolytes, and water exchange while
restricting the entry of microbes, toxins, and antigens. The epithelial or endothelial cells
which constitute the barrier have unique elements that promote barrier function, including
apical-basolateral polarity and intracellular tight junctions. Two common pathways by
which drugs cross these cellular layers are transcellular (through the cells), paracellular
(between the cells) pathways. Transcellular drug transport is referred to the transportation
of the drug across the membrane through penetration through the cell layer. The main
mechanisms by which drugs penetrate through the cell layer are: (a) Passive diffusion represents the primary mechanism where the drug molecules from outside of the cell
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surface diffuse into the cells through the cell membrane spontaneously because of the
concentration gradient; (b) Carrier-mediated diffusion - is the movement of molecules
across the cell membrane with the help of some special transmembrane carrier molecules
(or transport proteins) that are embedded in the cell membrane. This process can take
place with (facilitated diffusion) or without (active transport) the need for energy
consumption; (c) Vesicular transport: is a transcellular transportation mechanism in
which the cell membrane frames a small pit that gradually encloses extracellular material
to form a vesicle and then internalize them into the cell. The process is called endocytosis
when the material is taken into the cell, exocytosis (reverse of endocytosis) when the
material is exited out of the cell, and transcytosis when the material is transported across
the cell. Paracellular drug transport is referred to the transportation of the drug across the
membrane/barrier through the junctions between the cells. This process can be initiated
by concentration (passive diffusion) or hydrostatic pressure (filtration) gradient across the
layer. Paracellular transport between epithelial/endothelial cells is regulated by structures
at cell-cell contact sites known as tight junctions [248]. All these transport mechanisms
are regulated, different substances move using various aspects of trans/paracellular
routes. Each of these pathways can be targeted to alter barrier function and enhance the
drug permeability [249].
Some of the important physiological barriers that pose hurdles to drug transport
are the intestinal epithelium, skin, ocular barriers, and blood-brain barrier. The barriers of
interest to this project (ocular and blood-brain barriers) are discussed in detail below:
Ocular Barriers
The structure of the eye and ocular barriers for drug delivery is illustrated in
Figure 3-1. Clinically, the anterior segment diseases/disorders are more often treated by
using eye drops, or ointments, while the posterior eye segment diseases are treated by eye
drops, or intravitreal injection/implantation. Local therapy via topical, periocular or
intravitreal administrations is more favorable over the therapy via systemic
administration such as oral and intravenous administrations to manage ocular diseases.
The first reason is that the eye has much less blood vessels and blood flow than the whole
body blood circulatory system so that the amount and rate of drugs to be cleared through
local eye administration is much less than through systemic administration. The second
reason is due to the presence of blood-aqueous barrier (BAB), and BRB which limits the
drug penetration from the systemic circulation into the anterior and posterior segment of
the eye, respectively.
Routes of Administration and Ocular Barriers
Several routes of administration for drugs to treat eye diseases include topical,
intracameral, periocular routes (such as subconjunctival, sub-Tenon’s, retrobulbar),
intravitreal and systemic routes. Depending on the routes of administration, one or more
ocular barriers need to be circumvented for drugs to reach the disease/action sites in the
eye. Table 3-1 lists the routes of administration and their associated advantages and
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Figure 3-1. The structure of the anterior segment of the eye and ocular barriers
for drug delivery.
Notes: A) Tear film barrier: Main components of the tear film include mucins, water, and
lipid, and acts a defensive barrier to the foreign-object access to the cornea and
conjunctiva. B) Corneal barrier: avascular and comprised of three major layers which are
epithelium (multiple layers stacked on each other), stroma and endothelium (single
layer). Acts as a barrier preventing the drug absorption from the lacrimal fluid into the
anterior chamber after the topical administration. C) Conjunctival barrier: mucous
membrane consisting of conjunctival epithelium (2-3 layers thick), and an underlying
vascularized connective tissue. Acts a barrier to the topically administered drugs, and
relatively inefficient compared to the corneal barrier. D) Blood-aqueous barrier: located
in the anterior segment of the eye. Formed by the capillary endothelium in the iris, and
the ciliary epithelium which both contain tight junctions. The barrier is relatively
inefficient compared to the BRB, and small molecules can reach the aqueous humor by
permeation through fenestrated capillaries in the ciliary processes. E) Blood-retinal
barrier (BRB): located in the poster segment of the eye. Formed by the retinal pigment
epithelium (outer BRB) and the endothelial membrane of the retinal blood vessels (inner
BRB), both contain tight junctions. The tight junctions restrict the entry of the drugs from
the blood (systemic) into the retina/aqueous humor.
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Table 3-1.

Administration routes for delivering drugs to the anterior segment of the eye.
Route of administration
Topical

Advantages
simple, convenient, self-administrable
and noninvasive administration;
avoiding the blood-aqueous barrier; no
first-pass metabolism

Intracameral

avoiding the cornea, conjunctiva, and
blood-aqueous barrier; no first-pass
metabolism; high efficacy; high
bioavailability

Subconjunctival

easy and minimally invasive
conjunctival blood and lymphatic
administration; avoiding the cornea and clearance
blood-aqueous barrier; no first-pass
metabolism; good efficacy; good
bioavailability; sustained release

Intravitreal

direct delivery to the back of the eye;
highly invasive; inherent potential
surpass all the barrier; sustained release complications such as hemorrhage,
(intravitreal implants)
cataract, endophthalmitis, and retinal
detachment; rapid clearance

Systemic

convenient to deliver a large dose of
the drug; noninvasive; avoiding the
cornea
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Limitation
short contact time of drug on the
ocular surface; low efficiency and
low bioavailability due to corneal and
conjunctival barriers, tear clearance,
and nasolacrimal drainage
usually need reconstitution; correct
dosing and preparation are critical.

low bioavailability due to systemic
absorption and blood-aqueous
barrier; first-pass metabolism

limitations. In the following, we will discuss the details of the routes of administration
and related ocular barriers.
Topical Administration
Topical administration is the simplest, convenient, self-administrable, noninvasive, and most dominant drug administration route for the management of eye
diseases/disorders. It is a local drug delivery method, avoiding the blood–aqueous barrier,
and the side effects and first-pass metabolism that may occur in some systemically
administrated drugs. Drugs administrated through the topical route are usually formulated
into eye drops. Depending on the formulation and drug’s physiochemical characteristics,
the drugs can reach various external (cornea, conjunctiva sclera) and internal (iris, ciliary
body, aqueous humor, vitreous humor, retina) sites in the eye after topical instillation
[250]. However, only 1-7% of the administered drugs can reach the intraocular tissues
due to the tear film, cornea and conjunctiva barriers and another obstacle such as
lachrymal drainage, tear drainage and tear turnover [246, 251, 252]. Tear film is the first
obstacle faced for topically administered drugs. It consists of three layers: an outermost
lipid layer, a thicker aqueous middle layer and an innermost mucin layer (Figure 3-1A).
Due to the fast turnover rate and time of tear film, the topically administered eye drops
are quickly washed away and drained into nasolacrimal duct after instillation [253].
Cornea is the second ocular barrier limiting the penetration of exogenous substances into
the eye. It is composed of five layers: epithelium, Bowman’s membrane, stroma,
Descemet’s membrane, and endothelium (Figure 3-1B). The layers which form
substantial barriers to drug penetration are: epithelium, stroma and endothelium. The
superficial corneal epithelium is composed of multiple layers of stratified squamous nonkeratinized epithelial cells. It limits the permeation of hydrophilic drugs through the
cornea due to the hydrophobicity of the epithelium and the presence of tight junctional
proteins between the corneal epithelial cells [250, 254]. The inner layer next to the
corneal epithelium is stroma. The stroma is comprised of glycosaminoglycans and
collagen fibrils in lamellar structures, and has hydrophilic environment. It restricts the
penetration of lipophilic drugs through the cornea [250]. The innermost layer of the
cornea is monolayer corneal endothelium composed of hexagonal-shaped endothelial
cells. This corneal endothelium is leakier than the epithelium and allows the penetration
of macromolecules into the aqueous humor on the other side [250]. Overall, cornea acts
as a physical barrier to hydrophilic drugs due to the superficial corneal epithelial layers;
and to lipophilic drugs due to the stroma. Besides the cornea route, topically administered
drugs can be absorbed into the eye through non-cornea route: the conjunctiva/sclera
pathway as the conjunctiva has a large surface area than the cornea (17 vs. ~ 1 cm2) [251,
252, 255, 256]. Conjunctiva is a rate-limiting barrier for permeation of water-soluble
drugs [257, 258] due to rapid drug elimination by conjunctival blood and lymphatic flow
(Figure 3-1C). After escaping from the conjunctival elimination, drugs penetrate through
the sclera to inner ocular tissues (trans-scleral pathway).
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Intracameral Administration
Intracameral administration is a method for direct injection of drugs into the
anterior chamber in the anterior segment of the eye [259]. It is a local drug delivery
method, avoiding the side effects and the first-pass metabolism that may occur in some
systemically administrated drugs. It also avoids the cornea, conjunctiva and bloodaqueous barriers. Therefore, intracameral injection can deliver drugs to the eye relatively
easily with high efficiency and was expected to achieve 300 to 600 times aqueous humor
drug level than topical application [260, 261]. After intracameral injection, the
mechanism for drugs to reach the inner ocular tissues was via diffusion and the bulk flow
of aqueous humor. However, intracameral antibiotics usually need reconstitution
including dilution and other special preparations which require sterilization, nonpreservatives, and proper concentration and dose. If incorrect dosing and preparation
occur, corneal endothelial toxicity and toxic anterior segment syndrome become
significant concerns [261, 262].
Subconjunctival Administration
Subconjunctival administration (periocular routes) places drugs in the
subconjunctival space around the outside of the sclera, and then drugs penetrate through
the sclera into the eye. This route is safer and less invasive and effective for delivering
drugs to the eye, avoiding the cornea and blood–aqueous barriers, and the side effects and
the first-pass metabolism that may occur in some systemically administrated drugs. It is a
local drug delivery method, and can offer sustained drug delivery depending on
formulations or devices. Through this route, the primary pathway to reach the retina is via
sclera and underlying choroid–Bruch’s layer and retinal-pigment epithelium (RPE). The
sclera is the white outer elastic and microporous tissue layer comprised of proteoglycans
and closely bundled collagen fibers, containing about 70% water. The pathway for drugs
to diffuse across sclera is through the interfibrillar fluid media of the gellike
proteoglycans. Sclera has large surface area and relatively high permeability than cornea,
and the transscleral permeation mainly depends on the size of the drug molecules rather
than their lipophilicity [250, 263, 264]. However, the subconjunctival route has
limitation of possible loss of drugs to the systemic circulation due to the drainage via the
conjunctival blood and lymphatic vessels [263, 265].
Intravitreal Administration
Intravitreal administration is a highly invasive route that provides the direct
approach for delivering medications to the back of the eye with a greater probability of
achieving effective drug concentrations in the posterior tissues while lowering the risk of
systemic exposure. Several of the current therapeutics (eg. Avastin, Lucentis,
Dexamethasone) relies on intravitreal administration for treating posterior eye diseases.
Although intravitreal route is very advantageous as it overcomes all the ocular barriers
and allows direct entry of drugs into the back of the eye, it suffers from various inherent
potential complications such as hemorrhage, cataract, endophthalmitis, and retinal
detachment. Because of its invasive nature, it lacks the patient compliance. Moreover,
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drugs administered directly into the vitreous humor undergo rapid elimination. To avoid
multiple injections, intravitreal sustained release systems such as implants, microspheres,
liposome can be used. However, intravitreal implants too suffer from similar
complications as intravitreal injections.
Systemic Administration
Systemic administration can deliver drugs to the anterior segment and posterior
segment of the eye, but with low bioavailability due to the presence of the BAB, and
BRB. The two layers that comprise the BAB are the endothelium of the iris/ciliary blood
vessels and the nonpigmented epithelium of the ciliary body (Figure 3-1D) [266]. BRB is
located in the poster segment of the eye. As the retina is in contact with the highly
vascularized chordal tissue which has fenestrated capillaries, there are two BRBs. It is
formed by the retinal pigment epithelium (outer BRB) and the endothelial membrane of
the retinal blood vessels (inner BRB), both contain tight junctions (Figure 3-1E). The
outer BRB is a monolayer of tightly joined RPE and separates the posterior side of the
retina from the choroid. Both outer and inner BRBs have tight junctional complexes and
limit the penetration of blood-borne components into the aqueous humor/retina.
However, both the layers are expressed by wide range of selective transporters for the
solutes. In order to achieve therapeutic levels of drugs in the internal ocular tissues, high
doses are necessary. High doses can cause adverse systemic side effects so that systemic
administration route is rarely used to treat eye disease/disorders.
Blood Brain Barrier*
BBB is the protective interface that separates the brain from the systemic
circulation and this barrier has several common features as outer BRB (the retinal
endothelium, Figure 3-1E). Anatomically, the BBB is composed of endothelial cells
which are lining the cerebral microvessels and buttressed by astrocyte and pericyte cells
(Figure 3-2) [267, 268]. The BBB functions as a physical barrier due to tight junctions
between the adjacent endothelial cells, a selective ‘transport barrier’ due to specific
transport systems on the luminal and abluminal membranes of the endothelial cells, and a
‘metabolic barrier’ due to the presence of intracellular and extracellular enzymes [269272]. The tight junctions are composed of three integral membrane proteins including
claudin, occludin, and junction adhesion molecules, and a number of cytoplasmic
accessory proteins including ZO-1, ZO-2, ZO-3, cingulin, etc. [267, 269]. Fully
developed tight junctions serve as a gatekeeper to restrict the paracellular transport across
the BBB. The transport systems are influx and efflux transporters. The influx transporters
------------* Adapted with permission from “Pharmaceutical research. Overcoming the blood-brain
barrier in chemotherapy treatment of pediatric brain tumors. 31(3). 2013. p. 531-540. Wu,
L., Li, X., Janagam, D. R., Lowe, T.L. © Springer Science + Business Media New York
2013. With permission of Springer.”
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Figure 3-2.

Anatomy of the blood-brain barrier (BBB).
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include solute carrier superfamily facilitating brain uptake of glucose, amino acids, ions,
and other nutrients; while the efflux transporters are ATP-binding cassette (ABC) efflux
transporters such as P-glycoproteins and multidrug resistance-associated proteins [273],
which efflux lipophilic toxins including many therapeutics away from the brain to reduce
the penetration of these molecules into the brain. The intracellular and extracellular
enzymes are monoamine oxidase and cytochrome P450 (CYP1B1), and ectoenzymes,
respectively, responsible for inactivating many neuroactive and toxic compounds in the
BBB [267, 272, 274]. While the three physical, transport and metabolic barriers allow
nutrients in the blood stream and waste generated in the brain to cross the intact BBB,
they prevent or limit non-selected substances to penetrate the intact BBB and get into the
brain. It has been well-known that 98% of small molecule drugs with a molecular weight
smaller than 400 Da including many chemotherapeutics such as carboplatin, vincristine,
cyclophosphamide, cisplatin, methotrexate and etoposide cannot cross the intact BBB to
get into the brain. Almost 100% of large molecule drugs with a molecular weight greater
than 400 Da also cannot penetrate the intact BBB by themselves [270].
Strategies for Circumventing the BBB
The strategies to circumvent/overcome the limitation of the BBB could be
categorized into i) by-passing the BBB by directly administrating therapeutics into the
brain, ii) disrupting the BBB by temporarily opening the tight junctions in the BBB, iii)
active transport across the BBB by exploiting transport mechanisms associated with the
BBB, and iv) by-passing the BBB by directly delivering therapeutics to the brain through
intranasal nose to brain route [38, 50, 275-277].
By-passing the BBB
Drugs could be directly administrated into the central nerve system (i.e. brain and
spine), thus bypassing the BBB and blood-cerebrospinal fluid (CSF) which are
formidable obstacles faced by systemic administrated (e.g. oral and intravenous) drugs.
Intrathecal administration and convection-enhanced delivery are mainstays of such
administration methods (Figure 3-3). For intrathecal administration, drugs are injected
into the fluid-filled space in spine via a needle or under the scalp via an outlet catheter
connected to the ventricles (Figure 3-3A) [278-280]. Compared to systemic
administration in which the whole body acts as a sink for the administrated drugs, the
intrathecal administration needs much lower drug dose to achieve higher drug
concentrations in the brain due to the small volume of CSF (about 150 ml). Moreover, as
the drugs are administrated behind the BBB and thus the BBB is not a concern or
obstacle for administration through this method. Intrathecal drug administration has been
used in the management of brain diseases such as brain tumors for several decades [279,
281-285]. One disadvantage for intrathecal administration is that intrathecal drug
administration can result in non-targeted drug distribution, inhomogeneous dispersion,
and ineffective volume of drug distribution due to drug molecular weights and infuscate
diffusivities.
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Figure 3-3.

Intrathecal administration (A); Convection-enhanced delivery (B).

Notes: Intrathecal administration and convection-enhanced delivery are the methods that
directly administer the drugs into the central nerve system (i.e. brain and spine), thus
bypassing the BBB and blood-cerebrospinal fluid (CSF) [280, 286, 287].
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Convection-enhanced Delivery (CED)
CED is another regional drug administration method introduced by Oldfield and
his associates to overcome the limitations for intrathecal administration [286]. In CED,
intracranial catheters are connected to target sites to deliver therapeutics under a
continuous pressure gradient over periods of hours to days and thus enhance the
distribution of drugs by convection rather than diffusion (Figure 3-3B) [288]. This
method allows delivery of high concentration of drugs directly into diseased sites in the
brain and the adjacent parenchyma, thus eluding the BBB and limiting systemic toxicity.
Small molecule drugs, macromolecules, and even nanocarriers have been successfully
method allows delivery of high concentration of drugs directly into diseased sites in the
brain and the adjacent parenchyma, thus eluding the BBB and limiting systemic toxicity.
Small molecule drugs, macromolecules, and even nanocarriers have been successfully
delivered into the brain using CED [286-290]. CED has been employed in the clinic and
clinical trials to manage brain diseases [288-293]. For instance, in the case of treating
cancer, positive response and tumor regression have been observed in the clinical studies
using CED to administer drugs [293, 294]. Even though CED, and intrathecal injection
are effective in delivering drugs into the brain, these two administration methods are
invasive in general.
Disrupting the BBB
The BBB can be disrupted by osmotic means, vasoactive substances, and focused
ultrasound [295-304]. The disruption induced transiently opens the BBB and thus allows
therapeutics, which are generally prevented from entering the brain, to pass this barrier
and get into the brain tissues. In the osmotic BBB disruption approach, a hypertonic
solution is infused into the arterial blood to cause brain microvascular endothelial cells in
the BBB transiently and reversibly shrink so that the tight junctions in the BBB is
transiently opened to allow the entrance of hydrophilic therapeutics into the brain [295].
Mannitol is the most widely used hyperosmotic agent for this osmotic BBB disruption. In
the clinic, osmotic BBB disruption has been used to deliver chemotherapeutics into the
brain for decades [298, 305-309]. However, this osmotic BBB disruption is global, nonselective disruption covering both diseased areas and normal brains region. This
nonselective opening of the BBB may allow the entrance of other substances which
might lead to adverse effects as seizures and chronic neurological changes [310]. A
delayed recovery of the BBB also increases the risk of neurotoxicity [310]. These
stimulated researchers and clinicians to seek methods to open the BBB at the diseased
lesions selectively. Vasoactive substances were found to be capable of stimulating
receptors preferentially expressed in the brain tumor vascular vessels over normal brain
vessels and thus initiate second messenger systems that induce reversible opening of the
tight junctions in the brain tumor vascular vessels [310]. This unique property was
exploited by researchers and clinicians to open the BBB at the diseased sites selectively
[297, 310-313].
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Active Transport across the BBB
It has recently been recognized that therapeutics could be successfully delivered
into the brain after intravenous injection by crossing the BBB without the need of
disrupting the BBB. The methods that have been developed are to utilize the transport
mechanisms found in the BBB to rationally design drugs and/or drug delivery systems to
enhance drug permeability across the BBB. The transport mechanisms exploited include
the transcellular lipophilic pathway responsible for the uptake of some lipid-soluble
agents, carrier-mediated transcytosis for the transport of glucose, amino acids, purine
bases, nucleosides, choline and other substances, receptor-mediated transcytosis for
certain proteins such as insulin and transferrin, and adsorptive-mediated transcytosis for
native plasma proteins such as albumin [267]. Especially, in the recent 15 years
nanocarriers such as polymeric micelles [314], dendrimers [315], polymer-drug
conjugates [316, 317], polymeric nanoparticles [318], liposomes [319-321], and
inorganic nanoparticles including gold [322], mesoporous silica [323-325] and
superparamagnetic iron oxide (SPIO) [326, 327] were investigated. In some cases, cell
penetrating peptides such as TAT (trans-activator of transcription) or receptor targeting
molecules such as transferrin, OX26 (anti-transferrin receptor IgG2a antibody) have also
been conjugated to the nanocarriers to enhance drug penetration through the BBB after
intravenous injection as transferrin receptor is expressed on the BBB [328-330].
Intranasal Nose to Brain Delivery
In the recent years, several reports have been published on the intranasal nose to
brain delivery where the olfactory region of the nasal mucosa located on the roof of the
nasal cavity that provides a direct connection between nose and brain was exploited for
delivering drugs to the brain [331-333]. Advantages of this route include noninvasiveness, circumvention of the BBB, escape hepatic first-pass metabolism, simple,
and convenience of administration. Therapeutics have been shown to reach the central
nervous system through the olfactory neuroepithelium located at the loft of the nasal
cavity, by trigeminal nerve systems and olfactory nerve pathways [331-333].
Nanoparticle-based Drug Delivery
In an attempt to surpass the limitations associated with the aforementioned
barriers, considerable investigation has been done for improving the efficacy of drugs in
vivo and such attempts resulted in the design, study and use of nanoparticulate drug
delivery systems, such as biodegradable polymeric nanoparticles [334], nanocapsules
[335], liposomes [336], dendrimers [62-66], micelles [314], inorganic nanoparticles [78].
Various nanoparticles with their structures are illustrated in Figure 3-4. Currently, one of
the most interesting fields of research in drug delivery is the design of nanoparticles
capable of delivering the therapeutics to the right site predictably over time [38, 49, 50,
275-277, 315, 317, 321, 337-342]. These are submicron sized systems (1-1000 nm)
containing the encapsulated drugs intended for administration [18]. Because
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Figure 3-4.

Nanocarriers for brain drug delivery.

Notes: Nanocarriers for brain delivery [343]: a. Polymeric micelles: core-shell nanosized
structures formed by a spontaneous self-assembly of polymers as a result of ionic or
hydrophobic interactions between polymer chain segments [314]; b. Dendrimers:
macromolecules with highly branched 3D structure offering a high degree of surface
functionality and versatility [315]; c. Polymer-Drug conjugates: nano-sized and multicomponent constructs with therapeutics and targeting ligands covalently attached to the
polymer chains [316, 317]; d. Polymeric nanoparticles: submicron sized particles
prepared from pre-synthesized polymers or through in-situ polymerization from
monomers/macromers directly [318]; e. liposomes: spherical and self-closed lipoidal
vesicles (unilamellar or multilamellar) of colloidal dimensions formed as result of selfassembly of phospholipids in an aqueous media into closed bilayered structures [319321]; and f. inorganic nanoparticles: nanosized inorganic core including gold [322],
mesoporous silica [323-325] and SPIO [326, 327], coated with polymers and conjugated
with targeting and imaging agents on the surface [344, 345]. Reprinted with permission.
Wu, L., et al., Overcoming the blood-brain barrier in chemotherapy treatment of
pediatric brain tumors. Pharmaceutical research, 2014. 31(3): p. 531-540.
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nanoparticles are small-sized with large surface area and can be made of many types of
safe materials (such as synthetic biodegradable polymers, natural biopolymers, lipids)
with multi-functional surface groups, they possess outstanding advantages such as: i) can
pass through the smallest capillary vessels; ii) potential of cellular internalization of drug;
iii) hold significant advantages in transporting drugs across biological barriers; iv)
reducing drug clearance in the path by protecting drugs from degradation and
metabolism, and improving drug stability and bioavailability at the target site; v)
sustained drug release which consequently leads to reduction in dosage frequency,
resulting in better patient compliance; vi) reduced incidence of toxicity and side
effects,;vii) maintaining long shelf-life; viii) biocompatible and biodegradable. [18, 37,
81-86].
Among various nanoparticles, polymeric nanoparticles are gaining increasing
attention and have been extensively studied for imaging, diagnosis and drug delivery due
to their superior properties over others [37-43]. Therapeutics are loaded into the
nanoparticles by adsorption, entrapment, and covalent attachment. They are released
from the nanoparticles by desorption, diffusion, drug dissolution and polymer erosion, or
some combination of these mechanisms. They can be optimized to have higher
permeability across the specific barriers and/or prolonged contact time with the tissue
surfaces by adjusting their properties such as particle size, surface charge, and surface
chemistry [346, 347]. Meanwhile, targeted delivery can also be achieved by conjugating
specific targeting moieties to the nanoparticles [67, 348-351]. Since the polymeric
nanoparticles can be made of various types of materials, have large surface areas, and
multi-functional surface groups these systems hold a great promise and were widely
explored for transporting therapeutic agents across various biological barriers such as the
ocular/blood-brain barriers. Various biodegradable polymers that have been used for the
preparation of these nanoparticles are polysaccharides (chitosan, dextran, and hyaluronic
acid), polyesters (PLA, PLGA, PCL), PVA, polyacrylic acid family, proteins or
polypeptides (such as gelatin), etc. Among them, polysaccharides are the most popular
biopolymers used for the fabrication of the nanoparticles for drug delivery because of
their wide availability in nature, low-cost processing, biocompatibility, biodegradability,
non-toxicity, hydrophilicity and bioactivity [18, 352].
Polysaccharide-based Nanoparticles for Drug Delivery to the Eye and Brain
Polysaccharides are long chain carbohydrate molecules where the
monosaccharide units are linked through a glycosidic linkage which undergoes enzymatic
degradation. Most common sources of polysaccharides are plant (starch, cellulose,
carboxyl methyl tamarind, pectin), animal (chitosan, chitin, hyaluronic acid), microbial
(dextran, pullan, gellan gum, xanthan gum), algae (alginate, agar). Table 3-2 lists out
some of the commonly used poly-, oligosaccharide polymers, and their structures. They
have a large number of reactive functional groups varying in a chemical composition and
having a broad range of molecular weight thus contributing to their diversity in structures
and properties. Common hydrophilic groups present in the polysaccharides are hydroxyl,
carboxyl, and amino groups. These functional groups in polysaccharides can form
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Table 3-2.
Chemical structures of various polysaccharides that were used for
drug delivery.
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hydrogen bonds with mucosa. Thus, their mucoadhesive nature depends on the noncovalent bond forming ability [353]. These bioadhesive polymers are used as carriers as
they could prolong the residence time of the drugs. Besides the mucoadhesive property,
nature-originated polysaccharides such as chitosan and its derivatives, dextran, alginate,
hyaluronic acid, gum cordia, and carboxymethyl tamarind kernel polysaccharide,
cyclodextrins (Table 3-2) possess other appealing properties such as acceptable
biocompatibility, excellent in vivo tolerance [354-356], biodegradability [357], and
ability to enhance drug membrane permeability both in vitro [358] and in vivo [359].
Certain polysaccharides possess some special characteristic capability to recognize
special cell types, enabling to design targeted drug delivery systems through receptormediated endocytosis, while others can be effectively modified with different polymers
and utilized as a part of the drug delivery systems. The combination of these properties
makes polysaccharides versatile biopolymers for drug delivery to the eye and brain [18,
67, 68, 349, 360-373]. Also, availability of new synthetic routes can be adopted to easily
modify polysaccharides or synthesize oligosaccharide units, tunable biodegradability by
structural modification, and ability to fabricate suitable structures such as nanoparticles,
make them one of the most important and extensively studied natural biomaterials for
nanoparticle-based drug delivery applications [352, 374-376]. Initial studies were mainly
focused on evaluating chitosan-based nanoparticle carriers, and in the long run more
number of polysaccharides (dextran, pectin, gum cordia, carboxymethyl tamarind kernel
polysaccharide, hyaluronic acid, mannan, maltodextrins, and pullan) have emerged for
the formulation of nanoparticles thereby increasing the versatility of nanoparticle carriers
in terms of category and function [18, 346, 377-383]. A brief discussion is given below
about the polysaccharides of interest to this project which includes Dextran and
Cyclodextrins.
Dextran is one of the widely investigated natural polysaccharide that has been
successfully used for drug delivery applications due to its excellent biocompatibility,
biodegradability, hydrophilicity, and nonfouling properties [384-388]. Dextran is
enzymatically degradable by dextranases present in various parts of the human body. For
more than five decades dextran has proven its clinical safety as antithrombotic agents and
as substitutes for plasma volume expansion [385]. It is produced industrially on a large
scale, and there are many varieties of dextran polymers that are commercially available in
wide range of MWs and with relatively narrow MW distribution. The degree of
branching in this polysaccharide can be as small as 0.5%, making them suitable for
scientific studies [385]. Apart from being water soluble, dextran polymers are also stable
under slightly acidic and basic conditions, and also possess a large number of hydroxyl
functional groups for conjugation [385]. Recently, several reports have been published on
altering the dextran properties to make various detrain graft polymers via various
chemical modifications for specific applications, for example, polymeric drug delivery
systems and hydrogels [388-391]. Although dextran has been widely investigated for
various drug delivery applications, only limited number of papers have been published on
dextran-based nanoparticles for drug delivery to the eye or brain [372, 392-396].
Chaiyasan et al. synthesized hybrid nanoparticles made of chitosan and dextran sulfate
with around 400 nm particle size and around 40 mV zeta potential, which were stable in
the presence of lysozyme for at least 4 h and showed at least 60 min prolonged adherence
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to the ex vivo porcine corneal surface [372]. Phenylboronic acid surface functionalized
poly(D,L-lactide)-b-dextran nanoparticles were investigated by Liu et al. for ocular
delivery, and the results demonstrated that nanoparticles were nontoxic and can sustain
the drug (cyclosporine A) release for 5 days in vitro [397]. Dextran polymer was also
used as a stabilizer during the nanoparticle preparation [398]. Alonso et al. found that
PBCA nanoparticles made with dextran 70 kDa as the stabilizer has shown statically
significantly increased drug concentrations in the cornea and aqueous humor compared to
the other nanoparticle formulations made with other stabilizers (Synperonic F 68 and
sodium lauryl sulfate) and the control amikacin sulfate drug solution [334]. Delgado et al.
studied dextran and protamine-based solid lipid nanoparticles as potential non-viral
vectors for ocular gene delivery and found that the vectors were able to transfect corneal
cells after topical application. Here dextran was used to form polyplex with the protamine
and then combined with SLN to obtain dextran–protamine–DNA–SLN hybrid non-viral
vectors [393]. Another group studied the hybrid nanoparticle design based on cationized
gelatin and the polyanions dextran sulfate for ocular gene delivery, and the results
showed that nanoparticles were nontoxic to the corneal cells and were able to protect the
DNA from degradation by DNase I [394]. Dextran was also successfully used in making
nanoparticles with magnetite for imaging the BBB breakdown after experimental
hyperosmotic disruption [392]. Further, following this BBB disruption, when the
magnetite-dextran nanoparticles were injected into the carotid artery, they have
penetrated into the brain tumor [396]. Although dextran has been studied for making
nanoparticles for ocular delivery, to the best of author’s knowledge no report has been
published on dextran-based nanoparticles that can cross the ocular barriers and sustain the
drug release at the back of the eye. Therefore, in this project, the dextran polysaccharide
was modified to improve the properties and practicability of polymeric nanoparticles for
ocular drug delivery applications with the potential to overcome the ocular barriers. The
modifications or the procedure include i) hydrolytically degradable component was
incorporated into the dextran polymer chain by grafting with PLA units; ii) polylactide
grafted dextran was then copolymerized with NIPAAm and acrylic acid (AA) using
emulsion photopolymerization to from poly(NIPAAM-co-DEXlactateHEMA) nanogels.
The addition of NIPAAm and AA imparts thermoresponsive and anionic nature
(carboxylic groups) to the nanogels. Because of the amphiphilic nature of the dextranlactide, the nanogels were synthesized in an entirely aqueous solution without the need of
surfactants and organic solvent. The size, charge, and degradability of this dextran-based
nanogels can be easily tuned by altering the composition.
Another polysaccharide-based material used in this work was derived from β-CD.
Cyclodextrins are cyclic oligosaccharides consisting of 6 (α-CD), 7 (β-CD) or 8 (γ-CD)
glucopyranose units, which form a hydrophobic inner cavity and hydrophilic outer
surface. The size of this inner hydrophobic cavity is the significant determinant as to
which cyclodextrin is utilized as a part of complexation. The interior cavity size of β-CD
was found to be the most appropriate size suitable to accommodate many of the drugs. βCD and its derivatives have a unique property of forming inclusion complexes with
hydrophobic drugs and increase the drugs’ water solubility [399, 400]. The β-CDs have
been extensively used in eye drops for improving the solubility of the drugs, and improve
their bioavailability. β-CD also offer a number of hydroxyl surface functional groups for

102

further conjugation or alteration via various chemical modifications for specific
applications. β-CD and its derivatives have been widely used in various drug
formulations such as eye drops, nasal spray, and oral and parenteral preparations to
increase the solubility and stability of hydrophobic drug molecules and reduce their
irritancy/toxicity. Additionally, several studies have reported the use of synthetic β-CDbased polymers units for the drug delivery applications [87, 370, 401, 402]. Although
drug/cyclodextrin complexes have been widely employed in the past, incorporating them
into nanoparticles seems to bring significant advantages. In ocular application,
sulfobutylether-β-cyclodextrin was used to make hybrid nanoparticles with chitosan to
form inclusion complexes with econazole nitrate to increase the water solubility of
econazole nitrate. The resulting econazole nitrate-containing complexes showed
improved bioavailability and prolonged 8 hours’ steady antifungal effect while econazole
nitrate solution could provide antifungal effect for only 3 hours which also dramatically
decreased with time [370]. Tao et. al. demonstrated that hydroxypropyl-β-CD during the
fabrication of puerarin-PLGA nanoparticles has improved the solubility and entrapment
efficiency of the puerarin, and also proposed that nano-carriers or cyclodextrin inclusion
complex enhanced the penetration of drug across the BBB [403]. Gill et. al from our
group has earlier modified β-CD to generate cationic quaternary ammonium -β-CD (QAβ-CD) nanoparticles for potential drug delivery across BBB [87]. When doxorubicin was
loaded into these nanoparticles, they enhanced the permeability of doxorubicin across the
in vitro BBB model and masked its cytotoxicity to the endothelial cells of the BBB [87].
As biodegradable polymers can achieve sustained drug release and polyamine can
enhance drug permeability across the BBB, another β-CD-based poly(β-amino ester)
(CD-p-AE) nanoparticles were designed, which contains ester bond and amine, into β-CD
[50]. These nanoparticles also showed sustained release of doxorubicin and showed
enhanced permeability across in vitro BRB models. The β-CD based nanoparticles have
demonstrated promising potential as drug carriers for brain delivery [50]. In this study,
(CD-p-AE) nanoparticles was selected for conducting the in vivo studies to evaluate the
potential for delivering 17-AAG to the brain.
Diabetic Retinopathy
Diabetic retinopathy (DR) is a chronic eye disease and one of the most frequent
complications of diabetes. DR is affecting 60–75% of persons with diabetes and is the
leading cause of visual impairment in working-age Americans [404]. Retinal neuronal
damage and increased vascular permeability occurs in early phases of diabetes and may
lead to clinically noticeable vascular changes [404]. Insulin has been investigated as a
potential therapeutic option to protect the retinal neurons from apoptosis and prevent the
neuronal degeneration [405-407]. Studies showed that intensive systemic insulin therapy
lowers the risk of retinal neural apoptosis in diabetic rats, and systemic glycemic control
with systemic insulin treatment lowers the risk of the development and progression of DR
in diabetic human subjects (Diabetes Control and Complications Trial, 1994). However,
the degree of systemic insulin treatment is restricted by the risks of hypoglycemia,
including seizures and unconsciousness [4]. Therefore, there is a need for long-term local
delivery of insulin to the retina. Our group has attempted to address this need by
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developing insulin-loaded biodegradable chemically cross-linked poly(NIPAAm-coDEXlactateHEMA) hydrogels for local delivery of insulin in the eye after
subconjunctival administration [408]. Previous work from our group demonstrated that
Humalog® (insulin lispro) could be continuously released from subconjunctivally
implanted hydrogels for one week and showed a reduction of DNA fragmentation in the
retinas of diabetic rats [409]. Even though the hydrogels can continuously release insulin
at the subconjunctival space, insulin still needs to cross the sclera and the BRB and to
access the retina by itself and faces the issue of low bioavailability in the retina.
Therefore, there is a need for an effective drug carrier that can enhance the permeability
of insulin across various ocular barriers. Nanoparticles show great promise for
transporting drugs across biological barriers, reducing drug clearance, and improving the
bioavailability of drugs at targets [36]. However, no nanoparticle has yet been developed
to deliver drugs across the BRB effectively.
Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of dementia characterized by
progressive memory loss and cognitive dysfunction [410]. According to Alzheimer's
Association report 2016, more than 5 million people are living with AD in the United
States, and a new case is expected to develop every 66 seconds. AD is the 6th leading
cause of death in Americans [411]. The disease development mechanisms of AD are still
not entirely clear [412]. However, AD is characterized by the potentially neurotoxic
aggregation of β-amyloid (Aβ) peptide and tau protein within the brain, and their
deposition as amyloid plaques and neurofibrillary tangles (NFTs) [413, 414]. Common
therapeutic approaches in case of AD treatment include lowering the brain concentrations
of Aβ and tau or inhibiting their aggregation [414]. The selective neuronal loss observed
in AD, coupled with the growing body of evidence that chaperone protein heat shock
protein 90 (Hsp90) inhibitors can clear protein inclusions (e.g. alfa-synuclein and tau)
and rescue degenerating neuronal cells, has supported a therapeutic role for Hsp90
inhibitors in treating AD [415-418]. 17-Allylamino-17-demethoxygeldanamycin
(17AAG), an Hsp90 inhibitor, have poor water solubility and short half-lives, do not or
hardly cross the BBB, and can cause toxicity and side effects at the high dose. Though
local invasive (direct injection/infusion) is effective in delivering drugs to the brain but
has been associated with risk of infection, high neurosurgical cost and a limited delivery
area in brain [45]. There is an unmet clinical need to develop effective methods to
enhance the BBB permeability of 17-AAG and sustain the release of 17-AAG in the brain
to treat AD. According to a review of drugs for AD states that “successful treatment of
AD will require drugs that can negotiate the BBB”[419].
Objective
Although there are several nanoparticles made of various materials such as
polyesters (poly(D,L-glycolide-co-lactide) [44], poly(lactic acid) [45-47], poly(εcaprolactone)[48, 49]); poly(amino ester)[50], lipid [liposomes [51-54], niosome [55, 56],
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solid lipid [57, 58]); polyamines [59-61], polyethyleneimine [420, 421]; polylysine [422]
and dendrimers [62-66]; polysaccharide (chitosan [67-70] and hyaluronic acid [70]);
polyalkylcyanacrylate [71-74]; albumin [75-77], and inorganic metals [78], however
there are certain limitations associated with each of these nanoparticles. For instance, the
polyester nanoparticles have shown to achieve sustained drug release, but not reported to
cross the biological barriers themselves without the need to be conjugated or coated with
some specific functional moieties [44-49]. Liposomes, solid lipid nanoparticles,
dendrimers, surfactant-coated PBCA nanoparticles were reported to be able to cross the
barrier; however, they cannot achieve sustained release and also can have toxicity issues
[57, 73, 79, 80]. The other nanoparticles have not been reported to be able to either
sustain drug release or cross the barrier without the need to be conjugated or coated with
some specific functional moieties. Therefore, there is still an unmet need to develop
nanoparticles that can carry drugs across the ocular/blood-brain barriers and sustain the
release of drugs to treat chronic ocular and brain diseases such as DR and AD. The
primary objective of this work was to develop biodegradable polymeric biomaterials for
drug delivery across ocular and blood-brain barriers for treating in the eye and brain,
respectively. For this purpose two types of new nano-sized, cross-linked, hydrolytically
degradable, and charged polysaccharide-based particles were prepared for drug delivery
to the eye and brain which include a) poly(N-isopropyl acrylamide-co-dextran-lactate-2hydroyethyl methacrylate) [also referred to as Poly(NIPAAm-co-DEXlactateHEMA)]
nanogels, and β -cyclodextrin-poly(β-amino ester) (CD-p-AE) nanoparticles. These
materials combine the merits of biodegradable nature, charge, and nano-sized particulate
properties. The degradation property of the polymeric matrix can be used to modulate the
release of encapsulated drugs for an extended period of time and helps to avoid the
removal of the system after treatment. Meanwhile, the surface charge and nano-sized
dimensions impart the advantages of nanoparticulate systems such as internalization into
the cells, transporting drugs across biological barriers, improving drug stability and
bioavailability at the targets [18, 37, 81-88]. Additionally, the surface functional groups
of these nanoparticles can be used for further conjugation with a ligand. Hence, in an
attempt to minimize the constraints and disadvantages of conventional drug delivery
systems for eye and brain treatment, a contemporary poly(NIPAAm-coDEXlactateHEMA)/ (CD-p-AE) nanoparticles based sustained drug delivery systems
could be very promising.
Biodegradable Poly(NIPAAm-co-DEXlactateHEMA) Nanogels for Ocular Delivery
for the Treatment of DR
Hypothesis and Specific Aims
The long-range goal of this project in chapter 3 was to develop novel
poly(NIPAAm-co-DEXlactateHEMA) nanogels for long-term release of insulin across
the ocular barriers for treating retinal diseases. Another advantage of choosing
poly(NIPAAm-co-DEXlactateHEMA) nanogels is that they are hydrophilic in nature and
offer the flexibility of aqueous loading of insulin thereby improving the drug stability.
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The immediate objective was to develop subconjunctivally injectable biodegradable
nanogels with similar composition to the earlier hydrogels that can have the potential to
enhance the permeability of the drugs, such as insulin, across ocular barriers and also
sustain the release of drugs to treat ocular diseases like DR.
The hypothesis of this project in chapter 3, which was the sub-hypothesis 2 of the
central hypothesis, was that the subconjunctivally injectable nanogels composed of
DexlactateHEMA and NIPAAm can cross the ocular barriers for the potential delivery of
drugs such as insulin to diabetic retinopathy.
Specific Aim 1. Prepare and characterize poly(NIPAAm-co-DEXlactateHEMA)
nanogels. A series of thermoresponsive and biodegradable nanogels with different
hydrophobicity, hydrophilicity, crosslinker amount, surface charge and particle size were
synthesized in water.
Specific Aim 2. Assess in vitro cytotoxicity, in vitro and ex vivo permeability of the
poly(NIPAAm-co-DEXlactateHEMA) nanogels. The synthesized nanogels were tested for
their cytotoxicity on human fetal retinal pigmented epithelial (hfRPE cells). Ex vivo
permeability of the nanogels was evaluated using in vitro BRB model of adult retinal
pigmented epithelial cells (ARPE-19) grown on polyester Transwell filter. Porcine sclera
and cornea were used as ex vivo ocular barriers.
Material and Methods
Chemicals and Reagents
Dextran (MW -15,000 g·mol-1) was purchased from Polysciences, Inc.,
Warrington, PA. The following materials were obtained from Sigma–Aldrich, Inc (St.
Louis, MO): NIPAAm, 2-hydroxyl methacrylate (HEMA), 4-(N,N-diethylamino)
pyridine (DMAP), N,N’-carbonyl diimidazole (CDI), L-lactide, stannous octoate
(SnOct2), tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), fluorescein isothiocyanate
(FITC), 5-(4,6-dichlorotriazinyl) aminofluorescein (5-DTAF), FITC-dextran (MW - 70
kDa, and 4 kDa), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT).
All the chemicals were used as received. Deionized distilled water was used in all the
experiments.
Synthesis and Characterization
DEX-lactateHEMA macromer with different degree of polymerization (DP) and
degree of substitution (DS) was synthesized according to the previously published
procedure by adjusting the feeding ratios of the corresponding precursors [423]. The
structure is given in Figure 3-5. The lactide chain length (DP) of the lactate unit controls
the hydrolytic degradation, and the number of lactide chains on dextran (DS) in the DEXlacateHEMA macromer controls the degree of crosslinking (swelling) in the nanogel,
respectively. The DP and DS of the macromer were calculated based on the 1H NMR
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The structure of dextran macromer (DEX-LacateHEMA).
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spectra. In present work, the DEX-LactateHEMA macromer of DP/DS - 5/5.5 was
synthesized and used in the preparation of nanogels.
Poly(NIPAAm-co-DEXlactateHEMA) nanogels were synthesized by UVinitiated free radical emulsion polymerization method. A prepolymer solution was
prepared by dissolving NIPAAm/DEXlactateHEMA at different weight ratios: 7/2, and
6/3 in DI water while stirring in RBF at 200 rpm at 45°C with nitrogen bubbling. Later,
10 mol% (with respect to NIPAAm) of anionic charge modifier acrylic acid (AA) was
added to the prepolymer solution. The UV initiator 0.066% wt% Irgacure 2959 dissolved
in DI water was added dropwise, and then the mixture was exposed to UV light at 1
W/cm2 for 1 h under constant stirring at 200 rpm (at 45°C and N2 purging). The scheme
of synthesis is given in Figure 3-6. The obtained emulsion was cooled down to room
temperature and dialyzed against the large (10-fold) volume of DI water for 4 h using 50
kDa molecular cutoff cellulose dialysis tubes. The reason to use short 4 h for the dialysis
was to limit the nanogel degradation during the dialysis process. The purified nanogel
product was then freeze dried, and FTIR confirmed the synthesis.
DTAF-labeled nanogels were prepared as follows. DTAF (10 mg) and the
nanogels (250 mg) were dissolved in DMSO (0.3 mL) and sodium carbonate buffer (0.1
mol ·L-1, 5 mL, pH 9), respectively. The DTAF solution was added dropwise into the
nanoparticle solutions with stirring. The reaction was carried out overnight at 4 °C. The
final solution was dialyzed with MWCO 50 kDa membrane against deionized water
while changing the outer water every 8 h for 24 h and freeze-dried.
The hydrodynamic size and zeta potential of the nanogles were measured at a
concentration of 200 μg·mL-1 in PBS at 37°C using dynamic light scattering (DLS)
(Zetasizer NS, Malvern, United Kingdom). An average was taken from three
measurements.
Cell Culture
Human-fetal retinal pigment epithelial cells (hfRPE) and adult retinal pigmented
epithelium cells were seeded in T25 flasks at a density of 8000–12,000 cells cm2, and
cultured in Dulbecco’s Modified Eagle Medium (DMEM-F12) containing 10% fetal
bovine serum (FBS), vitamins, essential amino acids, and penicillin/streptomycin at 37 C
with 95% humidity and 5% CO2. The medium was changed every other day. The cells
were harvested with trypsin (0.05% trypsin with 0.4 mM EDTA) when they were 80%
confluent.
In Vitro Cytotoxicity of the Nanogels
Cytotoxicity of the nanogels to hfRPE cells was examined by an MTT cell
viability assay. The cells were seeded at a density of 7,500 cells per well in a 96-well
plate containing 150 μL media at 37 C for 24 h. The nanogels and the degradants after
one week of incubation of nanogels in the medium at 37°C were then incubated with the
cells for 48 h. Wells containing cells alone were used as a control. 20 μL of MTT
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The synthesis scheme of poly(NIPAAm-co-DEXlactateHEMA)

Notes: A prepolymer solution in DI water was exposed to UV light while stirring in RBF
at 200 rpm at 45°C under nitrogen bubbling. Poly(NIPAAm-co-DEXlactateHEMA)
nanogel structure reprinted with permission. Huang, X., et al., Novel nanogels with both
thermoresponsive and hydrolytically degradable properties. Macromolecules, 2008.
41(22): p. 8339-8345. © 2008 American Chemical Society.
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solution (5 mg MTT/mL PBS) was added to each well and incubated for 4 h at 37 °C and
5% CO2. The medium was then removed completely from the wells without disturbing
the cells, and 150 μL of DMSO was added to each well. The plate was covered with foil
and placed on the rocking platform for 15 mins to dissolve the formazan crystals in
dimethyl sulfoxide. The absorbance of the reduced form of the MTT was measured at
570 nm using a microplate reader ((BioTek Instruments, Inc., Winooski, VT, USA) with
background subtraction. The sample and control samples were measured in
quadruplicate, and the relative cell viability (%) was calculated as percentage absorbance
of the samples relative to the absorbance of the untreated control cells.
In Vitro Permeability across ARPE-19 Monolayers
Confluent ARPE-19 monolayers were constructed on coated polyester Transwell
inserts (24 well-plate, 0.4 μm pore size). Briefly, ARPE-19 cells were seeded on the
insert at 50,000 cells·cm-2 and grown at 37 °C with 95% humidity and 5% CO2 in a cell
culture incubator. The medium was changed as usual until the transepithelial electrical
resistance (TEER) values reached the plateau to get the confluence ARPE-19 monolayer
as the in-vitro RPE model (Figure 3-7).
DTAF-labeled nanogels or FITC-dextran control (Mw = 70 kDa) was dispersed or
dissolved in the culture medium and added to the apical chamber of each well at 1 mg·ml1
. The transport experiments of nanogels from the apical to the basal direction at 37 °C
was conducted for four hours. At selected time points (0, 15, 30, 60, 90, 120, 150, 180,
210, 240 min), 30 μL of the medium was sampled from the basal/receiver chamber and
replaced with 30 μL of fresh medium. In the end, 30 μL media was sampled from both
the apical and basolateral chambers. The fluorescence of the aliquots was quantified by
using microplate reader (BioTek Instruments, Inc., Winooski, VT, USA) at 430 nm of
excitation and 530 nm of emission wavelengths. The permeability (P0) of the
components across the ARPE-19 monolayer was calculated as below [38, 424]:
The flux of the DTAF-nanogels or control FITC-dextran from the apical side of the tissue
layer to the basolateral direction was measured. “Flux is defined as the amount of solute
crossing a plane of the unit surface area, which is normal (perpendicular) to the direction
of transport, per unit time” [425]. The apparent flux (J) or permeation rate was calculated
from the slope (ΔFr/Δt) of the linear region of the plot of the cumulative fluorescence (Fr)
of the permeant FITC-4k dextran transported across the membrane into the receptor
chamber versus time (t) divided by the effective diffusion surface area (Ad). The apparent
permeability coefficient (P0) was calculated based on the flux of the system (J) divided
by the concentration (fluorescence) difference between the donor and receiver chamber
(Equation 3-1). Typically, the concentration (fluorescence) in the receiver chamber is
significantly smaller than the donor chamber, the concentration of the receiver chamber is
considered as zero, and the concertation in the donor chamber is obtained by dividing
donor cell fluorescence (Fd) with the volume of the donor chamber (Vd).
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Transwell insert

Apical chamber

Sample (nanoparticles)
Tissue Monolayer

Transport

Microporous membrane

Figure 3-7.

Receiver chamber

Experimental set-up for in vitro permeability.

Notes: After the formation of an ARPE-19 monolayer on the porous transwell inserts, the
nanogels suspension was added to the apical chamber and the medium from the receiver
chamber was sampled at selected time points and analyzed for the nanogels. The
experiment was conducted at 37 °C.

111

AFM Measurements
After the in vitro permeability experiment, the medium from the receiver chamber
was collected and was dialyzed against DI water for 4h and freeze-dried. To confirm the
permeation of the nanoparticles, the freeze-dried contents from the receiving chamber
was investigated for the presence of particles by using Atomic Force Microscopy.
Ex Vivo Permeability across Porcine Ocular Tissues
Porcine sclera and corneal tissues were separated from the freshly isolated porcine
eyeballs within two hours are prepared for the ex vivo permeability experiments
immediately. The tissues were carefully mounted in the side-by-side perfusion devices
(Figure 3-8). Side-by-side diffusion cells are known as Valia-Chien Cell apparatuses
(Permegear, Inc., Hellertown, PA, USA) were used to conduct the permeability study.
The apparatus consisted of two glass chambers; each had an outlet for sampling and a
port for heater circulator. The membranes isolated were placed in the spherical joints of
Valia-Chien Cell apparatuses, and a clamp is placed on the spherical joints to hold the
membrane in place. Immediately after the tissue was clamped, both chambers were filled
with Glutathione Bicarbonate Ringer’s Solution (pH 7.2-7.4). The solution in each
chamber was gently stirred using a small Teflon-coated magnetic stir bar for the
homogenous distribution of the solutes. The FITC-dextran/DTAF nanogels was dissolved
in the media for the ocular tissues and added to the donor chamber at 1 mg·mL-1. The
chambers were maintained at 34°C by circulating warm water through them. Passive
transport of the FITC-dextran across the sclera and cornea tissues was carried out at 34°C
over 4 h period of time. 200 μL of the samples was taken out from the receptor chamber
as a function of time and replaced with 200 μL of fresh medium. The TEER values of the
ocular tissues were monitored through the whole permeability studies to check the
integrity of the membrane. The fluorescence intensities in the solutions sampled from the
donor and receptor chambers were quantified using a fluorescence microplate reader
(BioTek Instruments, Inc., Winooski, VT, USA) and the permeability (P0) of the samples
across the sclera and cornea tissues were calculated as described earlier.
Results and Discussion
Synthesis and Characterization of Nanogels
Previously, Huang et. al from our group has published a report [426] on the
synthesis of a series of poly(NIPAAm-co-DEXlactateHEMA) nanogels via thermoinitiated polymerization from DEXlactateHEMA macromer and NIPAAm monomers at
various feeding ratios of the macromer and NIPAAm. In the earlier synthesis method, a
high temperature (70°C) and long reaction time were used for the synthesis of nanogels.
However, use of such harsh conditions may not be suitable for loading of protein drugs as
they may get denatured at high temperatures. To avoid such harsh conditions, in the
current synthesis procedure a slightly modified technique was used by shifting from the
thermo-initiated polymerization to a milder UV initiated photo emulsion polymerization
using Irgacure 2959 as an initiator instead of KPS. This procedure offered the flexibility

112
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Receptor chamber
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to maintain temperature

Stir bar

Tissue mounted

Figure 3-8.

Experimental set-up for ex vivo permeability.

Notes: After mounting the freshly isolated porcine ocular tissue (sclera/cornea), the
medium was added to both the chambers. The DTAF-nanogels suspension was added to
donor chamber, and the medium from the receiver chamber was sampled at selected time
points and analyzed for the fluorescence.
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of fabricating the poly(NIPAAm-co-DEXlactateHEMA) nanogels under mild conditions
such as low temperature and short reaction, aiming at in situ aqueous loading of protein
drugs (insulin) for ocular drug delivery. Also, the initiator Irgacure 2959 solution has
been widely used for in situ polymerization in vivo and does not cause eye irritation
according to the MSDS [408].
Table 3-3 shows the average hydrodynamic radii and zeta potential of the
nanogels in PBS at 37 °C for two types of nanogels synthesized (72A and 62A). The size
of the nanogels was within 70-87 nm, and no significant difference was observed
between two types of nanogels. Both the nanogels showed a zeta potential around -10
mV and the negative zeta potential observed on the nanogels could be attributed to the
ionization of carboxylic acid groups of the acrylic acid introduced into the nanogels at pH
7.4, as well as any carboxylic groups resulted due to partial degradation of ester bonds of
lactide units. Similar to particle size, no significant difference was observed in zeta
potential among the two nanogels. Prior studies in the literature have suggested that
charged polymers (both cationic and anionic charge) could potentially interact with tissue
surface proteins such as mucins through hydrogen bonding or other electrostatic
interactions and render them mucoadhesive [427]. Also, it is reported that the presence of
carboxylic functional groups in the nanoparticles helps in the permeability by various
cellular internalization mechanisms [428, 429]. Because of these advantages, the charged
component with a carboxylic functional group (acrylic acid) was incorporated into the
nanogels. Another rationale for adding carboxylic acid groups is that functional moieties
like targeting ligand and drugs could be easily conjugated to the nanogels.
As the nanogels are intended for ocular delivery, the cytotoxicity of these
nanogels to hfRPE cells (part of the BRB) was tested using MTT assay. MTT assay is the
most widely used colorimetric technique to check the cell viability in vitro [408]. The
underlying principle of MTT assay is that mitochondrial reductase in viable cells with
active metabolism convert the tetrazolium into a purple colored formazan product which
shows absorbance near 570 nm. Therefore, any metabolic dysfunction in the cells caused
by toxic substances leads to reduced activity of the mitochondrial enzymes which in turn
decreases the conversion of MTT to formazan. The cell viability is expressed as the
percent relative absorbance of the treated cells to the untreated control cells. In vitro
cytotoxicity studies of the synthesized nanogles showed that no matter whether the
nanogels (72A and 63A) were incubated with the hfRPE cells directly for 48 h or they
were degraded in the culture medium for one week and then the cells were exposed to the
degraded solution (72A-D, and 63A-D) for 48 h, the viability of the treated cells was
close to 100% of control values at concentrations 0.1, 0.5, and 1 mg·ml-1 (Figure 3-9).
These results indicated that both the nanogels and their degradation products are nontoxic to cultured hfRPE for at least 48 h, and the nanogels have the potential for further in
vivo evaluation.
In Vitro Permeability of Nanogels
In order to test the nanogels for potential ocular delivery applications, an in vitro
ARPE-19 monolayer was constructed on Transwell interest as the in vitro blood-ocular
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Table 3-3.
Notation

Composition, particle size and zeta potential of the nanogels.
NIPAAm/
DEXlactateHEMA
(w/w ratio)

72A

7/2

Charge modifier
(acrylic acid/AA)
10 mol% wrt
NIPAAm
x

63A

6/3

x
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Size
(nm)

Zeta
potential
(mv)

73.65±4.55

-10.53 ± 0.57

83.99±3.25

-10.36 ± 0.76

A
120

63A_D

120

100

100

80

80

%Cell Viability

% Cell Viability

B
63A

60
40
20

72A

72A_D

60

40
20

0

0
1mg/ml

0.5mg/ml

0.2 mg/ml

1mg/ml

0.5mg/ml

0.2 mg/ml

Figure 3-9. Cell viability of the nanogels to hfRPE cells, to nanogels and
degradants.
Notes: The cell viability was determined by MTT assay after 48 h exposure to either
nanogels (63A, 72A) /degradants of the nanogels (63_D, 72_D). 63A/63A_D (A) and
72A/72A_D (B). (Mean ± SD, n=4)
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barrier model. The plateau TEER value obtained for the confluent monolayer was
160±10 ohm·cm2. The permeability was measured by examining the transport of DTAFlabeled nanogels from the apical to the basolateral side of the in vitro RPE monolayers.
RPE monolayer is part of BRB that separates the outer surface of the neural retina from
the choroid. Because of the presence of tight junctions the RPE forms a strong barrier;
however, it is capable of a number of specialized transport processes. Figure 3-10A, B
shows the transport and permeability across the in-vitro ARPE-19 monolayer for the two
types of nanogels and dextran-70k control at 1 mg·mL-1. Compared with the control
dextran-70k, the nanogels have a significantly higher permeability (≥35 fold) across the
in vitro BRB model. Meanwhile, no statistically significant difference was observed
between the two types of nanogels in terms of in vitro permeability. TEER values of the
ARPE-19 monolayers before and after the permeability studies remained similar
confirming the integrity of the membrane during the study. To further confirm if the
detected fluorescence in the receiver chamber is from the nanogels or any leaked DTAF
dye, the medium from the receptor chambers was collected to analyze for the presence of
nanoparticles by AFM and the representative AFM images from the 63A receptor
chamber (Figure 3-10C) confirm the presence of anionic nanogels. As the pore of the
paracellular pathway between the cells is very small, because of the larger hydrodynamic
size of the nanogels (>75 nm) in PBS (pH 7.4), it is very unlikely that the nanogels can
cross the in vitro BRB model by a paracellular pathway. Further, the presence of tight
junction restricts the paracellular entry of solutes. Therefore, the negative zeta potential,
carboxylic functional groups, nano-sized particle nature might have helped the nanogels
to cross the RPE cell monolayer through transcellular route by various mechanisms such
as endocytosis/exocytosis mechanisms [346, 430-432].
Ex Vivo Permeability of Nanogels across Porcine Ocular Tissues
The nanogels were further evaluated for their penetrating capacity across porcine
ocular tissues (i.e. sclera, and cornea) mounted in side-by-side perfusion devices.
Figure 3-11 showed the permeability of both prototype nanogels and dextran-70k control
across porcine sclera and cornea. Compared with the control dextran-70k, both 63A and
72A nanogels have a significantly higher permeability (at least four-fold) across the
sclera and cornea tissues. Similar to the in the in-vitro permeability study, no statistically
significant difference was observed between the two types of nanogels. Because of the
similar particle size and zeta potential, both 63A and 72A nanogels might have behaved
in a similar way in terms of permeability across in vitro and ex vivo ocular barriers.
Further studies needed to be conducted to understand the transport mechanisms of these
nanoparticles.
Permeability of Porcine Ocular Tissues at Different Stages of Development
The prevalence of DR is more common in elderly population, and as aging causes
a multitude of changes in biological membrane properties, it is important to investigate
the permeability of ocular tissues at different stages of development for understanding
physiological conditions of the eye and developing strategies (such as nanocarriers) to
enhance drug permeability across these tissues for treating many ocular diseases.
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Figure 3-10. In vitro transport (A) and permeability (B) of nanogels (63A, 72A) and 70kDa-dextran across ARPE-19 cell
monolayer; AFM image of the nanoparticle from the receptor chamber (C).
Notes: Nanogels showed higher (at least ~35-fold) permeability than control dextran across in vitro ARPE-19 monolayer, and the
AFM results confirmed the presence of nanogels in the receiver chamber. (Mean ± SE, n=4, p<0.05).
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Therefore to understand the ocular permeability with aging a short study was conducted
where the permeability differences of the porcine sclera and the cornea at different stages
(preterm, normal term, adult) of development was examined ex vivo using a fluorescent
probe FITC-dextran-4k. Figure 3-12 and Figure 3-13 illustrate the thickness and
permeability of the ocular tissues, respectively. The sclera became thicker with the
growth of pigs from preterm to normal-term to the adult stage, while the transscleral
permeability was decreased with age. In case of the cornea, it was observed that the
normal-term cornea has a similar thickness and permeability as the pre-term porcine
cornea, but at the adult stage, the thickness increased and the permeability was
significantly lowered. The permeability of the porcine cornea and sclera showed to be
dependent on the developmental stage of the pig.
Conclusions
Poly(NIPAAm-co-DEXlactateHEMA) nanogels were successfully synthesized
using photopolymerization under mild temperature. In vitro cytotoxicity evaluation of
these nanogels showed that high cell viability could be retained after incubating the
nanogels with hfRPE cells at up to 1 mg·ml-1 for 48 h, indicating that the nanogels were
not toxic to the cells tested. The nanogels were highly permeable across the ARPE-19
monolayers as compared with the controls dextran-70k. Further, ex vivo permeability of
the nanogels showed they were at least four-fold more permeable than the control
dextran-70k. In addition, it was found that the development stages of pigs affect the
permeability of ocular tissues depending on the tissue types. These results could provide
insight into designing drug carriers to enhance drug permeability across ocular tissues at
different development stages.
Future Work
The future work of Poly(NIPAAm-co-DEXlactateHEMA) nanogels include - i)
optimization of the nanogels for loading and sustained release of insulin; ii) evaluation of
in vitro and ex vivo permeability of the nanogels evaluation of insulin-loaded nanogels;
iii) investigation of in vivo safety, biodistribution and efficacy of the insulin-loaded
nanogels for DR. The permeability differences with age can be understood by further
continuing the work to evaluate morphological properties of the membranes across
different stages of development.
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Figure 3-12. Comparison of the thickness of porcine sclera (A) and cornea (B) at
different stages of development.
Notes: Preterm (28 week preterm piglets), the normal-term (one-week old normal-term
piglets), Adult Pigs (3-3.5 month old adult pigs). (Mean ± SE, n=4-sclera, 3-cornea), p <
0.05). Thickens of porcine sclera was observed to be increased with increase in the age.
However, in case of the cornea, no increase was observed between the preterm and
normal, but the thickness of adult cornea increased significantly.
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Figure 3-13. Comparison of ex vivo permeability of porcine sclera (A) and cornea
(B) at different stages of development.
Notes: Preterm (28-week preterm piglets), the normal-term (one-week old normal-term
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the age. However, in case of the cornea, the preterm and normal showed similar
permeability, but the permeability of adult cornea decreased significantly.
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Beta-cyclodextrin-poly(β-amino ester) (CD-p-AE) Nanoparticles as Drug Carriers
to Enhance BBB Permeability of 17-AAG to Treat AD
Hypothesis and Specific Aims
Our group has developed and characterized CD-p-AE nanoparticles for the
potential application of drug delivery across BBB [50]. Incorporation of β-cyclodextrin
(β-CD) into the nanoparticle structure facilitates the loading of hydrophobic drugs and
thereby expected to improve the solubility of the hydrophobic drugs. Earlier reported
studies showed that CD-p-AE nanoparticles were nontoxic, hydrolytically degradable,
very permeable to the in vitro BBB, and sustained the release of a hydrophobic drug
doxorubicin. The long-range goal of this project in chapter 3 was to develop 17-AAG
loaded CD-p-AE nanoparticles for AD treatment. The immediate objective was to
investigate the feasibility of biodegradable E-CD-based nanoparticles containing tertiary
amine groups for enhancing the BBB permeability and efficacy of 17-AAG in AD
treatment.
The hypothesis of this project in chapter 3, which was the sub-hypothesis 3 of the
overall hypothesis of the dissertation, was that the nanoparticles composed of βcyclodextrin and poly(β-amino ester) segments can enhance the solubility and BBB
permeability of Hsp90 inhibitors such as 17-AAG to treat Alzheimer's disease.
Specific Aim 1: Prepare and evaluate in vitro drug release of 7-AAG-loaded βcyclodextrin-poly(β-amino ester) nanoparticles. CD-p-AE nanoparticles were
synthesized through Michael addition of acrylated E-CD macromer and 1,4-butanediol
diacrylate with an amine molecule such as N, N-dimethylethyldiamine. 17-AAG was
loaded into the nanoparticles, and the release studies were carried out in PBS (pH 7.4) at
37 °C.
Specific Aim 2: Evaluate in vivo efficacy of 17-AAG-loaded β-cyclodextrinpoly(β-amino ester) nanoparticles. The 17-AAG-loaded CD-p-AE nanoparticles were
injected into mice through iv route, and the drug levels in the brain and activation of
Hsp70 was studied and compared to the drug alone.
Material and Methods
Chemicals and Reagents
The following materials were obtained from Sigma-Aldrich, Inc., St. Louis, MO:
β- CD, acryloyl chloride (96%), anhydrous 1-methyl-2-pyrrolidinone (NMP), dimethyl
sulfoxide-d6 (DMSO-d6, 99.9%), 1,4-butanediol diacrylate, N,N-dimethyl
ethylenediamine, chloroform, ethyl acetate, phosphate buffered saline (PBS, pH 7.4),
N,N-dimethylformamide (DMF, HPLC grade), DTAF. 17-AAG was obtained from LC
Laboratories. All these chemicals were used as received without further purification
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unless otherwise noted. Dialysis membrane (molecular weight cutoff (MWCO)
12000−14000 Da) was bought from Spectrum Laboratories. Polyester Transwell inserts
(24 well-plate, 0.4 μm pore size) were obtained from Costar (Cambridge, MA).
Preparation of 17-AAG-loaded CD-p-AE Nanoparticles
CD-p-AE nanoparticles were synthesized according to the Michael addition of
Acrylated CD Macromer and 1,4-butanediol diacrylate with an amine N, Ndimethylethyldiamine by following previously published procedure [50]. The synthesized
CD-p-AE nanoparticles were confirmed by using 1H-NMR. Five parts of CD-p-AE
nanoparticles was dissolved with 1 part of 17-AAG in ethanol and incubated overnight at
room temperature. The resulting solution was diluted with water and freeze dried to
obtain the 17-AAG loaded nanoparticle. The size and zeta potential of the nanoparticles
was measured by using Malvern Zetasizer.
17-AAG In Vitro Release
The release of 17-AAG from CD-p-AE nanoparticles was conducted in PBS (pH
7.4) at 37 °C using the dialysis method. Briefly, 17-AAG loaded CD-p-AE nanoparticles
were dispersed in PBS (pH 7.4) at 1 mg·ml-1, and then loaded into dialysis membrane
tubing (MWCO 12 -14 kDa). The sealed membrane tubing was immersed into PBS (pH
7.4) release medium (400 mL) in a tube at 37 °C. At each scheduled time point, entire
release medium was replaced with the fresh medium to maintain the sink conditions. The
sampled release medium was analyzed for 17-AAG by using LC-MS/MS.
In Vivo Studies of 17-AAG-loaded CD-p-AE Nanoparticles
To investigate the efficiency of nanoparticles in enhancing the BBB permeability
of 17-AAG, a study was conducted where a group of wild-type C57BL/6 was injected
with 17-AAG alone and 17-AAG loaded CD-p-AE nanoparticles at a dose equivalent to 5
mg drug. After 24 hours of injection, the mice were sacrificed, and the brain samples
were isolated to study the concentration of 17-AAG in the brain. The brain tissue was
placed in cryopreservation vials and preserved by snap freezing using liquid nitrogen, and
stored at 80 °C until analysis. Brain tissues were homogenized in water (1:2, tissue:
buffer) prior to analysis using LCMS [15]. To evaluate the efficiency of drug loaded
nanoparticles in improving the efficacy of 17-AAG, another group of wild-type C57BL/6
mice were selected and injected with 17-AAG alone and 17-AAG loaded CD-p-AE
nanoparticles at a dose equivalent to 2.5 and 5 mg drug. The mice were sacrificed post 24
h injection, and a western blot analysis was performed according to the previously
described procedure to study the expression of Hsp70 in the brain [433]. The drug was
extracted using protein precipitation by ACN, and the reconstituted samples were
analyzed by LC-MS/MS. LC was performed on a UPLC system (Nexera XR, Shimadzu
Corporation) consisting of a binary pump, column oven, degasser units, and autosampler
units. 10 μL of sample extracts were injected into the reversed-phase Luna C18 (2)
column (50 × 2.0 mm i.d., 3 μ; Phenomenex, Torrance, CA, USA). Acetonitrile/water
mixture (70/30, v/v) containing 0.01% formic acid was used as a mobile phase and was
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pumped at a flow rate of 0.3 mL.min−1. Total run time was 4.5 min for each sample
injection. The column temperature was kept at 25 ◦C. The LC elute was introduced into
the Applied Biosystem Triple QuadTM 5500, a triple–quadrupole tandem mass
spectrometer equipped with turbo spray ionization source, for quantification of the
analytes in negative ion mode (ESI+). Detection of the analyte ions was performed in a
multiple reaction monitoring modes and transitions of m/z 584.4 → 305.2, and 615.3 →
474.4 were used for LNG and 17-DMAG (IS), respectively. Analyst® 1.6.2 software was
used for processing the data. The detailed experimental conditions are: ion spray voltage
4500 v, collision gas 7 psi, temperature 550 ◦C, collision energy -38 v, entrance potential
-10 v, collision exit potential -17 v, declustering potential -15 v, curtain gas 20 psi, ion
spray gas I 40 psi and ion spray gas II 40 psi.
Results and Discussion
17-AAG Loading and Release from CD-p-AE Nanoparticles
Our collaborators work on 17-AAG showed that it was effective in attenuating the
synaptic toxicity induced by soluble Aβ and memory impairment in mice [433].
However, 17AAG has poor water-solubility and blood-brain barrier permeability, which
are potential problems for clinical construction and hurdles for its clinical application
[434]. Preliminary results from earlier studies by Gil ES et. al from our group
demonstrated that CD-p-AE nanoparticles do not affect the integrity of the in vitro BBB
models, and the nanoparticles have much higher permeability than dextran control across
the in vitro BBB models [50]. Therefore, CD-p-AE nanoparticles were selected to
investigate the feasibility of using this system as a drug carrier for improving the
solubility and permeability of the 17-AAG for AD treatment. The CD-p-AE nanoparticles
were synthesized according to the previously published procedure [50], and 17-AAG was
loaded at 16.67%. The average hydrodynamic size and zeta of the CD-p-AE
nanoparticles were 74.01 ± 1.7 nm and +14.5 ± 1.04 mv, respectively. Solubility testing
studies demonstrated that loading of 17-AAG into the CD-p-AE has enhanced the
solubility of the drug by at least 20 times. Beta-cyclodextrin is known to increase the
solubility of the hydrophobic drugs by their ability to form reversible inclusion
complexes with the drugs by taking the drug moieties into the central cavity of the
cyclodextrin by displacing water [435]. This complexation effectively encapsulates the
drugs within the cyclodextrin, rendering them water-soluble [435].
Figure 3-14 shows that release of 17-AAG from the CD-p-AE nanoparticles. The
initial burst release during first 24 h could be attributed to any excess or free surface drug
that was not loaded into nanoparticles. After the initial burst, a slow drug release was
observed for at least 8 days. Earlier reported studies showed that the CD-p-AE
nanoparticles showed a gradual degradation for more than one month, and this slow
degradation rate might contribute to the long release time for 17-AAG. Additionally, the
favorable hydrophobic interaction between 17-AAG and CD-p-AE nanoparticles might
be strong enough to limit the dissociation of 17-AAG from the nanoparticles leading to
the sustained 17-AAG release [50].
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Figure 3-14. In vitro release of 17-AAG from CD-p-AE nanoparticles.
Notes: CD-p-AE nanoparticles released about 30% of the drug in the initial 24 hours,
followed by a sustained release for at least 9 days. Data represent the mean±SD (n=3).
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In Vivo Studies of 17-AAG-loaded CD-p-AE Nanoparticles
Earlier studies on in vitro permeability of CD-p-AE nanoparticles showed that the
nanoparticles were very permeable (≥1.6 fold) to the in vitro BBB models (BBMVEC
and HBMVEC monolayers) compared to the dextran control, and the results suggested
that the nanoparticles have a high chance of delivering drugs across BBB. Therefore, to
demonstrate the ability of CD-p-AE nanoparticles in improving the permeability of 17AAG, a preliminary in vivo study was conducted where the 17-AAG-loaded
nanoparticles and 17-AAG alone in 5% DMA were injected intravenously into the mice
(dose 5 mg·kg-1) and the brain tissues concentrations of the drug were estimated after 24
hr. The results showed that CD-p-AE nanoparticles were able to achieve 2-fold higher
brain concentration of 17-AAG compared to the drug alone (Figure 3-15). Also, an
efficacy study was conducted where induction of heat shock response by 17-AAG alone/
17-AAG-loaded nanoparticles (5 & 2. 5 mg·kg-1) was measured by estimating the levels
of Hsp70 in the cortex. Results demonstrated that 17-AAG conjugated with nanoparticles
induced more heat shock response compared with 17-AAG alone, as evidenced by
increased Hsp70 protein level (Figure 3-16). This enhanced activity could be attributed
to the increased drug levels in the brain. The data suggested that CD-p-AE nanoparticles
did increase the accumulation and efficacy of 17-AAG in the brain, which might result
from the fact that the nanoparticles enhanced the permeability of 17-AAG through the
BBB. The presence of cationic polyamine group and β-CD might have helped the
nanoparticles to cross the BB through carrier-mediated transport [87]. About the transport
mechanism of CD-p-AE nanoparticles across the BBB, the assumption is that
adsorptive-mediated transcytosis (AMT) may be involved in the process because of
favorable electrostatic interactions between the positive surface charge of CD-p-AE
nanoparticles and negative charges on the endothelial surface of the BBB [88, 436].
However, further studies are needed to confirm these assumptions.
Conclusions
CD-p-AE nanoparticles were synthesized and loaded with 17-AAG. Incorporation
of 17-AAG into the nanoparticle structure has allowed improving the water solubility of
the drug. CD-p-AE nanoparticles sustained the release of 17-AAG for at least one week
in vitro. Crosslinking of β-CD with poly-AE enabled the fabrication of promising CD-pAE nanoparticles that showed increased permeability of the loaded drug 17-AAG across
BBB by 2-fold, and resulted in enhanced expression of the Hsp70 protein in the brain.
These results suggested that the developed CD-p-AE nanoparticles can be used as
potential drug carriers for transporting the drug across the BBB to treat chronic diseases
such as AD in the brain.
Future Work
The future work of CD-p-AE nanoparticles include, a) continue optimization of
the CD-p-AE nanoparticles for enhanced water solubility and sustained release of
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Figure 3-15. 17-AAG levels in the brain at 24 h following intravenous injection of
17-AAG alone/17-AAG loaded CD-p-AE nanoparticles.
Notes: Control: 17-AAG alone in 5% DMA (filled); Sample: 17-AAG-loaded CD-p-AE
nanoparticles in 5% DMA (pattern); Injection dose: 5 mg·mL-1 equivalent to 17-AAG.
Nanoparticles resulted in ~2-fold higher 17-AAG levels in brain compared to the 17AAG alone. Data represent the mean±SE (n=3 p<0.05).
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Figure 3-16. Hsp70 levels in the brain at 24 h following intravenous injection of 17AAG alone/17-AAG-loaded CD-p-AE nanoparticles.
Notes: 17: 17-AAG in 5% DMA; 17+N: 17-AAG-loaded CD-p-AE nanoparticles in 5%
DMA. Injection doses: 2.5 and 5 mg·mL-1 equivalent to 17-AAG. Nanoparticles resulted
in higher expression of Hsp 70 levels in cortex compared to the 17-AAG alone.
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17-AAG; c) Modification by active targeting to direct more socially to the target site and
minimizing the exposure to other tissues; b) Assessment of in vitro bioeffects, in vivo
safety, biodistribution, pharmacokinetics and bioeffects of systemically injected 17AAG-loaded CD-p-AE nanoparticles.
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CHAPTER 4.

CONCLUSIONS

Polymer-based drug delivery systems can significantly influence the overall
performance of a drug by altering various parameters such as concentration, location, and
duration in vivo. In this way, it gives a promising approach to minimize the side effects,
increase the overall therapeutic efficacy of the drug, and improve patient compliance and
adherence. Despite the advances in using different drug delivery systems for various
medical applications, still, there are certain conditions which lack effective and compliant
delivery systems. One of such unmet medical needs was identified to be the affordable
injectable LARCs that can provide contraception for five months to one year, and the
other requirement was the need for drug carriers that can enhance the permeability of the
drugs across the biological barriers and sustain the release as well.
The main objective of this research has been to develop biodegradable polymeric
biomaterials in different forms for long-acting contraception and drug delivery to the eye
and brain. This has been achieved by fabrication of polyester-based ISD systems for
sustained release of LNG for long-acting contraception (chapter 2), and polysaccharidebased nanoparticles for sustained drug delivery across the biological barriers (chapter 3).
The following is the summary of the project of LNG-containing ISD systems for
long-acting contraception (chapter 2):
x

x
x
x

x

A simple, fast and sensitive LC/MS/MS method for quantifying levonorgestrel
(LNG) in rat plasma was developed, fully validated and successfully applied to
PK study of LNG injected SubQ in rats. Rat plasma of 100 μL, liquid–liquid
extraction and LLOQ 0.5 ng·mL-1 were used for the method development.
An accelerated release method for the evaluation of ISD formulations that can
effectively correlate the months of long-term release in a short time such as days
or weeks was developed.
The prototype formulations (64 and 96) have suppressed the rat normal estrous
cycles for at least 5 months after one SubQ injection, and a rapid return of fertility
was observed after the end of the treatment.
The optimized lead formulation 96r [4% LNG, 4% PLGA (0.63 iv), 16% PLA
(0.47 iv), 4% PLA (0.63 iv), 72% NMP/TEC (9:1)] designed by unique strategy
has shown favorable injectability (23 G) and a low in vivo initial burst, and has a
high chance that it can show a promising long-term in vivo LNG release.
Overall, the results demonstrated the injectable ISD formulations can serve as an
effective means of administering LNG for long-term reversible contraception
suggesting that the designed ISD formulations have great potential for developing
future robust and affordable injectable LARC products that could improve access
to family planning around the globe.

The summary from the project of polysaccharide-based nanoparticles for
sustained drug delivery across the biological barriers (chapter 3) are:
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x

x

x

The developed dextran-based poly(NIPAAm-co-DEXlactateHEMA) nanogels
were nontoxic, and were highly permeable than dextran-70 kDa control across the
in vitro ARPE-19 monolayers (~35-fold), ex vivo porcine sclera and cornea (at
least 4-fold).
The developed β-CD-based CD-p-AE nanoparticles sustained the release of 17AAG in vitro for at least one week, and showed increased permeability of the
loaded drug 17-AAG across BBB by 2-fold, and resulted in enhanced expression
of the Hsp70 protein in the brain cortex.
Overall, the developed nanoparticles have shown great potential for delivering the
drugs to the eye and brain.

In conclusion, the hypothesis of the dissertation that different biodegradable
polymeric biomaterials based on polyesters or polysaccharides can act as effective
systems for long-acting contraception for five months or longer, and drug delivery to the
eye and brain was accepted. While the initial objectives of this work were met, still
extensive further in vitro and in vivo investigations need to be conducted with the
developed biomaterials for optimization, and demonstration of the long-term therapeutic
safety, efficacy; and scale-up potentials. Besides, the developed biodegradable
biomaterials can be optimized to be a versatile drug delivery platform and could be
employed for encapsulating other therapeutics for sustained systemic or local drug
delivery.
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APPENDIX. MECHANICAL, THERMAL AND HYDRATION
CHARACTERIZATION OF POLY (HEMA)-BASED HYDROGELS*
Introduction
Hydrogels are polymeric materials comprised of hydrophilic and hydrophobic
components that assist in closely controlling physicochemical properties [437, 438]. They
have made a significant contribution to the field of biomedical sciences through various
applications such as delivery systems of therapeutics or as scaffolds for tissue
engineering or to fill a defect [437, 439, 440]. Poly(2-hydroxyethyl methacrylate)
[poly(HEMA)] based hydrogels have gained extensive attention because of their inherent
biocompatibility, hydrophilicity, and synthetic flexibility. Synthesis of poly(HEMA)
based hydrogels readily permits incorporation of various other components (such as
monomers/prepolymers) containing unique functional groups for their use in novel
industrial formulations and biomedical applications [441-444]. They have been used as
constructs for the effective hosting of biomolecules, whole cell encapsulation, soft
contact lenses and membranes that confer biocompatibility to in vivo biosensors.
The physicochemical properties of the hydrogels such as mechanical, thermal and
hydration characteristics are typically controlled through bifunctional crosslinking agents
such as oligo- and poly- ethylene glycol diacrylates e.g. tetra(ethylene glycol) diacrylate
(TEGDA), which, when added at varying concentrations, influence the modulus and the
void volume through the cross-link density of the hydrogel [445, 446]. However, such
crosslinks may, in addition, be virtual and thus arise from hydrogen bonding [447, 448],
electrostatic interactions[449], polyplex formation [450] and molecular physical
entanglements. The physicochemical properties of the hydrogel systems such as
mechanical, thermal and hydration characteristics play a significant role in deciding the
fate and overall functionally of the hydrogels. As these systems are implanted at various
physiological locations in the body, it is important to mimic the local tissue mechanical
environment and should be able to withstand the shear and compression forces excreted
by the surrounded tissues. Inappropriate mechanical properties may lead to failure of the
system. Thermal properties of the system such as glass transition temperature (Tg) are
also critical for biomedical applications especially in terms of considerations of
processing, handling quality and storage.
Hydrogels have shown their potential as drug delivery systems for controlled
release of biological therapeutics such as peptides and proteins, primarily due to their
high hydrophilicity, tissue similarity and chance to tailor the drug release [439, 440, 451].
--------------* Adapted with permission from (ii) “Partitioning of coomassie brilliant blue into
DMAEMA containing poly(HEMA)-based hydrogels 72. Kotanen C.N., Janagam, D.R.,
Idziak, R., Rhym, L., Sullivan, R., Wilson, A.M., Lowe, T.L., GuiseppiElie, A. European
Polymer Journal. p. 438-450. © 2015 Elsevier Ltd., with permission from Elsevier.”
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Therapeutics can be loaded into the hydrogels either during the hydrogel synthesis (preloading) or after the synthesis of hydrogels (post-loading). Pre-loading of biologics may
expose them to various harsh conditions and crosslinking agents which may either
damage the drugs or covalently graft them to the polymeric network [451-453]. Therefore
post loading can be more favorable for loading of therapeutics specifically into the
hydrogels to preserve their activity. Some of the commonly used post loading techniques
are solvent sorption where the hydrogel is soaked in drug or drug/polymer, and drug gets
into the system by driving forces such as swelling or partitioning in salt-rich phase, but
these techniques has shown poor loading and fast washing out of the loaded drug [452,
454-457]. Another alternative way of achieving post loading is by exploiting the
reversible electrostatic interactions between the oppositely charged units such as
immobilization of charged proteins in oppositely charged hydrogels at low ionic strength
and released at physiological ionic strength. This post-loading technique has shown to be
very promising in attaining high efficiency and controlled release of biologics [451].
Poly(HEMA)-hydrogels can be readily molecularly engineered to contain a wide
variety of pendant and crosslinking bioactive moieties that render them biologically
responsive wherein the response of the hydrogel is triggered by recognition of a
biological agent conferred by an immobilized biorecognition species. These hydrogels
can be easily modified to possess a positive charge, and there are several negatively
charged biomolecules that can have potential applications in bioactive poly(HEMA)
hydrogels such as cell adhesive factors [458], heparin [459], DNA aptamers [460],
plasmids [461], and antimicrobial peptides [462]. The cationic charge can be introduced
into the poly(HEMA)-hydrogels by copolymerization with carcinogenic monomers such
as dimethyl amino ethyl methacrylate (DMAEMA) or aminoethyl methacrylate (AEMA)
and the hydrogels can be employed for encapsulating biomolecules by post-loading
technique. However, incorporation of these additional components into the poly(HEMA)
structure may affect the physicochemical properties of the hydrogels. Therefore, the
objective of this study was to evaluate the impact of ionizable modifiers DMAEMA on
mechanical, thermal and hydration properties of the poly(HEMA)-based hydrogels.
Materials and Methods
Chemicals and Reagents
Octadecyltrichlorosilane (OTS), 2-hydroxyethyl methacrylate (HEMA),
tetra(ethylene glycol) diacrylate (TEGDA, technical grade), oligo(ethylene
glycol)(400)methacrylate (OEG(400)MA), N [Tris(hydroxymethyl)methyl]acrylamide
(HMMA, 93%), polyvinylpyrrolidone (pNVP, Mw ~1,300,000), 2-(Dimethylamino)ethyl
methacrylate (DMAEMA, 98%), the photo-initiator 2,2-Dimethoxy-2phenylacetophenone (DMPA, 99+%), and all other common solvents and buffers were
purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). HEPES buffer was prepared
at 0.025 M and pH = 7.35. The HEMA, methacrylate, and diacrylate reagents were
passed over an inhibitor removal column (Sigma-Aldrich) for removal of the
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polymerization inhibitors hydroquinone and monomethyl ether hydroquinone before
using them in the preparation of the hydrogel cocktail. Solutions were prepared in
deionized water prepared by purifying distilled water through a Milli-Q® plus (Millipore
Inc.) ultrapure water system.
Synthesis of Poly(HEMA)-based Hydrogels
The composition of the hydrogels is given in Table A-1. 5 mol% of charged
modifiers either DMAEMA or AMEA were incorporated into the hydrogels. Our
collaborators synthesized the hydrogels with and without the charge modifiers according
to the procedure published [463]. The resulting structures are schematically illustrated in
Figure A-1.
Mechanical Characterization of Hydrogels
Rheological and compression measurements were performed on poly(HEMA)based hydrogel formulated with and without 5 mol % DMAEMA. Samples were run
using the simple parallel plate geometry on an AR-G2 Rheometer (TA Instruments).
Following equilibration in deionized water, hydrogel samples (I=4.5 mm and t=1.0 mm)
were first subjected to an oscillating strain sweep survey test to define the linear
viscoelastic (LVE) region wherein the storage modulus (G′) and loss modulus (G″) were
independent of the applied strain. The hydrogels were then subjected to a frequency ramp
from 0.1 to 30 Hz at a constant strain (25%) from the LVE region while maintaining the
temperature at 37 °C and the sampling rate of 10 points per decade. The resulting graph
of G´ and G´´ over the range of frequency was created at the end of the procedure.
The compression profiles of the equilibrated and swollen hydrogels were
evaluated with the compression clamp using a Dynamic Mechanical Analyzer (DMA)
Q800 (TA Instruments). The DMA was calibrated before each set of experiments, and the
dimensions of the hydrogels were measured and recorded in the accompanying DMA
software before testing. Starting at a normal force of 0.001N, the hydrogel was heated to
37 °C and put under a force ramp of 0.25 N/min until the machine reached 8 N. After the
force ramp was complete, a graph of the resulting stress/strain curve was produced. To
determine Young’s modulus of the compressed hydrogel, the slope of the stress/strain
curve was analyzed at a point where the profile was linear and most consistent.
Compression profiles of the hydrogels under a compression ramp that went up to 18 N
(maximum force) was used to determine the rupture force the hydrogels.
Glass Transition Temperature (Tg) of the Hydrogels
Tg of the hydrogels with and without 5 mol% DMAEMA was determined by
thermal analysis using a DSC Q2000 (TA Instruments). Around 7 to 10 mg of dried
hydrogel was cut, placed into individual hermetically sealed aluminum pans (Tzero
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Table A-1. Monomer cocktail formulations for the preparation of varying mol%
TEGDA crosslinked poly(HEMA)-based hydrogels prepared in triplicate.
Crosslink density (mol%)
HEMA
TEGDA
OEG(400)MA (n=10)
HMMA
pNVP
DMAEMA/AEMA
DMPA

Control
86
1
5
5
2
0
1

DMAEMA
modified
79
3
5
5
2
5
1

AEMA
modified
79
3
5
5
2
5
1

Notes: HEMA, 2-hydroxyethyl methacrylate; TEGDA, tetra(ethylene glycol) diacrylate;
OEG, oligo(ethylene glycol) methacrylate; pNVP, polyvinylpyrrolidone; HMMA, N[Tris(hydroxymethyl)methyl]acrylamide; DMAEMA, 2-(dimethylamino)ethyl
methacrylate; AEMA, 2-aminoethyl methacrylate; DMPA, 2,2-Dimethoxy-2phenylacetophenone.
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AEMA

A
Figure A-1.

B

Schematic illustration of the polymerized hydrogels.

Notes: Control hydrogel (A), DMAEMA modified hydrogel (B), AMEA modified hydrogel (C).
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C

hermetic lid, 901684.901; Tzero pan, 901683.901). Each sample was equilibrated at -20
°C and run for two consecutive cycles at a heating rate of 10 °C/min from -20 °C to 200
°C. The first heat cycle will assess the hydrogels’ properties in the as-molded condition
and will erase the thermal history of the hydrogels. The second heat cycle will evaluate
the inherent properties of the hydrogels. Three different drying methods were employed:
Hydrogel samples were vacuum (23 inHg) dried at room temperature, vacuum dried (23
inHg) at 80 °C, and freeze dried for overnight before the Tg measurements.
Hydration and Water States Characterization
The degree of hydration (DoH) of the hydrogels with and without 5 mol%
charged modifier DMAEMA /AEMA in DI water at RT (22 °C) was determined by
gravimetric analysis. Firstly, following overnight equilibration and the removal of excess
surface water with lint-free paper (Kim wipes®), the weight of the fully hydrated
hydrogels (HG) equilibrated in DI water was measured using an analytical balance (± 0.1
mg). Hydrogel samples were then dried to constant weight using Freeze Dry System
(Freezone 4.5, Labconco). The samples were further kept in the -80 °C freezer for 12 h
then allowed to dry in the lyophilizer for 2 days at a pressure of 100 mtorr and -80 °C and
the weight repeatedly measured to constant weight. Equation A-1 was used to calculate
the percentage hydration is given below
§ M HG  M DG ·
¸100%
M HG
©
¹

DOH (wt%) = ¨

(Eq. A-1)

Where MHG is the weight of the hydrated hydrogel at equilibration, MDG is the
weight of the dry hydrogel, MHG - MDG is the equilibrium water content (EWC) of the
hydrogel
The water states in the hydrated hydrogels containing 3 mol% TEGDA
crosslinker with and without 5 mol% DMAEMA were measured and calculated using a
differential scanning calorimeter (DSC) (Q2000, TA Instruments) equipped with a lowtemperature cooling module and using, the method previously reported with slight
modification [19-21]. Briefly, the hydrated hydrogels in DI water with known DoH were
surface wiped, weighed and sealed in individual hermetically sealed aluminum pans
(Tzero hermetic lid, 901684.901; Tzero pan, 901683.901). Samples were equilibrated at –
40 °C and then heated up to 30 °C at a rate of 10 °C/min under constant purging of
nitrogen at 50 mL/min. For each measurement, five samples were analyzed. The enthalpy
of the endotherm, ΔHm, at 0 °C was obtained by integration of the endothermic peak
using TA Universal Analysis software and normalized to the weight of the hydrated gel
with a unit of J/g of hydrated gel. The deionized water was used as a reference and the
melting enthalpies for freezing free water and freezing bound water were assumed to be
the same as that of bulk water (ΔH0=334 J/g). Small differences in the enthalpies of the
melting ice of different crystals were neglected. Ratio ΔHm/ΔH0 represents grams of
freezable water per gram of the swollen hydrogel as shown in Equation A-2.
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Wf
MHG

ሺwt%ሻ=

ΔHm

(Eq. A-2)

ΔH0

The amount of non-freezing bound water per gram of hydrated gel was taken as
the difference between the DoH and the amount of freezing water per gram of hydrated
gel using Equation A-3.
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(Eq. A-3)

Results and Discussion
The presence of the hydrophobic but potentially ionizable 3° amine, DMAEMA,
as a co-monomer at 5 mol% is expected to alter the mechanical and thermal properties of
the poly(HEMA)-based hydrogel. Such change, reflected in the physicochemical
properties of the hydrogels, may arise because of the altered structure, potential
crosslinking and hydration characteristics of the hydrogel that is co-incident to the
chemical modification of the backbone.
Mechanical Properties of Hydrogels
Figure A-2A. illustrates the LVE region of the hydrogels under oscillatory strain
sweep. Figure A-2B shows the storage G′ and loss G″ moduli of the hydrogels with and
without 5 mol% DMAEMA as a function of frequency. There was no difference between
both the G′ and G″ of the two types of hydrogels over the entire frequency range from 0.1
to 100 Hz. The G′ was always higher than G″ suggesting that the elastic behavior
dominates the viscous behavior in these hydrogels, which is the typical characteristic of a
hydrogel. Figure A-2B also shows that both the G′ and G″ increased linearly with
increasing frequency, suggesting that the both types of hydrogels were in the rubbery to
glassy transition stage and became stiffer with increasing frequency. Figure A-3 shows
the stress-strain profiles resulted in the compression measurements of the hydrogels with
and without 5 mol% DMAEMA. The addition of 5 mol% DMAEMA increased the onset
stress and onset strain from 5±1kPa and 4.3±0.6% to 13±kPa and 7.1±1.1%, respectively
(Figure A-3A). More significantly, the addition of 5 mol% DMAEMA increased the
compression modulus three-fold, from 1.5± to 4.8± MPa (Figure A-3B). Incorporation of
hydrophobic modifiers may increase the toughness of the hydrogels [464]. The results
could be explained by the higher hydrophobicity of the DMAE moiety than the HE
moiety acting to reduce the total free water content and hence compressibility. Also, the
additional crosslinking caused by the hydrogen bond to DMAE and other components of
the hydrogels such as HEMA or/and HMMA may also be a factor in increasing the
compressibility (Figure A-3C). In combination, the results shown in Figures A-2A, B
and A-3A, B confirm that the addition of 5 mol% DMAEMA did not change the
viscoelastic shear properties of the hydrogels, but significantly increased the hydrogels’
resistance to compressive deformation.
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Figure A-2. Shear storage modulus (G′) and shear loss modulus (G″) as a function
of strain% (A) and frequency (B) for the hydrogels.
Notes: Control hydrogels - no DMAEMA; Modified Hydrogels - 5 mol% DMAEMA.
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Figure A-3. Stress-strain curve for hydrogels under compression (A);
Compression modulus of hydrogels (B); Scheme representing the hydrogen bonding
ability of DMAEMA (C).
Notes: Control hydrogels - no DMAEMA; Modified Hydrogels - 5 mol% DMAEMA
Compression modulus data represents mean±SD, n=3. Hydrogel structure reprinted with
permission.
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Glass Transition Temperature (Tg) of Hydrogels
DSC was used to determine the glass transition temperatures (Tg) of the hydrogels
with and without 5 mol% DMAEMA. The Tg values were obtained from the second heat
cycle of the hydrogels dried through three different processes: vacuum (23 in Hg) at room
temperature, vacuum (23 in Hg) at 80°C, and freeze drying are shown in Table A-2. The
drying condition had a considerable influence on the measured Tg. For the hydrogels
without 5 mol% DMAEMA, vacuum drying at 80 °C caused the Tg to shift to a higher
temperature than the vacuum drying at room temperature, and the freeze drying shifted
the Tg to an even higher temperature than the vacuum drying at 80 °C. For the hydrogels
with 5 mol% DMAEMA, the vacuum drying at room temperature and the freeze drying
produced a similar Tg, while the vacuum drying at 80 °C caused the Tg to shift to a higher
temperature than the other two drying processes. The reason might be that the different
drying processes resulted in the hydrogels having different amounts of residual water
which acted as a plasticizer to decrease the Tg. The vacuum drying at 80 °C and freeze
drying made the hydrogels drier (containing less water) than the vacuum drying at room
temperature. Depending on the chemical structures of the hydrogels (with or without
DMAEMA), the vacuum drying at 80 °C could cause the hydrogels to contain more or
less water than freeze drying. However, irrespective of the drying condition, in all three
drying processes it was observed the addition of 5 mol% of DMAEMA increased the Tg
of the polymer.
It is well known that the value of Tg depends on the mobility of the polymer
chain, the more immobile the chain, the higher the value of Tg [465]. In this case, the
primary factors that may have played a role in increasing the Tg of the polymer after
incorporation of DMAEMA are: water content and cross-linking. It is reported in the
literature that water acts as a plasticizer by reducing the interaction forces between the
polymer chains-i.e., the hydrogen bonds and improve flexibility thereby lower Tg [466].
As DMAEMA is hydrophobic, replacement of 5 mol% HEMA with DMAEMA might
have imparted hydrophobicity to the hydrogels and may have lowered the water content
of the hydrogels and has increased Tg. Further, as increased crosslinking between the
chains restricts the polymer mobility [467], the physical crosslinks formed by the
hydrogen bonding between the DMAEMA and poly(HEMA) polymeric network might
be another factor that caused the shift to higher Tg. To confirm these assumptions
hydration studies and swelling studies were conducted with both modified and control
hydrogels.
Hydration and Water States within Hydrogels
The physicochemical, transport and sorption properties of hydrogels are re
expected to be strongly influenced by the amount of water and the distribution of this
water among the many possible states within the hydrogel [468]. Therefore to study the
effect of the modification on hydrogel properties, hydration studies were conducted. The
DoH of the control and DMAEMA modified hydrogels obtained in water is presented
Table A-3. The presence of 5 mol% DMAEMA dramatically alters the hydration
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Table A-2.
The glass transition temperatures (Tg) from the second heat cycle for the hydrogels with and without 5 mol%
DMAEMA under different drying processes.
Hydrogel/
Tg (°C)
Control
DMAEMA modified

Vacuum dry at room
temperature
Onset
Midpoint
47.14
67.78
79.47
99.99

Vacuum dry at 80°C
Onset
69.57
102.80
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Midpoint
75.60
111.06

Freeze dry
Onset
80.02
85.87

Midpoint
89.73
98.19

Table A-3. The gravimetrically determined degree of hydration (DoH %) of the
p(HEMA)-based hydrogels with and without DMAEMA.
Hydrogels
Control
With 5 mol% DMAEMA

Dry gel,
mg
22.9 ± 0.6
22.5 ± 0.8

Hydrated gel,
mg
41.6 ± 0.6
34.4 ± 0.5

174

Degree of hydration,
wt%
43.7 ± 1.3
31.7 ± 1.2

characteristics of the p(HEMA)-based hydrogel, reducing its DoH from 43.7±1.28 to
31.7±1.17. The hydrophobicity of DMAEMA significantly reduced the water intake into
the hydrogels, and the modified hydrogels were less swollen compared to the control.
To more deeply investigate the distribution of water states within these hydrogels, the 3
mol% TEGDA crosslinker formulation possessing 0 mol% or 5 mol% DMAEMA was
studied by DSC following equilibration in DI water or HEPES buffer. Water present in
hydrated hydrogels is known to be present in three conditions, (i) freezable free water
(Wff), (ii) freezable bound water (Wfb) (freezing point depressed), and (iii) and nonfreezable bound water (Wnfb) . The freezable free water Wff does not participate in any
interaction with the polymer chains while the freezable bound Wfb water slightly interacts
with the polymer chains. The sum of these two states of water is collectively named
freezable water (Wf) which exhibits a phase transition at a temperature of 0 °C. On the
other hand, the non-freezable bound water Wnfb interacts strongly with the polymer chains
through hydrogen bonding and does not show any phase transition at 0 °C. The sum of
the freezable water (Wf) and non-freezable bound water Wnfb normalized by the weight of
the hydrated hydrogel at equilibration (MHG) equals to the degree of hydration DoH as
shown below in Equation A-4. Thus, the DoH determined by DSC may be directly
compared with the DoH obtained by gravimetry and is expected to be in close agreement.
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(Eq. A-4)

Figure A-4 shows that warming the frozen hydrated hydrogels containing
hydrogels with and without 5 mol% DMAEMA resulted in a broad ice-melting
endodermic peak at around 0 °C correlated to the freezable free water in each hydrogel.
The endothermic peak is smaller for hydrogels containing 5 mol% DMAEMA suggesting
less overall hydration. The broad peak at around 0 °C, representing freezable free water
within the hydrogels, was split into two not so clearly resolved peaks which might be due
to different ice structures of the freezable free water within the hydrogels [469]. Figure
A-4 also shows that the 0 °C peak areas of the hydrogels with DMAEMA were
significantly lower than those of the hydrogels without DMAEMA. Besides the peak at
around 0 °C, the hydrogels without DMAEMA showed another relatively small broad
peak at around -6 °C. This little broad peak could be due to the water that was loosely
bound to the hydrogel polymer chains and could be frozen but at a temperature lower
than 0 °C (depression of freezing point) [469-471]. Further observation showed that the
small broad peak at around -6 °C was stronger in the hydrogels without DMAMEA that
were equilibrated in HEPES buffer than the same hydrogel that was equilibrated in DI
water, indicating that the buffer salts enhanced water to be bound to the polymer chains,
consistent with the literature report [472]. As the areas of the endothermic peaks at
around 0 °C and around -6 °C correlate to the freezable free water content and freezable
bound water content, respectively, we further measured the peak areas and calculated the
freezable water content which equals the sum of freezable free water content and
freezable bound water content. By using Equation A-4, the non-freezable bound water
content was calculated from the DoH obtained from the gravimetric measurements at 25
°C and the freezable water content obtained from the DSC results of the hydrogels and
listed the results in Table A-4.
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Figure A-4. Endothermic curves of swollen hydrogels synthesized with and
without 5 mol% DMAEMA.
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Table A-4.

Distribution of water content in the hydrogels possessing 0 or 5 mol % DMAEMA and equilibrated in DI water.

Hydrogels
Control
DMAEMA modified

Degree of hydration DoH
(wt%)
DI H2O
43.7 ± 1.3
31.7 ± 1.2

HEPES
43.4 ± 0.5
29.7 ± 1.1



Freezable water 

۶۵

(wt%)
DI H2O
HEPES
18.7 ± 1.4
18.6±0.3
5.5 ± 0.6
3.8 ± 0.5
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Non-freezable bound water
(wt%)
DI H2O
25.0 ± 0.9
26.2 ± 0.9

܊ܖ
۶۵

HEPES
24.8 ± 0.6
25.9 ± 0.9



Table A-4 shows that a small amount (5 mol%) of the hydrophobic DMAEMA
can dramatically alter the hydration characteristics of cross-linked poly(HEMA). From
the results it can be observed that the major part of the equilibrium water content in the
hydrogels with and without 5 mol% DMAEMA is in non-freezable bound water state and
the addition of 5 mol% DMAEMA did not have much influence on the non-freezable
bound water amount. However, the addition of 5 mol% DMAEMA significantly
decreased the amount of freezable water three-fold (18.7 ± 1.4 vs. 5.5 ± 0.6 in DI water;
18.6 ± 0.3 vs. 3.8 ± 0.5 in HEPES buffer) and thus the total hydration (43.7 ± 1.3 vs. 31.7
± 1.2 in DI water; 43.4 ± 0.5 vs. 29.7 ± 1.1 buffer), and also disturbed the loose binding
between the water and the polymer chains causing the disappearance of the small peak at
around -6 °C in Figure A-4. The reason might be because the non-freezable bound water
is derived from water that is strongly bound to the polar hydroxyl groups of the
poly(HEMA) repeat unit via hydrogen bonds [473] and since poly(HEMA) was the
majority component with a similar amount in both types of hydrogels one may expect the
non-freezable water content to be about the same. The freezable water is derived from the
free or slightly bound water that resides within the nano-dimensioned pores of the
hydrogels [474, 475]. The addition of 5 mol% DMAEMA could make the pores
effectively smaller because of the physical crosslinking by hydrogen bonding with the
poly(HEMA) and also the free water in the pores might have been repelled as the
DMAEMA moiety [δDMAEMA = 27.92 (cal·cm-3)1/2] is more hydrophobic than the
HEMA moiety [δHEMA = 31.2 (cal·cm-3)1/2] [476-478], as reflected in their respective
solubility parameters, d, calculated from group contributions. The presence of the HEPES
buffer did not affect the non-freezable bound water content in both the hydrogels with
and without 5 mol% DMAEMA, and as well as the DoH and the freezable water contents
in the hydrogels without DMAEMA. However, the presence of the HEPES buffer slightly
decreased the DoH and the freezable water contents in the hydrogels with 5 mol%
DMAEMA, probably due to the salting out effect as the DMAEMA is slightly positively
charged at pH 7.4. The hydrogels without DMAEMA in both water and HEPES buffer
had similar freezable water content but higher freezable bound water content in HEPES
buffer (Figure A-4), suggested that the salts in the buffer redistributed the freezable
water within the hydrogels. Further investigation is needed to better understand the exact
mechanisms for the observed redistribution of water content within the DMAEMA
hydrogels. However, there is an indication that this may arise from the unique
mesostructure adopted by the amphiphilic nature of the hydrogel [479]. It is noteworthy
that the DoH values at 25 °C in Table A-4 are similar to the corresponding
gravimetrically determined DoH values at 37 °C (43.7 ± 1.3 and 31.7 ± 1.2% vs. 42 ± 1.4
and 34 ± 1.2% in DI water; and 43.4 ± 0.5 and 29.7 ± 1.1% vs. 41.3 ± 0.8 and 33.1 ± 1.0
in HEPES), suggesting that changing temperature from 37 °C to 25 °C did not
appreciably affect the degree of hydration of the hydrogels. Reduced freezable water of
gels containing DMAEMA are due to hydrophobicity and physical cross-linking [480,
481] within the hydrogel via hydrogen bonding resulting in a tight network. The results
were in agreement with the earlier assumption that the modification of hydrogels with
hydrophobic cationic modifier DMAEMA altered the degree of hydration and water
states of the hydrogels thereby affected the physicochemical properties of the hydrogels.
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To understand the effect of a hydrophilic cationic modifier, 5 mol% AEMA was
added instead of DMAEMA, and the hydration studies were repeated with AEMA
modified hydrogels. Comparison of hydration characteristics of all the three hydrogels in
DI water is given in Table A-5. The addition of 5 mol% AEMA to the control hydrogels
did not resulted in any change in the equilibrium water content of the hydrogels but
significantly decreased the bound water content in the hydrogels from 25.0 ± 0.93 to 16.5
± 0.27, and increased the freezable water content from 18.7±1.43 to 27.8±0.95. Increased
hydrophilicity of the AEMA hydrogels may have led to improved DoH of the gels
compared to the DMAEMA hydrogels (44.3 vs. 31.7), however, the reason for lower
bound water could be attributed to the hydrogen bonding of primary hydrogen atoms
attached to the amine of the AMEA moiety with HEMA/HMMA units, thereby limiting
the hydrogen bonding chances of water with HEMA/HMMA units in the polymer chain.
This interference might have resulted in lowering the bound water content of the
hydrogels after addition of AEMA (Figure A-5). This interpretation of the results needs
further investigation.
Conclusions
The addition of cationogenic DMAEMA at low mol% (5 mol%) has significantly
altered the mechanical, thermal and hydration properties of the hydrogels. The
incorporation of 5 mol% DMAEMA into HEMA-based hydrogels did not alter the
shearing modulus. However, this changed has resulted in an increase in the compression
modulus and Tg of the hydrogels, owing to the hydrophobicity and physical crosslinking
of the DMAEMA. The degree of hydration and the distribution of water within the
hydrogels varied significantly depending on the hydrophobicity/hydrophilicity &
hydrogen bond forming ability of the cationic modifier used in the gels thereby affecting
the hydrogel properties. Freeze drying produced the most consistent drying condition.
Future Work
Some of the near future work on this project include - i) continuing evaluation of
the AEMA modified hydrogels for the physicochemical properties for further
understanding the influence of cationogenic modifiers with hydrophilic and hydrophobic
characteristics; ii) evaluating the effect of inclusion of both AEMA and DMAEMA as
cationic modifiers in the hydrogels; and iii) optimizing the hydrogels for loading and
release of biomolecules for drug delivery applications.
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Table A-5.
Distribution of water content of hydrogel possessing 0 or 5 mol %
DMAEMA or AEMA and equilibrated in DI water.
Hydrogels
Control Hydrogel
5 mol% DMAEMA
5 mol% AEMA

DoH, wt%
43.7±1.28
31.7±1.17
44.3±1.15
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Wf, wt%
18.7±1.43
5.5±0.64
27.8±0.95

Wnbf, wt%
25.0±0.93
26.2±0.86
16.5±0.27

Nitrogen charged at
physiological pH

“H” from water or of
adjacent units of the
polymeric chain

Hydrogel with AEMA

“O” from water or adjacent HEMA/HMMA units of polymeric chain
“N” from adjacent AEMA units in polymeric chain

Hydrogen Bonding

Figure A-5. Scheme representing the possible hydrogen bonding between AEMA
units with adjacent HMMA or HEMA units.
Notes: The hydrogens on AEMA might have involved in H-bonding with HEMA or
HMMA units on the hydrogel network and thereby limiting the bonding of water to gels;
thereby minimizing the bound water content. Though the primary hydrogens of amine
(AEMA) could also involve in hydrogen bonding with water molecules, but the bonding
of these hydrogen's with HEMA/HMMA might be more predominant than bonding to
water. Hydrogel structure modified with permission.
APPENDIX A.
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